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Abstract
Recent breakthroughs in biotechnology and immunology have allowed the immune system to be
harnessed in the cure of some cancers. Thus far clinical successes using immunotherapy have largely
been limited to liquid tumors and solid tumors bearing high mutational burden, while the majority of
cancers currently remain poor candidates for these therapies. Here we demonstrate a proof-of-principle in
addressing one of the main bottlenecks currently impeding widespread application of immunotherapy, the
paucity of tumor specific targets in low mutational solid tumors, and the engineering of T cells to
recognize tumor-specific self-antigens. Using neuroblastoma, an aggressive, low mutational, cold tumor,
we developed a process combining proteomics of MHC-presented antigens with computational methods
and genomic/transcriptomic analyses of normal and tumor tissues, to identify and prioritize tumorspecific antigens derived from lineage restricted oncogenes crucial to tumor biology (derived from
PHOX2B, IGFBPL1, HMX1, TH, CHRNA3, and GFRA2). We then developed methodologies for engineering
CAR and TCR receptors, using phage display and single-cell sequencing of functionally-expanded antigenspecific T cells, respectively. Using these methods, we demonstrate specific binding of CAR and TCR
receptors to tumor antigens and potent killing of neuroblastoma cells using engineered T cells. We
describe new methods of multiplexing targets for accelerated T cell engineering and propose a vision for
personalized target discovery and T cell engineering.
Additionally, we explore the ability of the immune system to recognize and eliminate neoantigens arising
from early cancer driver genes. We developed a model of immunoediting using TCGA data to measure the
underrepresentation of HLA alleles in tumors predicted to present neoantigens as a measure of
immunoediting. We show that the most common tumor driver mutations such as KRAS G12D and BRAF
V600E are immunogenically silent, such that peptides derived from these mutations are not presented on
HLA in the vast majority of the population, thus conferring additional evolutionary advantages to these
mutations in the evasion of the immune system in addition to their oncogenic properties. We show that
HLA alleles offer varying degrees of immunogenic protection against cancer, and thus propose HLA as a
factor contributing to cancer susceptibility.
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ABSTRACT
IMMUNOTHERAPEUTIC TARGETING OF LINEAGE RESTRICTED ONCOPROTEINS IN
IMMUNOGENICALLY SILENT TUMORS
Mark Yarmarkovich
John M. Maris, MD

Recent breakthroughs in biotechnology and immunology have allowed the
immune system to be harnessed in the cure of some cancers. Thus far clinical
successes using immunotherapy have largely been limited to liquid tumors and solid
tumors bearing high mutational burden, while the majority of cancers currently
remain poor candidates for these therapies. Here we demonstrate a proof-ofprinciple in addressing one of the main bottlenecks currently impeding widespread
application of immunotherapy, the paucity of tumor specific targets in low mutational
solid tumors, and the engineering of T cells to recognize tumor-specific self-antigens.
Using neuroblastoma, an aggressive, low mutational, cold tumor, we developed a
process combining proteomics of MHC-presented antigens with computational
methods and genomic/transcriptomic analyses of normal and tumor tissues, to
identify and prioritize tumor-specific antigens derived from lineage restricted
oncogenes crucial to tumor biology (derived from PHOX2B, IGFBPL1, HMX1, TH,
CHRNA3, and GFRA2). We then developed methodologies for engineering CAR and
TCR receptors, using phage display and single-cell sequencing of functionallyexpanded antigen-specific T cells, respectively. Using these methods, we demonstrate
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specific binding of CAR and TCR receptors to tumor antigens and potent killing of
neuroblastoma cells using engineered T cells. We describe new methods of
multiplexing targets for accelerated T cell engineering and propose a vision for
personalized target discovery and T cell engineering.

Additionally, we explore the ability of the immune system to recognize and
eliminate neoantigens arising from early cancer driver genes. We developed a model
of immunoediting using TCGA data to measure the underrepresentation of HLA
alleles in tumors predicted to present neoantigens as a measure of immunoediting.
We show that the most common tumor driver mutations such as KRAS G12D and
BRAF V600E are immunogenically silent, such that peptides derived from these
mutations are not presented on HLA in the vast majority of the population, thus
conferring additional evolutionary advantages to these mutations in the evasion of
the immune system in addition to their oncogenic properties. We show that HLA
alleles offer varying degrees of immunogenic protection against cancer, and thus
propose HLA as a factor contributing to cancer susceptibility.
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Preface
In recent years, a number of clinical successes have emerged in which the
patient’s own immune system has been utilized to elicit enduring eradication of
cancer. These successes have engendered a revolution in clinical practice, patient
outcomes, rapid FDA approvals, and have sparked the imagination of the research
community. As the principles mediating the interactions between immune cells and
tumor cells become increasingly elucidated, their underlying mechanisms have been
applied towards engineering and enhancing the immune response against tumors.
The clinical application of immunotherapy lies at the nexus between understanding
immunological mechanisms and rapidly evolving biotechnologies. A growing interest
and rapid acceleration of research in both spheres has the potential to revolutionize
cancer treatment for an increasing proportion of patients. Here, we demonstrate
examples of how novel technologies can be coupled towards understanding
tumor/immune interactions to identify new targets, develop receptors to engineer
immune responses, and gain insights into tumor immunogenicity. Although there are
many components of the immune system that are important contributors to cancer
immunity and evasion, here we largely focus on the adaptive immune arm of CD8 T
cells interacting with peptides presented on MHC class I, as we postulate that this
interaction is most crucial in driving target-defined cytotoxic response.

High-risk neuroblastoma is a deadly and refractory pediatric tumor that
exhibits the hallmarks of an “immunogenically silent” tumor. Owing to low expression
of major histocompatibility complex (MHC) proteins, relatively few somatic

ix

mutations, and low infiltration of immune cells into the tumor, neuroblastoma has
not been considered a viable target for various modes of immunotherapy.
Furthermore, as a tumor of developmental origin, neuroblastoma exhibits the
properties of tumor stem cells, which have been shown to be refractory to adoptive
cell therapy. Taken together, these factors make neuroblastoma an excellent model of
immune silence and for targeting tumor stem cells using immunotherapy, and
highlights its utility in overcoming major barriers to more widespread application on
immunotherapy.

Using neuroblastoma tumors, we present methods that can be divided into
three aims: 1) characterization of MHC-mediated immunogenicity in low MHC
tumors, 2) discovery of tumor-specific target in low mutational tumors, 3) design of
reactive immune receptors targeting tumor-self-peptides presented on MHC.
Through these methods we demonstrate the discovery of novel tumor antigens in
neuroblastoma including those derived from lineage restricted oncoproteins
previously considered undruggable (e.g. PHOX2B), and the engineering of T cell
receptors (TCRs) and chimeric antigen receptors (CARs) directed at these antigens
presented on MHC. We show that redirecting the immune response using engineered
receptors against these targets can result in potent tumor cell killing. We will also
discuss methods we have developed for assessing cross-reactivity and optimizing
receptor specificity. We will propose a path for applying these approaches towards
other cancers currently limited in immunotherapeutic options.
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Additionally, here we describe computational tools that we have developed to
model immunogenicity and immunoediting using genomic data. Using the Tumor
Genome Atlas (TCGA), we will discuss the application of these tools in assessing
immunoediting in large cohorts of cancer patients, uncovering a dearth of
immunogenicity in frequently occurring cancer mutations such as KRAS G12D and
BRAF V600E. We also uncover differential contributions of individual HLA alleles on
the immunoediting process, highlighting their potential role in cancer susceptibility,
and illustrating how these tools can be used to study mechanisms of immunogenicity
and immune evasion occurring in early tumorigenesis.

We will close by proposing a vision for how the advent of recent technologies
across the fields of genomics, proteomics, synthetic biology, immunology, single-cell
biology,

machine

learning,

computational

modeling,

and

high-throughput

multiplexing, can be utilized towards elucidating critical interactions of the immune
system with cancer, and applied to more rapidly develop safe and effective
immunotherapies towards the goal of delivering personalized cancer treatments.
While many groups are focused on solving the challenges of deploying effective
immunotherapy within the immunosuppressive tumor microenvironment, we think
that our focus on target discovery, receptor engineer, and safety optimization, will
provide a necessary component in expanding the application of immunotherapy.
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Chapter 1: Introduction
Overview
In recent years, the role of the immune system has become increasingly
appreciated in the early elimination of tumor cells. A growing body of knowledge of
these interactions has been harnessed to augment the endogenous immune response
against cancer and to engineer novel molecules engendering tumor specificity to
immune cells. Cumulative progress on multiple fronts of research has converged to
deliver long term survival in previously incurable tumors. Despite great strides, the
fact remains that the majority of patients currently are either not eligible to receive,
or do not respond to, modern immunotherapy. Filling this gap will require a better
understanding of tumor intrinsic factors (such as antigen processing and
presentation, inhibitory signals), tumor extrinsic factors (such as immune cell profile,
antigen receptor repertoire, tumor microenvironment), and the interplay among
these factors in driving immune response and immune evasion. Immune checkpoint
inhibitors (i.e. anti-PD-1, anti-CTLA4) function by priming or reinvigorating the
immune response, but rely on the presence of tumor-directed exhausted or naive T
cells in the repertoire (i.e. a response is not possible without a subset of pre-existing
tumor-antigen-specific T cells). Most successes in checkpoint modulation have
occurred in cancers such as melanoma and small cell lung cancer, at least in part
owing to a higher mutational load occurring with carcinogenic exposure burden (such
as from UV-induced DNA damage in melanoma which have a mean expression of >10
mutations per megabase and smoking-induced DNA damage in lung cancer), and thus
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the increased probability of reactive neoantigen/TCR pairs being present (Chalmers
et al., 2017; Schumacher & Schreiber, 2015). However, these therapies have had very
limited success in mid-to-low mutational tumors, which represent the majority of
cancers, particularly with pediatric cancers which are one-to-two orders of
magnitude lower in their mutational burden (Lawrence et al., 2013).

Conversely, adoptive cellular therapy using chimeric antigen receptors (CAR)
allows T cells to be deployed against conventionally non-immunogenic targets using
a highly specific antigenic target binder coupled to one or more T cell signaling
domains. To date, these therapies have been effective against cell surface proteins
restricted to tumors such as CD19 and CD22, but with modest success against other
such putative targets. This strategy uses an antibody fragment with specificity for a
particular tumor antigen at the extracellular domain of the protein, and an
endogenous TCR signaling domain tethered to the intracellular domain (CD3ζ).
Second and third generation CAR receptors employ additional co-stimulatory
domains including 4-1BB and CD28 to enhance T cell proliferation, survival, and
memory cell formation. CAR receptors have thus far been almost exclusively directed
at cell membrane proteins, which comprise only 16% of the 719 cancer-associated
genes described by Cancer Gene Census (Sondka et al., 2018). Of these membrane
proteins, good targets must have high on-tumor expression and low expression in
normal tissues to avoid on-target, off-tumor reactivity in healthy tissue. Thus far, the
identification of specific targets, trafficking to solid tumors and overcoming the
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immunosuppressive tumor microenvironment have been the major bottlenecks to
the widespread deployment of CARs.

An additional form of adoptive cellular therapy uses tumor infiltrating
lymphocytes (TILs), which mount an effective response in the presence of shared
tumor antigen and a pre-existing subset of tumor reactive TILs against these antigens.
Given the low frequency with which mutations result in immunogenic epitopes (Lu
et al., 2014a; Schumacher & Schreiber, 2015), low mutational tumors are thought to
have a far lower probability of presenting sufficient quantities of canonical
neoantigen (i.e. those resulting from single nucleotide polymorphisms) to be
recognized and eliminated by the immune system (Maleki Vareki, 2018; Martin et al.,
2016; Z. Wang et al., 2019). Moreover, immune responses mounted against
neoantigens derived from passenger mutations (i.e. those mutations not resulting
from clonal parent genes that are critical to the cancer phenotype) may result in the
elimination of a subpopulation of tumor cells, leaving those cells harboring
immunogenically silent aberrations to persist and repopulate the tumor (Efremova,
Finotello, Rieder, & Trajanoski, 2017; Miao et al., 2019). Thus, there is a great need
for identifying shared tumor antigens that recur across patients, particularly in lowto-medium mutational tumors.

We present a method for identifying tumor-specific targets derived from
membrane, intracellular, and nuclear proteins. Our discovery process enables the
identification of a large number of tumor target candidates. We present additional
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methods for engineering CAR and TCR receptors targeting prioritized tumor antigens.
These approaches can be scaled to perform target discovery and immune receptor
engineering in additional tumor types, thereby significantly increasing the
probability of identifying tumor-specific receptors that can be safely delivered to
patients in a personalized manner. To achieve this, we use a process that combines
recent advances in the fields of genomics, proteomics, ligandomics, single-cell
sequencing, high throughput synthesis, and multiplexing technology, paired with
knowledge of tumor biology and immunology, to select and prioritize tumor targets
most likely to yield clinical efficacy.

Upon discovery and prioritization of candidate tumor targets, we have
developed tools and methods to allow for receptor screening at a larger scale, and the
ability to pre-emptively perform cross-reactivity safety studies. By employing
technology for high throughput synthesis of peptide-MHC target molecules, we are
able to generate thousands of pMHC target molecules in hours (a laborious process
that would previously take a full-time employee one week to make a handful of
molecules). This technology, paired with recent barcoding approaches such as CITEseq (Stoeckius et al., 2017) can allow for large-scale multiplexing of targets with T cell
receptors that bind these targets. We expect that the coupling of these technologies
will enable new applications, including safety screening of potentially cross-reactive
antigens on the front end, allowing for prioritization of safe and potent receptors
early in the process, thereby significantly reducing development timelines and
increasing throughput of high-quality therapeutic candidates. Importantly, the high
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throughput screen we have developed will amplify data collection between targets
and the receptors that bind them by several orders of magnitude. These data will be
crucial in understanding the ‘rules of engagement’ between T cell receptors and the
targets that they bind. Moreover, the data can be used to train a machine learning
algorithm, with the goal of eventually performing de novo receptor engineering and
optimization in silico. These two platforms are proposed solutions to the current
bottlenecks in both target identification and receptor engineering, in effect increasing
both the number of receptors developed, and the quality of those receptors, while
substantially reducing timelines and costs.

Given the low-mutational burden of neuroblastoma, the antigens we have
identified are overexpressed, non-mutated, ‘self-antigens.’ Negative thymic selection
and peripheral tolerance result in the depletion of TCRs capable of recognizing selfepitopes, leaving the majority of self-antigens as immunogenically silent, and creating
a major bottleneck for development of antigen specific TCRs directed against selfpeptide-MHC. By developing methods for engineering CAR receptors directed against
peptide-MHC, we are able to circumvent current limitations of TCR repertoires
following negative selection and induce immunogenicity to naturally nonimmunogenic epitopes.

The endogenous immune response can be separated into the innate and
adaptive components. The innate immune system responds to recurring patterns
associated with indispensable portions of pathogens, called pattern associated
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molecular patterns (PAMPS). The adaptive immune response is directed at specific
foreign targets (antigens or epitopes), as dictated by the specific amino acid sequence
and geometric conformation of a portion of a protein or other biomolecule. T cells, a
critical component of the adaptive immune system, serve to detect foreign antigens
on the surface of cells and initiate the appropriate response based on the T cell lineage
(killing of target cells, immune suppression, or signaling of secondary inflammatory
pathways). Developing T cells migrate to the thymus, where each T cell undergoes
recombination in the genomic region coding for the T cell receptor (TCR) through a
process in which they undergo selection against those antigens that are derived from
“self” proteins (negative selection), and positive selection for those receptors that are
capable of recognizing the molecule responsible for presenting antigens on their cell
membrane, major histocompatibility complex (MHC). This leaves the remaining T
cells with an enormously diverse repertoire of receptors, each capable of recognizing
foreign antigens that an organism has not previously encountered, but nonresponsive against peptides derived from self-proteins. The exquisite sensitivity and
specificity of TCRs to respond against foreign pathogen while remaining non-reactive
against

self-peptides

underscores

the fine balance required

to

achieve

immunogenicity against foreign pathogens while avoiding autoimmune responses.

The highly polymorphic human leukocyte antigen (HLA) genes encode the
MHC proteins that present a snapshot of all nucleated cell’s proteome on the cell
surface for surveillance by T cells. An individual harbors six distinct HLA class I
alleles, a total of 13,145 unique Class I (A, B and C) alleles have been characterized to
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date (Robinson et al., 2018), making these the most richly diverse gene loci in the
genome. Presentation of a pathogen-derived peptide (protein fragment) by at least
one of these alleles is one of the major bottlenecks in the initiation of an adaptive
immune response. Each HLA allele possesses the ability to present a distinct set of
antigens to T cells based on its biophysical properties thus driving the evolutionary
diversification of these gene loci such as to present broader repertoires of foreign
pathogens. Peptides presented in MHC class I are typically 8-14 amino acids in length,
while peptides presented on MHC class II can range from 11-30 amino acids owing to
its open binding groove. While a CD4 response against MHC class II peptides is crucial
in eliciting an antitumor response (Ostroumov, Fekete-Drimusz, Saborowski, Kühnel,
& Woller, 2018), our focus will be on the CD8 response against MHC class I peptides.

If a cancer mutation codes for an amino acid variant that maintains its ability
to be presented in the context of MHC (Schumacher & Schreiber, 2015), this leads to
an antigen that can be perceived by the immune systems as foreign (neoantigen).
Though neoantigens are a good source of tumor-specific targets, many so-called
passenger mutations are derived from mutated genes that are not essential to a
tumor’s survival (Schumacher & Schreiber, 2015), and thus can be shed without
major detriment to the tumor. We show that neoantigens are predicted to bind a given
MHC with high enough affinity to be recognized by a T cell in <10% of driver
mutations. Of these predicted binders, only a fraction are actually processed and
presented by cells, and only a subset of presented antigens are capable of inducing an
immune response (Gubin & Schreiber, 2015; Lu et al., 2014a; Schumacher &
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Schreiber, 2015; Yadav et al., 2014). Importantly, we find that many of the most
common mutations responsible for driving cancer (i.e. KRAS G12D and BRAF V600E)
are not predicted to be presented by MHC class I in 99.4% of the population, which
we posit confers additional evolutionary advantages to these “immunogenically
silent” oncogenic drivers.

To date, the greatest successes of CAR T cells has been in leukemias and
lymphomas, specifically, those expressing CD19, a cell surface protein found on all B
cells. Given that ablation of a patient’s B cells can be effectively managed with
immunoglobin therapy, this has enabled the use of CAR T cells directed at nonmutated CD19 to eliminate malignancies expressing this plasma membrane protein.
Solid tumors arise in organs usually comprised of non-expendable tissues, and
therefore solid tumor targets must be very tightly restricted to target expression only
in tumors (June & Sadelain, 2018; Klebanoff, Rosenberg, & Restifo, 2016). While
mutations play a very important role in initial tumorigenesis, a fully developed tumor
is dysregulated at many levels, including metabolically, epigenetically, harboring
structural

genomic

rearrangements,

gene

amplifications/deletions,

and

overexpression of master regulators of which orchestrate gene programs that drive
cell survival, growth, and proliferation. Tumors are comprised of a heterogeneous
milieu of cells, including normal stromal cells that are co-opted by the tumor to enable
its growth. It has become increasingly appreciated in many tumors that a crucial
population of tumor cells take on a stem-cell-like phenotype (Pattabiraman &
Weinberg, 2014). These cancer stem cells have proven to be particularly difficult to
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treat using conventional therapy, as they are known to resist cell death (apoptosis),
upregulate drug pumps, and remain quiescent during treatment. These cells are
thought to play a crucial role in tumor initiation, metastasis, and tumor relapse,
including post-immunotherapy (Miao et al., 2019).

Neuroblastoma, the most common extracranial childhood solid tumor, is a
developmental

tumor of the peripheral sympathetic neural

crest

cells.

Neuroblastoma is a genetically complex disease, with low mutational burden, very
few recurring mutations, and low MHC expression. Neuroblastomas are neural crest
cells that fail to differentiate and thus maintain stem-cell-like properties. These
tumors are an excellent model for tumors that are difficult to treat using
immunotherapy for these reasons: they are low in mutational burden and low in MHC,
and are thus not expected to present neoantigens to the immune system (Pugh et al.,
2013), and these cells resemble cancer stem cells. Having developed our methods
using neuroblastoma, we expect that these processes will be more widely applicable
in addressing challenges in other solid tumors.
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Neuroblastoma
Overview
Neuroblastoma is a tumor of the developing sympathetic nervous system,
arising from the sympathoadrenal precursor cells derived from the neural crest
(Figure 1), first described by James Homer Wright in 1910 (Wright, 1910). Most
neuroblastomas

are

diagnosed in the abdomen
and

associated

with

the

adrenal gland or sympathetic
ganglia,

the

controlling

the autonomic

“fight-or-flight”
The

vast

nerves

response.

majority

of

diagnoses (90%) are under
Figure 1. Neuroblastoma arises from sympathoadrenal precursor
cells derived from neural crest cells (Katherine K. Matthay et al.,
2016).

the age of 10, with a median
age

of

diagnosis

of 18

months. Neuroblastoma is a highly heterogeneous complex genetic disorder, with few
recurrent somatic mutations observed in the disease, which has generated great
interest in understanding the nature of genomic aberrations in this disease that lead
to a cancer phenotype. Neuroblastoma is stratified into risk groups based on the
genomic and morphologic features of the tumor. The most aggressive of these tumors
express an amplification of the MYCN, occurring in 20% of tumors. Conversely,
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another class of neuroblastoma (4S) is able to spontaneously regress even during
metastatic disease (Maris, 2010).

The genetic basis of neuroblastoma has been defined over the last decade.
Approximately 1-2% of neuroblastoma patients have a family history of the disease,
and these cases are caused by heritable germline mutations in ALK or PHOX2B
(Figure 2) that segregate in an autosomal dominant fashion with high penetrance
(Mossé et al., 2008; Raabe et al., 2007). On the other hand, the genetic basis of
sporadic neuroblastoma has been defined by a large genome-wide-association study
(GWAS) from the Maris Lab that has discovered dozens of susceptibility loci and
validated the idea that neuroblastoma is a complex genetic disease (Capasso et al.,
2009; Diskin et al., 2009; Pugh et al., 2013; K. Wang et al., 2011).
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Figure 2. Genetic predispositions for neuroblastoma reveal rare mutations with high penetrance acting in a
Mendelian fashion (ALK and PHOX2B). Many lower penetrance mutations increase susceptibility and
require cooperation.

Genomic analysis of over 200 neuroblastoma tumors revealed very low
mutational rate of 15 nonsynonymous mutations per tumor and low levels of
recurrent driver mutations, the highest of these being activation or amplification of
ALK (6-10% carrying activating mutations in addition to amplification in 3-4% of
cases), and others including activating mutations in tyrosine phosphatase PTPN11,
inactivating mutations in chromatin remodeling genes ATRX and ARID1A, and
activation of NRAS (Pugh et al., 2013). Studies comparing diagnostic and relapse
tumors demonstrate an enrichment of mutations in the ALK-RAS-MAPK pathway,
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highlighting these pathways as critical mechanism of resistance to therapy (Eleveld
et al., 2015).

Though multiple strategies are being developed to target neuroblastoma
including immunotherapy, targeted radiation therapy, differentiation therapy, cell
cycle

intervention,

kinase

inhibition,

and

rational

approaches

targeting

neuroblastoma resistance mechanisms observed in relapse tumors, survival rates
have only slightly increased (K. R. Bosse & Maris, 2016), highlighting the urgent need
for improved therapies.

Neural crest development
The neural crest is present only during embryogenesis in vertebrates and is a
bilaterally paired strip of cells arising in the ectoderm at the margins of the neural
tube after its closure. In early development, WNT, BMP, and FGF signals separate nonneural cells from the neural plate. After the neural fold is fused to create a neural tube,
the cells originally located at the border of the neural plate become neural crest cells,
which then begin migration into various tissue sites.

Neural crest cells are a highly migratory multipotent population giving rise to
a variety of cell types after undergoing epithelial-to-mesenchymal (EMT) transition
and completing migration. They differentiate into peripheral neurons, enteric
neurons, glia, melanocytes, Schwann cells, cells of the craniofacial skeleton,
fibroblasts, smooth muscle cells, and the adrenal medulla, contributing to various
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systems including neural, skin, teeth, head, face, heart, adrenal glands, and
gastrointestinal tract (Mayor & Theveneau, 2013). A complex transcriptional and
epigenetic program regulated by DNA methylation and histone modification dictates
the migration and differentiation at various sites (N. Hu, Strobl-Mazzulla, & Bronner,
2014). Due to the diverse tissue dissemination of neural crest cells, they are capable
of giving rise to multiple tumor types including melanoma, neuroblastoma,
paraganglioma, pheochromocytoma, schwannoma, esthesioneuroblastoma, granular
cell tumors, neurofibromas, perineuriomas, neurothekeoma, medullary thyroid
cancer and the neuroendocrine subsets of a variety of more common cancers
(pancreas, prostate and lung). It has been suggested that developmental properties
of neural crest cells (self-renewal and migration) confer to neuroblastoma a
predisposition for metastasis (Ratner, Brodeur, Dale, & Schor, 2016). These
properties are shared in many other tumors that undergo EMT, including the
upregulation of transcription factors such as Snail, Twist, SoxE, and FoxD
(Kholodenko, Kalinovsky, Doronin, Deyev, & Kholodenko, 2018).

Neuroblastoma tumorigenesis
Despite intensive study, the precise natural history of neuroblastoma
development remains controversial. It has been thought that neuroblastoma cells
arise from the sympathoadrenal lineage of neural crest cells which are normally
capable of differentiating into either chromaffin cells (the body’s main source of
circulating adrenaline and noradrenaline) or sympathetic ganglion cells (responsible
for delivering stress and danger signals associated with the fight-or-flight response).
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The sympathoadrenal lineage is derived from neural crest cells that aggregate on the
dorsal aorta after migrating through the ventral pathway. Cells migrating from the
dorsal aorta to become sympathetic ganglia will upregulate neuronal markers, while
chromaffin cells will upregulate proteins associated with adrenal glands. This
dichotomy is regulated by bone morphogenic proteins (BMPs), which induce the
expression of transcription factors including Sox10 and Mash1. An alternate
hypothesis proposes that chromaffin cells are derived from Schwann cell precursors,
and give rise to neuroblastoma (Kholodenko et al., 2018).

The MYC family of genes (MYC, MYCN, and MYCL) are transcription factors that
play an essential role in cell growth and differentiation. MYC plays an important role
in the early stages of neural crest progenitors, but is superseded by MYCN in later
stages of embryonic development as cMYC expression is downregulated. MYCN
functions to maintain the self-renewal and proliferative capability of neural crest cells
while blocking apoptosis, and is significantly downregulated during differentiation.
Recent studies have demonstrated a feed-forward circuit that maintains the
expression of MYCN and its core regulatory circuit genes: HAND2, ISL1, PHOX2B,
GATA3, and TBX2 (Durbin et al., 2018). MYCN is found on chromosome 2 at band 2p24
and is thought to be amplified through the formation of double minutes (DMs) which
initially become amplified outside of the chromosome and occasionally reintegrate
back into the chromosome, with amplicons reported ranging in size from 250 to
2000kb (Yoshimoto et al., 1999). Expression of MYCN under the regulation of the
tyrosine hydroxylase promoter is sufficient to drive neuroblastoma development in
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mice (Weiss, Aldape, Mohapatra, Feuerstein, & Bishop, 1997) and zebrafish (Zhu et
al., 2012), and GWAS identified susceptibility genes can further accelerate
tumorigenesis in cooperation with MYCN (Zhu et al., 2017). Despite its central role in
neuroblastoma biology, there are no therapies currently available to directly target
MYCN due to inherent lack of hydrophobic binding pockets of transcription factors.

The anaplastic lymphoma kinase (ALK) gene encodes a receptor tyrosine
kinase expressed during the embryologic development of central and peripheral
nervous tissue. ALK expression within the sympathoadrenal lineage of the neural
crest modulates the balance between cell proliferation and differentiation, acting
through various pathways including MAPK and RAP1 (Janoueix-Lerosey, LopezDelisle, Delattre, & Rohrer, 2018). ALK expression is regulated by PHOX2B (Bachetti
et al., 2010), and we have unpublished data that it is regulated by the entire CRC.
Activating mutations in ALK F1174L have been shown to be sufficient to induce
tumorigenesis in mice, recapitulating the morphology, metastatic patterns, and gene
expression seen in humans (Heukamp et al., 2012).

At the time of diagnosis, 73% of neuroblastoma patients will have metastatic
disease, more than half of which occur in the bone and/or bone marrow. Metastatic
disease is usually associated with losses in chromosome 1p, 3p, and 11q and gains in
17q as well as MYCN amplification. Twist, a transcription factor involved in epithelialmesenchymal transition (EMT), is upregulated in aggressive neuroblastoma and
neuroblastoma (Valsesia-Wittmann et al., 2004), and is associated with MYCN
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expression. Twist is thought to down-regulate cell-cell adhesion, increase migration,
and counteract apoptotic activity by interfering with p53 responses (Puisieux,
Valsesia-Wittmann, & Ansieau, 2006). Neuroblastoma cells express the CXCR4
chemokine receptor which responds to SDF-1, a factor expressed in the bone marrow,
and thought to contribute to the honing of neuroblastoma cells to the bone marrow,
and further promote tumor growth once localized in the marrow, in conjunction with
other bone marrow factors including (TGF-β), IGF-I and II, platelet derived growth
factor (PDGF), and bone morphogenic proteins (BMP) (Ara & DeClerck, 2006).

While driver mutations are rare in primary neuroblastomas at diagnosis (the
most frequent mutations occur in <10% of cases), there is a significant enrichment in
specific gene mutations in relapse tumors, with a large majority of relapse tumors
showing mutations in the canonical ALK-RAS-MAPK pathway (Eleveld et al., 2015;
Schleiermacher et al., 2014), suggesting that these mutations are essential in driving
resistance and likely arose from rare subclones. Ongoing work in the lab is tracking
these mutations over time with circulating tumor DNA from patient blood.

Presentation, risk assessment, current standard of care, and novel approaches
Neuroblastoma is a highly heterogeneous disease in which patients present
with varying symptoms based on the tumor sites. Neck and upper chest tumors may
cause Horner’s syndrome, resulting in ptosis, miosis, and anhidrosis. Other tumors
along the spinal column may result in paralysis due to cord compression. Abdominal
pain, weight loss, fatigue, and bone pain are commonly associated with clinical
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presentation. Metastatic tumors are most commonly found in lymph nodes, cortical
bone, bone marrow, and/or liver. The defining clinical features of neuroblastoma
used to stratify patients for therapy are based on age at diagnosis (younger patients
have a better prognosis), stage of disease, level of tumor differentiation, MYCN
amplification status, and presence whole or segmental chromosomal aberrations.
Amplification of the MYCN oncogene occurs in about 20% of cases and is associated
with a uniformly aggressive disease phenotype (Maris, 2010). The majority (65%) of
neuroblastomas arise in the adrenal medulla (cells derived from postganglionic cells
connect to the central nervous system that have lost expression of dendrites and
axons and which stimulate the release of catecholamines adrenaline, noradrenaline,
and dopamine) or lumbar sympathetic ganglia (Mayor and Theveneau, 2013). The
remainder are distributed in the chest, neck, and pelvis at a ratio of 4:1:1, respectively.
Small subsets of patients present with bilateral neuroblastoma, usually suggestive of
a genetic predisposition (Cheung & Dyer, 2013). Recent studies are revealing the
genomic differences between adrenal and non-adrenal tumors, finding higher rates
of MYCN amplification, chromosome 1q gain, and 11q loss in adrenal tumors
(Oldridge et al., 2019).

Treatment regimens and survival rates in neuroblastoma are dependent upon
risk stratification. Low and intermediate risk neuroblastomas have high five-year
survival rates after surgery and/or moderate-intensity chemotherapy (>98% in lowrisk and 90-95% in intermediate-risk), allowing these patients to be spared from the
morbidity associated with intensive treatments for high-risk patients. Only 40-50%
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of patients with high risk neuroblastoma currently survive the disease despite
intensive therapy, and survivors often suffer from significant treatment-related
morbidity. High-risk disease is treated with intensive induction chemotherapy
(including topotecan, cyclophosphamide, cisplatin, etoposide, doxorubicin and
vincristine), typically two or more surgical procedures, myeloablative chemotherapy
with peripheral blood stem cell rescue, external beam radiation therapy, and finally
monoclonal antibody therapy targeting GD2 combined with cytokines GM-CSF, IL-2
and isotretinoin.

Based on the increased understanding of neuroblastoma genomics and tumor
biology, a number of approaches are being developed to target the disease, including
ALK inhibitors, inhibitors of the RAS-MAPK pathway, cell-cycle inhibitors,
components on the p53 pathway, differentiation factors, targeted radiotherapy using
radiolabeled norepinephrine analogues, and immunotherapy (K. R. Bosse & Maris,
2016; Maris, 2010).

Immune landscape in neuroblastoma
Spontaneous remission and opsoclonus myoclonus ataxia syndrome
Spontaneous regression, the disappearance of localized or disseminated
cancer without therapeutic intervention, has long fascinated researchers as these
cases may provide valuable insight into therapeutic strategies for treatment of
tumors. Though these cases are difficult to measure, it is generally accepted that
neuroblastoma has the highest degree of spontaneous regression of all human
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cancers (K. K. Matthay, 1998; Katherine K. Matthay et al., 2016). The first evidence of
spontaneous regression in neuroblastoma was described by Quirin in 1921 and then
by Farber in 1941 (Everson, 1964). Further evidence of regressing tumors was
described in 1963, in which neuroblastic nodules were identified in the adrenal
glands of infants who had died of causes unrelated to neuroblastoma (Beckwith &
Perrin, 1963). These were later termed stage 4S in infants less than a year of age,
characterized by small abdominal primary tumors with metastases contain to liver
and skin, and limited bone marrow dissemination. These patients had very good
prognosis, often undergoing spontaneous regression without therapy. These cases
contrast to those in patients over 12-18 months of age with metastatic disease that
has generally disseminated to the bones (Evans, D'Angio, & Randolph, 1971). While
most stage 4 tumors are characterized by segmental chromosomal aberrations, 4S
tumors typically harbor whole chromosomal gains. Several mechanisms have been
proposed to explain spontaneous regression, including neurotrophin deprivation,
loss of telomerase activity, cell or antibody mediated immunity, or epigenetic
alterations. These tumor cells in culture have been shown to be dependent on nerve
growth factor (NGF), and demonstrate an upregulation of the NGF receptor, TrkA,
suggesting a depletion of NGF as a potential mechanism of regression in NGFdependent precursor cells (Brodeur, 2018).

High telomerase activity is generally associated with poor prognosis in cancer
patients, while telomere shortening has been proposed as another explanation for
spontaneous regression (Hiyama et al., 1995). Most 4S tumors have been reported to

20

have low telomerase activity and short telomeres, similar to that seen in senescent
cells. Another proposed mechanism of spontaneous regression is epigenetic
regulation. Epigenetic alterations (methylation, histone modifications, and chromatin
modifications), have been ascribed to cancer phenotypes and patient outcomes.
Reports have demonstrated reduced promoter methylation in 97% of genes known
to be differentially methylated in neuroblastoma (Decock, Ongenaert, Vandesompele,
& Speleman, 2011), suggesting an association between regression and methylation,
but not establishing causality.

The final proposed mechanism for spontaneous regression is one mediated
through the immune system. The evidence for this lies in regression associated with
acute infection, fever, of allergic reaction in neuroblastoma and other tumors
(Everson, 1964). In one study 13 of 16 (81%) patients with paraneoplastic
opsoclonus-myoclonus ataxia syndrome (OMAS; a group of patients with an
outstanding cancer prognosis, but with often devastating autoimmune neurologic
defects; more below) were found to have IgG antibodies responsive against neural
cells compared to 12 of 48 (25%) observed in that a non-OMAS population,
suggesting participation by a humoral component in spontaneous remission
(Antunes et al., 2000). Furthermore, a study of eight spontaneously regressing
patients revealed an expression of the variable beta chain 2 gene segment family,
suggesting that immunodominant clonotypes may be associated with tumor
regression (Valteau et al., 1996). While neuroblastoma cells are known to
downregulate HLA class I, it has been shown that 4S tumors express normal levels of
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HLA class I, suggesting that 4S tumors may have higher levels of antigens available
for T cell mediated response (Squire, Fowler, Brooks, Rich, & Cooney, 1990).

Opsoclonus myoclonus ataxia syndrome is a rare autoimmune disease
observed in some patients with spontaneously regressing neuroblastoma,
characterized by opsoclonus, myoclonus, and ataxia, associated with irritability and
behavioral changes. It is characterized by anti-neuronal antibodies in the serum, a
high degree of infiltrating lymphocytes, and high degree of survival, suggestive of a
local immune response directed at the tumor. Though little is known about this rare
disease, its association with spontaneous remission and indicators of immune
activation suggest a potential role of immune clearance of tumors in this subset of
patients, which may point towards immunotherapy targets in the future.

Neuroblastoma stroma: tumor-associated macrophages and fibroblasts (TAMs and
TAFs)
The tumor microenvironment (TME) is the stromal component of a solid
malignancy, comprised of a basement membrane, fibroblasts, extracellular matrix
(ECM), immune cells, and vasculature, is essential in maintaining normal epithelial
tissue as well as their malignant counterparts (Bussard, Mutkus, Stumpf, GomezManzano, & Marini, 2016). While tissue stroma normally suppresses tumorigenesis,
it can be co-opted by tumors and become essential to their proliferation and
migration. A growing body of evidence has highlighted the complex crosstalk
between tumor cells and stromal cells, resulting in a greater appreciation of stromal
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contribution to multiple hallmarks of cancer (Bremnes et al., 2011; Bussard et al.,
2016; Hanahan & Weinberg, 2011; Mao, Keller, Garfield, Shen, & Wang, 2013). The
stroma of neuroblastoma tumors is unique in that it is often comprised of a large
number of Schwannian cells, which are a defining morphological feature of
neuroblastoma and associated with a more favorable clinical outcome (Qualman et
al., 1987). Schwannian cells have been shown to possess the same genomic features
as neuroblastoma cells (Mora et al., 2001), suggesting that these cells either arise
from a common precursor, or more likely are differentiated from neuroblastic cells.
Schwannian cell-rich tumors are associated with favorable outcomes and inversely
correlated with tumor-associated fibroblasts. Though a direct causal effect of
improved outcome remains to be established, it is thought that Schwannian cells may
secrete angiogenic inhibitors, act to stimulate differentiation of neuroblastoma cells,
or prevent the accumulation of fibroblasts within the tumor (Zeine et al., 2009).

The presence of TAMs, regulatory T cells, and myeloid-derived suppressor
cells have each been associated with tumor-promoting properties (Ouzounova et al.,
2017; Shitara & Nishikawa, 2018; Zhang et al., 2012). In a study assessing differential
outcomes of patients with non-MYCN amplified neuroblastoma, a significant
correlation was observed between poor outcome and genes associated with M2
macrophages and myeloid cells in the tumor including CD33, CD16, IL6R, IL10, and
CD14 (Asgharzadeh et al., 2012). It is thought that these cells are inhibiting function
of infiltrating NK and T cells and also activating tumor cell growth via the IL6
pathway. Peripheral blood mononuclear cells (PBMC) and bone-marrow derived
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mesenchymal stem cells (BM-MSCs) treated with conditioned medium collected from
neuroblastoma cells resulted in a significant upregulation of TAM markers CD163 and
CD204. TAM-like macrophages enhanced the invasive capability of tumor cells as well
as the proliferation of BM-MSCs, highlighting a positive feed-forward loop that
generates favorable growth conditions for neuroblastoma cells (Hashimoto et al.,
2016). Others have shown that high-risk neuroblastoma tumors with deletion of
chromosome are 11q are inflammatory-driven, expressing high levels of M2
macrophages and tumor-associated fibroblasts expressing mPGES-1, the enzyme
responsible for synthesizing PGE2, which promotes tumor growth, angiogenesis, and
metastasis (Larsson et al., 2015).

Immunotherapy in neuroblastoma
GD2 is a membrane glycosphingolipid that plays an essential role in neural
differentiation and proliferation with high expression in neural-crest derived tumors
and low normal tissue expression. The first proof that immunotherapy could improve
outcomes for patients with high-risk neuroblastoma was through a randomized
phase III trial published in 2010 (Yu et al., 2010) of anti-GD2 monoclonal antibody
(mAb) dinutuximab combined with alternating cycles of IL-2 and GM-CSF with
isotretinoin (retinoic acid). The experimental are showed two-year event-free
survival (EFS) and overall survival rates of 66% and 86% respectively, compared to
46% and 75% for isotretinoin alone. This study led to the first FDA approved therapy
for high-risk neuroblastoma and is now considered standard-of-care, and established
the use of immunotherapy in treating neuroblastoma. However, while anti-GD2
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antibodies are effective against neuroblastoma metastases in the bone marrow, but
have not proven effective in achieving durable responses as single agents against
large tumors, and leave high-risk patients prone to relapse. As antibodies do not cross
the blood-brain barrier, relapse of neuroblastoma in the central nervous system
(CNS) has emerged since the clinical introduction of anti-GD2 therapy. Finally, GD2 is
expressed on pain fibers, and excruciating pain is a universal side effect of this
therapy (Richards, Sotillo, & Majzner, 2018; Yu et al., 2010).

CAR T cells have the potential to increase the effectiveness of these responses
and cross the blood-brain barrier. CARs have entered the clinic in neuroblastoma
patients and have generated occasional reports of objective responses. CAR therapy
has been hindered by the low activity of T cells, paucity of targets, and
immunosuppressive microenvironment. Early clinical studies of CARs used GD2
single-chain variable fragments used CD3ζ with no costimulatory domain, comparing
Epstein Barr virus (EBV)-specific T cells stimulated with EBV-transformed cells to
non-specific T cells stimulated with anti-CD3 antibodies (Pule et al., 2008). After 2
weeks, there was little persistence of CD3-stimulated T cells, but a strong persistence
of EBV-stimulated T cells associated with tumor regression in four of eight patients,
highlighting the necessity of costimulation in T cell persistence and efficacy. A more
recent study using third generation anti-GD2 CARs containing CD28 and OX40
costimulatory domains was tested with and without lymphodepletion by
chemotherapy showed limited efficacy, which has been attributed to tonic signaling
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through the scFv receptor leading to T cell exhaustion (Hombach & Abken, 2011;
Richards et al., 2018).

Our lab as well as others (Bernards, Dessain, & Weinberg, 1986; Coughlin et
al., 2006) have documented low MHC expression in neuroblastoma. MYCN has been
posited to reduce MHC expression and dampen response by NK cells (Brandetti et al.,
2017). Despite its potential role in downregulating MHC, T cells targeting MYCN
peptide have been reported to elicit a T cell response in neuroblastoma cells
(Himoudi, Yan, Papanastasiou, & Anderson, 2008). Neuroblastoma has been reported
to express melanoma (also derived from the neural crest) antigens MAGE-1, MAGE-3,
and MAGE-6, though natural immune responses have not been observed to these
peptides (Corrias et al., 1996; Seeger, 2011). Separate reports have shown T cell
activity against survivin and NY-ESO-1 (Coughlin et al., 2006; Singh et al., 2015).
Additional immunotherapy targets being pursued clinically and preclinically are B7H3, L1CAM, ALK, NCAM and GPC2 (Kristopher R. Bosse et al., 2017; Richards et al.,
2018). Taken together, these studies suggest that while there are major hurdles to be
overcome in the development of effective immunotherapy in neuroblastoma, T cell
responses to these tumors have been reported, and a number of preclinical and
clinical studies are aimed at overcoming the challenges of the immunosuppressive
tumor microenvironment, suggesting that a major remaining limitation will be the
paucity of immunotherapy targets in neuroblastoma and other cancers.
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Adaptive immune response in cancer
MHC class I antigen processing and presentation
Antigen processing, presentation, and recognition is essential to the function
of the adaptive immune response. The T cell, antigen presenting cell, and major
histocompatibility

complex

(MHC)

system

have

coevolved

as

complex

interdependent systems, each comprised of multiple pathways that converge at the
immunologic synapse to elicit immune protection against foreign pathogens and
maintain genomic integrity across the organism (Figure 3). Peptide-MHC class I
complexes (pMHC) are presented on all nucleated cells for surveillance by cytolytic
CD8 T cells (Rock, Reits, & Neefjes, 2016). The MHC is composed of an alpha chain and
beta chain, with the class I beta chain, beta-2-microglobulin binding to all class I MHC
variants (Figure 6D). The domains have evolved to form a groove composed of a beta
sheet at the base and two alpha helices far enough apart from one another to
accommodate a peptide in the so-called MHC groove (Figure 6A). The peptides that
bind within the groove follow a pattern of binding based on the anchor residues of
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the peptide that occupy defined pockets within the MHC groove, depending on charge,
hydrophobicity, and geometry. The human leukocyte antigen (HLA) genes encoded
by the MHC, presents a snapshot of all nucleated cell’s proteome on the cell surface
for surveillance by
T cells. Both normal
and

pathogenic

proteins

are

degraded by the
proteasome

into

peptide fragments,
some of which are
Figure 3. Antigen processing and presentation. Proteins are degraded by the
proteasome, resulting in peptide fragments which may be transported to the
ER by TAP proteins. In the ER, peptides compete with other peptides based
on biophysical properties for binding to one of six HLA class I molecules.
Bound peptides are transported on MHC to the cell surface for surveillance by
CD8 T cells.

transported
the

into

endoplasmic

reticulum

(ER)

through by the ER membrane proteins TAP1 and TAP2 (transporter associated with
antigen processing). Peptides transported into the ER by TAP then compete for
binding to MHC based on their binding affinity and abundance (Figure 3). The MHC
is held in an open conformation for peptide loading by chaperone tapasin (Rock et al.,
2016). MHC class I has a groove that is closed on both ends by conserved tyrosine
residues, limiting the occupation of the groove to peptides between 8-14 amino acids
in length in MHC class I, with the majority of peptides 9mers. Those peptides that are
too long to fit into the groove may be trimmed by an ER aminopeptidase, ERAP1.
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Peptides loaded in MHC class I are then transported to the cell surface for
presentation for surveillance CD8 T cells.

An individual harbors six distinct HLA Class I alleles, a total of 13,145 unique
class I (A, B and C) alleles have been characterized to date (Robinson et al., 2018),
reflecting the evolutionary selection towards rich polymorphism at this locus.
Presentation of a pathogen-derived peptide by at least one of these alleles is one of
the major bottlenecks in the initiation of an adaptive immune response. Each HLA
allele possesses the ability to present a
distinct set of antigens to the immune
system

based

on

the

biophysical

properties restricting the binding affinity
of anchor residues within peptides
available
Figure 4. Peptide/MHC/TCR interaction.
Peptide/MHC interaction is dictated by anchor
residues with conserved biophysical properties
based on the HLA allele. Residues facing out of the
MHC groove dictate the interaction between peptide
and TCR (Fritsch et al., 2014).

for

presentation.

This

specificity is largely dictated by two HLAfacing (Figure 4) anchor residues of the
peptide, which are restricted to a few

amino acids at these positions (Fritsch et al., 2014). The interactions between various
HLA alleles and the peptides they present has been well characterized, with canonical
motifs characterized for most common HLA alleles (Bassani-Sternberg et al., 2017).
Large datasets of MHC peptides have been used to train machine learning algorithms
that are able to correctly predict peptide binders to MHC with positive predictive
values of >60% for most HLA alleles (O'Donnell et al., 2018). New methods including
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mass spectrometry on mono-allelic cell lines continue to refine the understanding of
interactions between peptide and MHC and identify noncanonical binding motifs
(Abelin et al., 2017). The current understanding of peptide presentation does not
currently predict or explain immunogenicity of specific peptides, nor their
immunodominance as a private or shared antigen, though initial attempts have been
made at predicting immunogenicity (Calis et al., 2013), and will continue to evolve as
tools for cataloging immunogenicity are rapidly evolving. MHC antigen presentation
is further complicated by the altered proteasomal activity under inflammation
(immunoproteasome), which alters the specificity and rate of degradation of
intracellular proteins and thus the landscape of MHC-presented peptides (Ferrington
& Gregerson, 2012). Others have described enhanced MHC presentation of defective
ribosomal products (DRiPs) (Antón & Yewdell, 2014), in addition to potential posttranslational peptide splicing by the proteasome (Mishto & Liepe, 2017).
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T cell development
Lymphoid progenitor cells from the bone marrow enter the thymus through
venules in the corticomedullary junctions, where they travel to the outer cortex. Early
T progenitors do not
express TCR, CD4, or
CD8 and are termed
double-negative

DN

thymocytes (Germain,
2002). Cells progress
through four stages of
differentiation,

DN1-

DN4, defined by their
expression of CD44
and CD25 (Figure 5).
Figure 5. Lymphoid progenitor cells arrive at thymus, entering the outer cortex.
Early progenitors do not express TCR, CD4, or CD8 (double-negative). Cells
progress through DN1-DN4 differentiation stages as they undergo β chain
rearrangement, followed by rearrangement of the α chain, and finally
expression of CD4 or CD8 based on their interactions with MHC class I or II
(Zúñiga-Pflücker, 2004).

During
progression

the
through

the four stages, cells
express a pre-TCR, a non-rearranged pre-α chain that pairs with the arranged β chain.
Successful expression of the pre-TCR leads to proliferation and replacement of the
pre-α chain with a rearranged α chain. This double-positive (DP) T cell, expressing
both CD4 and CD8, then interacts with cortical epithelial cells that express MHC class
I and II presenting self-peptides. Further interactions with medullary thymic
epithelial cells expressing the transcription factor AIRE, which promiscuously
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transcribes the majority of the proteome for broad presentation of peptide on the
MHC molecules (Eldershaw, Sansom, & Narendran, 2011). The fate of the DP cells is
dictated by the strength of interaction with pMHC on the cortical cells: too weak a
binder to MHC results in apoptosis, and too strong a binder to self-antigen in the MHC
results in either apoptosis, or differentiation into regulatory T cells (Treg). About 7.5%
of thymic cells are positively selected and 7.5% are negatively selected (McDonald,
Bunker, Erickson, Oh-Hora, & Bendelac, 2015). This selection results in a highly
regulated window of binding affinity of the TCR to pMHC, and a deletion of those TCRs
that may be capable of inducing autoimmunity. After positive selection, DP cells
upregulate CCR7 which mediates migration into the thymic medulla. Further T cell
maturation into the CD8 or CD4 lineage is dictated by the strength of the interaction
of a particular clone with either MHC class I or II, respectively, resulting in a singlepositive population (SP) expressing either CD8 or CD4 (Germain, 2002). It is thought
that the resulting naive T cells emigrate from the thymus via either efferent
lymphatics or the blood vasculature (Weinreich & Hogquist, 2008). For cases in which
self-antigen-specific T cells are able to escape thymic selection, secondary safeguards
exist by which T cells can be peripherally tolerized against self-antigen, such as
receiving stimulations through the TCR (signal 1) without co-stimulatory signal
(signal 2) (Smith, Verdeil, Marquardt, & Sherman, 2014).
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T cell receptors (αβ)
The T cell antigen receptor (TCR) endows each T cell with its unique specificity
for foreign antigen. Since self-proteins are also presented on MHC, the TCR must
undergo a series of somatic recombination events that are tightly coupled with the
selection process described above, to generate a repertoire of receptors with
specificity directed away from self-proteins, yet still capable of recognizing foreign
pathogens. The TCR was first described in the 1980s as a glycosylated αβ heterodimer
capable of recognizing MHC (Reinherz, Meuer, & Schlossman, 1983). The αβ receptors
are encoded by recombined transcripts derived from the Variable (V), Diversity (D),
and Joining (J) gene segments, which are spliced together by site-specific
recombination activating gene encoded proteins (RAG-1 and RAG-2). RAG proteins
recognize recombinase heptamer and nonamer signal sequences (RSS), generating a
hairpin loop which is cleaved to generate novel junctions between V/D/J genes. This
recombination follows the “12/23 rule,” whereby one of the recombination occurs
only at gene segments flanked by 12 and 23 bp spacers, such as to maintain the
orientation of the recombination events. These spacers vary in sequence but all
possess a conserved heptamer and nonamer sequence, respectively.

Following

hairpin formation, unwanted segments are removed and coding ends are joined by
nonhomologous end-joining (NHEJ) proteins (Bassing, Swat, & Alt, 2002). The TCR
alpha is encoded by ~70 potential V gene segments paired with 61 J genes, while the
beta chain is encoded by 52 V genes, 2 D segments, and 13 J segments (Figure 6C).
Further diversity is introduced by insertions and deletions of nucleotides at the V(D)J
junction by terminal deoxynucleotidyl transferase (TdT) and exonuclease. The
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recombined segments are then paired with their α/β counterpart, resulting in a 1018
possible recombinations (Davis & Bjorkman, 1988). These variable regions are joined
to the constant domain, encoded by one gene for the alpha and two possible constant
genes for the beta chain. The constant domain does not mediate T cell signaling
directly, but through a short cytoplasmic tail of the constant domain that interacts
with the CD3 complex.

Figure 6. Peptide/MHC/TCR interactions. A) Peptide in closed MHC class I groove encoded by MHC alpha
chain. B) Peptide in open MHC class II groove encoded by MHC class II alpha and beta chains. C) V, D, J
gene segments (alpha in pink and beta in green) recombine to form TCR gene. CDR3 loops are located at
highly polymorphic V(D)J junctions, while CDR1 and CDR2 loops are encoded in germline sequence of V
gene segment. D) Genes encoded by alpha chain (pink) and beta chain (green). CDR1 a CDR2 loops
interact mainly with MHC, while CDR3 loops interact mainly with peptide. D) MHC class II peptide
presentation. E) Crystal structure of pMHC/TCR interaction (La Gruta, Gras, Daley, Thomas, & Rossjohn,
2018).

Following positive and negative selection in the thymus in which TCRs with
specificity for MHC are selected for, and those with strong affinity for self-antigen are
selected against, respectively, the diversity is greatly reduced to about 2.5x107, with
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this diversity representing the immune repertoire (La Gruta et al., 2018). Unlike B
cells, which undergo somatic hypermutation, this process is absent from T cells,
presumably to avoid the acquisition of self-reactivity, or the loss of binding capability
to MHC. The question remains how this limited pool of TCRs can recognize the
potential number of pathogen-derived antigens without undergoing somatic
hypermutation directed at particular antigens. The prevailing theory explaining the
functional antigen reactivity with limited TCR repertoire is that of TCR degeneracy,
in which TCRs promiscuously bind to multiple peptides. Cross-reactivity of TCRs has
been reported in the range of 2-200 peptides (Ishizuka et al., 2009), with one report
predicted cross-reactivity to over a million different peptides for a single
autoimmune TCR (Wooldridge et al., 2012).

The

TCR

typically

contacts

the

peptide-MHC

complex

with

the

complementarity-determining regions (CDR) 1, 2, and 3. CDR 1 and 2 are germline
encoded and located on the Vα and Vβ genes, and are thought to primarily interact
with the MHC molecule (Figure 6D). CDR3 loops are found at the V(D)J
recombination junction and are thus the most polymorphic (La Gruta et al., 2018).
The CDR3 loop is thought to primarily bind with the peptide within the pMHC
complex and therefore dictate the specificity of the TCR (Figure 6D). αβ T cells
constitute 90-95% of T cells in humans, while the remaining T cells express γδ chains.
TCR receptors have a wide range of affinity to pMHC (0.5uM to >100uM have been
reported), though most affinities are >10uM. It has been reported that most of
TCR/pMHC interactions occur at an angle of ~30 degrees, which appears to be
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important in signal transduction, as TCRs that bind parallel to the pMHC have been
shown to not signal (Jarrett J. Adams et al., 2011; Alcover, Alarcón, & Di Bartolo,
2018). It has also been shown that high affinity, non-agonistic TCRs form “slip bonds”
with pMHC, while agonistic TCRs form “catch bonds” which are capable of
transducing the signal necessary to trigger T cell activation (Sibener et al., 2018).
TCR signaling and activation
The T cell receptor has evolved to trigger signaling with exquisite sensitivity
and specificity to target peptides presented on MHC. The T cell receptor is comprised
of an alpha and beta chain that together determine the antigen specificity of the T cell
clone. The alpha and beta chains heterodimerize at the cell surface with a short
cytoplasmic tail that non-covalently assembles with several different signaling
subunits (typically six subunits: CD3εγ and CD3εδ heterodimers and a TCRζζ).
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Figure 7. Interactions mediating T cell priming (dendritic cell / T cell interaction) and tumor / T cell
interactions. T cell is primed by dendritic cell through signal 1 (pMHC/TCR contact) and signal 2 (CD28/B7;
B7 also called CD80/86). T cell responding to tumor releases secretory granules containing Perforin and
Granzyme (Martínez-Lostao, Anel, & Pardo, 2015).

Long-term T cell mediated immunity relies on priming and proliferation of
specific T cell clones specific against pathogenic antigens. CD8 T cells can be activated
by CD4 T cells, B cells, macrophages, neutrophils, but are most potently activated by
dendritic cells. Naive CD8 T cells encountering their cognate antigens in the context
of activated antigen-presenting cells (APCs) receive co-stimulatory signals via cellcell signals as well as through cytokines. Dendritic cells survey peripheral epithelial
tissue (trafficking more readily to sites of inflammation), ingesting foreign particles
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by phagocytosis and endocytosis, to be processed and presented on their MHC.
Immature dendritic cells are activated through cytokine or pathogen-associated
molecular patterns (PAMPs) binding to pattern recognition receptors (PRRs),
inducing activation of a “danger” response that upregulates the expression of MHC,
co-stimulatory molecules and proper cytokine production, and encourages trafficking
to lymph nodes (Mempel, Henrickson, & von Andrian, 2004). Circulating naive T cells
express the chemokine receptor CCR7 which is essential in trafficking them into the
lymph nodes, in which they encounter APCs. Initial contact between T cell and APC is
stabilized by an interaction between ICAM-1 on the APC and LFA-1 on the T cell,
allowing the TCR to survey MHC of the APC. If TCR is activated by a peptide presented
on the MHC of the APC, LFA-1 is thought to undergo conformational changes,
increasing its affinity to ICAM-1 and prolonging the interaction between T cell and
APC, forming an immune synapse (Ma et al., 2002). If in conjunction with TCR binding
to an antigen on the APC, co-stimulatory signal (B7) is expressed on the APC and
interacts with its receptor on the T cell (CD28), the naïve T cell will become activated
(Figure 7). If the TCR recognizes an antigen on APC (signal 1), in without with a costimulatory signal (signal 2), it will become anergic and lose its ability to respond to
antigen or to become subsequently activated. In order to induce priming of a T cell, it
must simultaneously receive three signals: 1) peptide/MHC complex, 2) costimulatory signal (B7 on dendritic cell binding to CD28 receptor on T cell), and 3)
cytokines controlling differentiation into various types of effector cells. Upon
activation, T cells will express an additional IL-2 chain, the alpha chain, and exit the
lymph node for to survey for their cognate antigen (Liao, Lin, & Leonard, 2013).
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Upon engagement of a TCR with its cognate pMHC, it is thought that a
conformational change is induced within the CD3 cytoplasmic tail, exposing immune
receptor tyrosine-based activation motifs (ITAMs) for phosphorylation by
lymphocyte specific protein tyrosine kinase Lck (Love & Hayes, 2010). Lck is
associated with the cytoplasmic regions of the CD4 and CD8 co-receptors which
cluster with TCR and stabilize the interaction with MHC through their extracellular
domains. Next, the tyrosine kinase ZAP-70 docks to phosphorylated ITAM residues
where it is activated by Lck. Subsequently, ZAP-70 phosphorylates SLP-76, resulting
in the recruitment of multiple SH2 domain-containing effector molecules. These
initial signaling cascades lead to activation of multiple pathways including Ras-MAPK,
NFκB, activation of T cell transcription factors including NFAT, and release of second
messengers including Ca2+ ions from the ER. These signals are further amplified by
activation of costimulatory receptors such as CD28 or cytokine receptors, or
dampened through activation of inhibitory receptors including PD-1 and CTLA-4
(Smith-Garvin, Koretzky, & Jordan, 2009).

Killing by cytotoxic CD8 T cells occurs through induction of caspase-mediated
apoptosis. T cells encountering their target pMHC form an immunological synapse,
also known as the supramolecular activation cluster (SMAC). Clustering of TCRs
signals the cytoskeleton to polarize at the immunologic synapse and allows for
trafficking of pre-formed cytotoxic granules containing Perforin A and Granzyme B to
be released into the synapse. Perforin mediates formation of pores in the target cell,
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allowing the entry of Granzyme B, which cleaves and activates caspase 3 to trigger
the apoptotic cascade, ultimately killing the target cell. Alternate killing mechanisms
including through Fas ligand (FasL) and TNF-related apoptosis inducing ligand
(TRAIL) have been characterized in T cell killing, though the degree to which these
mechanisms contribute to tumor cell killing remains to be elucidated (MartínezLostao et al., 2015).

Immunoediting
The idea that one’s own immune system has the ability to elicit a response
against tumors has existed in various incarnations throughout the centuries dating as
far back as 1777 when the Duke of Kent was injected with tumor tissue as a vaccine
to developing cancer (Ichim, 2005a). The first recorded success of immunotherapy
did not occur until 1891 with William Coley, who used heat-killed bacteria to induce
a cure rate of 10% in soft-tissue sarcoma (Wiemann & Starnes, 1994). In 1909 Paul
Ehrlich postulated that sporadically occurring tumors are recognized and cleared by
the immune system. This theory was built upon by Lewis Thomas and MacFarene
Burnet who postulated that early tumor formation could be halted in
immunocompetent organisms (Burnet, 1957), and was corroborated by the
observation that immunosuppressed solid organ transplant recipients were far more
likely to develop cancer (Birkeland et al., 1995). It remained controversial as to
whether the tumor clearance was specific to virally-induced tumors or whether the
immune system could recognize spontaneously occurring tumors, until the
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development of transgenic mice and monoclonal antibodies targeting specific surface
molecules in the 1990s elucidated a convergence on pathways essential to T cells as
the main players in suppressing tumor initiation. These studies showed that mice
lacking RAG recombinase genes and IFNγ signaling were deficient in their ability to
clear tumors as compared to wild-type mice (Kaplan et al., 1998; Shankaran et al.,
2001), establishing a definitive mechanism between the adaptive immune response
and early tumor elimination.

The role of the immune system in tumor clearance is complicated by its dual
role in either clearance or promotion of tumor growth, either in immunoediting of
tumor cells early in tumorigenesis, or in promoting tumor growth through the
activation of wound healing pathways, proteases, release of reactive oxygen species
(ROS), and the induction of angiogenesis (Grivennikov, Greten, & Karin, 2010). An
improper immune response to tumors has been shown to enhance tumor growth and
is believed to be mediated by Th2 responses and through an antibody-mediated block
of tumor response to cellular immunity (Ichim, 2005). In 1972 Richard Prehn
postulated the idea of immunostimulation of tumor growth, stating that a mild
immune response generated by spontaneous tumors could stimulate carcinogenesis
(Prehn, 1972). Therefore, a weak immune response, in which the immune system is
activated, but in an insufficient magnitude such as to eliminate the tumor cells, may
actually exacerbate tumor growth. This duality can be exemplified in the divergent
immune response to Mycobacterium leprae in either inducing a clearance of infection,
or inducing leprosy as attributed to a Th1 vs Th2 immune response (Modlin, 1994),
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demonstrating importance of type and magnitude of the immune response in
determining outcome.

The theory of early elimination of tumor cells was put forth in its current usage
as cancer “immunoediting,” a process consisting of three stages of tumor evolution:
elimination, equilibrium and escape (Dunn et al., 2004). During the elimination phase,
the host innate and adaptive immune system is able to successfully recognize and
eliminate early cancerous cells. Cells that are not eliminated during this process may
enter into a stalemate with the immune system, in which the balance between tumor
growth and immune elimination reaches a standstill, thought to be driven by the
balance of tumor promoting factors (IL-2 promoting elimination and IL-23 promoting
persistence) (Mittal, Gubin, Schreiber, & Smyth, 2014). If a tumor is to exit its primary
site of origin, it must undergo an escape phase, in which the immune system is no
longer able to recognize the tumor, and perhaps has even been co-opted by the tumor
to promote its own growth. Early elimination can occur by recognition of tumor
antigens through the adaptive immune response, or independently of specific
antigens through cells of the innate immune system such as natural killer (NK cells)
or macrophages. Evasion of these immune responses can occur by multiple
mechanisms including antigen loss, defects in antigen presentation machinery,
expression of immune evasion receptors on the cells surface, formation of an
immunosuppressive tumor microenvironment, exclusion of immune cells from the
tumor site, or a deficiency of oxygen and nutrients within the tumor necessary to
mount a proper immune response (Jerby-Arnon et al., 2018; Mittal et al., 2014;
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Sugiura & Rathmell, 2018; Vuillefroy de Silly, Dietrich, & Walker, 2016). Failure of
tumor mutations to generate antigens that are presented by the immune system is
another mechanism by which tumors can evade early elimination and confer
evolutionary advantages to the tumor cells, as we and others show (Marty et al.,
2017). Antigens may also be presented on tumor cells, but not recognized by immune
cells due to lack of specific receptors in the repertoire, lack of priming, or inhibitory
signals from the tumor cells. When developing strategies for augmenting the immune
response against tumors, each of these challenges must be considered in both the
development of novel therapies and in creating treatment plans for individual
patients.

Cancer Immunotherapy: Antibodies, TCRs, CARs, BiTEs
Over the past decades, an increasing number of therapeutic strategies have
migrated from research labs to clinical applications. Antibodies are immunoglobulin
molecules consisting of two light and two heavy chains composed of various domains,
originating from a single B cell clone in a natural system. The process of somatic
hypermutation rapidly accelerates the evolution of antibody specificity in the B cell,
resulting in molecules with extremely high affinity and specificity that can be several
orders of magnitude stronger in their binding that T cell receptors. This affinity and
specificity has made antibodies a very attractive clinical and research tool for
targeting, identifying, and purifying specificity targets. The clinical applications of
antigen-specific molecules derived from the immune system can be traced back to the
43

development of hybridoma technology in 1975 (KÖHler & Milstein, 1975). From this
milestone, it was another decade before monoclonal antibodies (mAbs) first reached
the clinic in 1986, initially using mouse-derived antibodies targeting CD3 for use in
preventing kidney transplant rejection (Leavy, 2010). These early mAbs suffered
from human anti-mouse antibody responses (HAMA), poor kinetics, and reduced
secondary immune action due to non-human Fc receptors (Liu, 2014). The advent of
recombinant engineering enabled a major leap in the development of antibodies, first
with chimeric antibodies using the Fc portion of the human antibody and the antigenbinding domain (Fab) derived from the immunized host species, to the full
humanization of the antibody. Modern antibody development can be performed fully
in vitro, using phage display libraries (Parmley & Smith, 1988) consisting of fully
humanized single chain variable fragments (scFvs) that can be grafted into a fullchain antibody (K. Li et al., 2015) and expressed at large scales using in vitro
expression systems, allowing the antibody to be specifically tailored for specificity
and secondary function depending on the desired clinical application.

Antibodies targeting cancer were first realized in the clinic with the approval
of Rituximab in 1997, targeting CD20 on B cell tumors. This antibody does not
specifically target tumors, but rather the entire B cell lineage from which they derive,
and is thought to act through antibody dependent cellular cytotoxicity (ADCC)
mediated through complement (Weiner, 2010). Since the initial successes of
Rituximab in the clinic, dozens of additional antibodies have been developed
targeting a growing number of antigens. While antibodies are extremely specific and
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potent in their binding, this binding alone is no always sufficient to elicit death to
target tumor cells. Cell death can be mediated through binding of receptors that
provide growth signals that are essential to tumor cell survival (e.g. anti-EGFR, antiHER2), which is amenable only to targets that provide essential growth signals to a
tumors cell, or through ADCC, which relies on infiltration and activity of secondary
immune components into the tumor. The use of antibodies alone in cancer treatment
is therefore limited by the constraints of these targets. To overcome these constraints
antibodies have also been engineered with conjugated drug payloads for delivery to
target cells, antibody-drug conjugates (ADCs).

Chimeric Antigen Receptors (CARs) and Bispecific T Cell Engagers
(BiTEs)
The advents of antibody engineering and recombinant protein technologies,
paired with developments of technology for gene transfer into T cells, have also
enabled the development of a novel class of synthetic molecules that can be deployed
in cells (chimeric antigen receptors: CARs), and off-the-shelf bi-specific antibodies or
T cell engagers (BiTEs). These approaches combine the potent cytotoxicity of a T cell
with the specificity of an antibody, bypassing the restriction of T cells to MHC antigens
and allowing the targeting of cell membrane proteins. The use of CAR T cells can allow
for a long-term persistence of active T cells following a single injection, leading to the
classification of these therapies as “living drugs,” in which each T cell is capable of
killing multiple tumor cells and establishing a memory population capable of
surveying the host for relapse.
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The idea of a chimeric antigen receptor was first conceptualized by Israeli
scientist Zelig Eshhar during a yearlong sabbatical in the late 1980s in Steven
Rosenberg’s lab at the NIH. The first CAR used an antibody domain fused to the
constant domain of the TCR (Gross, Waks, & Eshhar, 1989), and later linked to
various signaling domains of the CD3 complex (Eshhar, Waks, Gross, & Schindler,
1993). A rapid evolution in CAR design has taken the idea from concept to clinical
success in a relatively short period. The first generation of CARs used a single CD3ζ
chain fused to receptors, which were able to induce calcium influx and T cell
activation. Since tumor cells not express costimulatory signals found on antigenpresenting cells such as CD80, T cell activation in first generation CARs was typically
followed by apoptosis. While expression of CD80 in tumor cells was able to prevent
apoptosis, it was not until the addition of a costimulatory domain in second
generation CARs that the clinical promise of this modality was fully appreciated.
Studies have tested various costimulatory domains including 4-1BB, OX40, DAP10,
and ICOS (Sadelain, Brentjens, & Rivière, 2009). While the addition of the
costimulatory domain was the most important modification in eliciting a clinical
response, other receptor-related parameters that dictate CAR efficacy include its
binding affinity to antigen, location of epitope on target molecule, length of CAR hinge
domain, and tonic signaling induced by the receptor. While most CARs utilize an
antibody-derived antigen-binding domain (scFv), other CARs have utilized receptor
or ligand domains as the targeting moiety to bind its cognate ligand or receptor.
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Another essential component of CAR therapy was the activation of the T cells
being transferred into patients. These protocols dovetailed from efforts in stimulating
CD4 T cells in HIV patients, in which anti-CD3 and anti-CD28 antibodies were used to
activate T cells with signal 1 and 2 (Levine et al., 1998). Early clinical successes using
CARs were achieved using these T cells expansion protocols paired with delivery of
second-generation CAR constructs harboring either 4-1BB or CD28 costimulatory
domains delivered by lentivirus (Maher, Brentjens, Gunset, Rivière, & Sadelain, 2002;
Milone et al., 2009). Since these early studies, it has become apparent that mousederived antibody sequences can trigger the rejection of CARs so humanized
sequences have become preferable. Response rates using 4-1BB CARs targeting CD19
have been reported up to 93% in B cell ALL. This treatment is exemplified in its first
recipient, Emily Whitehead, who shed 1kg of tumor mass and experienced an
expansion of T cells that resulted in 1kg of CAR T cells in circulation following
treatment; she remains tumor free 7 years following treatment at the time of this
writing (June & Sadelain, 2018). Side effects include the predicted on-target, offtumor B cell aplasia, and side effects due to with significant release of high levels of
cytokines associated with fever, hypertension, hypoxia, and unexpected neurological
toxicity (recently attributed to CD19 expression in pericytes; Avery Posey
unpublished). These side effects correlate with the tumor burden, and regress upon
withdrawal of T cells. These effects can be managed using anti-IL6R antibodies
(Tocilizumab), which has been FDA approved for managing cytokine release
syndrome associated with CAR T cell therapy. Moving CAR T therapy to an earlier line
of treatment is also expected to reduce treatment-related side effects.
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Various CAR trials have been launched targeting the majority of membrane
proteins which have been previously targeted using monoclonal antibodies, given the
ease of grafting known antibody sequences into CAR receptors, but clinical success
has largely been limited to liquid tumors to date. Though T cells can eliminate solid
tumors, as demonstrated by checkpoint inhibition and adoptive transfer of TILs, only
a single striking case has been reported using CAR T cells targeting IL-13 receptor
alpha 2 in multifocal glioblastoma using intracranially-delivered T cells (Brown et al.,
2016). Other challenges in CARs have been in T cell persistence, as T cells derived
from patients after chemotherapy are often sub-optimally functional. Efforts to
collect T cells from patients prior to treatment are being explored to mitigate this
challenge. Gene transfer, antibody, and small molecule approaches have been
deployed in tuning T cell phenotypes and functions (i.e. improved survival, expansion,
generation of memory subsets, reduction of apoptosis, anergy, and immune
suppression) necessary to overcome the immunosuppressive microenvironment of
solid tumors. These include deletions of genes including PD-1, CTLA4, LAG-3, TIM-3,
TIGIT, TGFBR2, and others (M. A. Morgan & Schambach, 2018). Other modifications
have been used to direct T cell extravasation and trafficking into desired tissues to
increase T cell availability in tumors (Slaney, Kershaw, & Darcy, 2014). Further efforts
have focused on the development of safety switches which use inducible suicide
genes to deplete genetically modified T cells in case adverse events are observed
(Casucci et al., 2012).
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Additional work is directed at developing logic-gated CARs such as AND-gated
CARs requiring the presence of two antigens, or NOT-gated CARs requiring the
presence of one antigen and absence of the other. Furthermore, T cells are being
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Figure 8. Comparison of CARs and TCRs. A) Summary of CAR/TCR properties. B) Comparison of
CAR/TCR structure. Multiple signaling domains present in TCR, while CARs are limited in signaling
domains to those which can be expressed on a single chain. C) Sensitivity of immunotherapies to number
of molecules on target cell surface ranging from 100,000 molecules for an unmodified antibody to 1
molecule for a TCR (Fesnak, June, & Levine, 2016; June, O’Connor, Kawalekar, Ghassemi, & Milone,
2018; Preeti Sharma & David M. Kranz, 2016).

modified to secrete cytokines and other molecules to enhance T cell activity and
trafficking. Other efforts are focused on the development of off-the-shelf CAR T cells
which would allow reduce manufacturing costs and batch-to-batch variability as well
as allowing for better control of T cell populations, which have been stymied by
immune rejection from the host (June & Sadelain, 2018). Many CAR constructs have
been shown to induce T cell signaling independent of antigen exposure, presumably
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due to aggregation of scFv at the cell surface (Ajina & Maher, 2018). Strategies for
engineering CAR receptors, costimulatory domains as well as modifying T cells to
restore activity under immunosuppressive conditions are rapidly evolving, and the
most effective approaches have yet to be determined.

TCR-based therapies
Early studies using adoptive transfer of T cells were pioneered by Steven
Rosenberg at the NIH, using expanded resident tumor-infiltrating lymphocytes (TILs)
in combination with IL-2 (Rosenberg et al., 1994). These treatments have resulted in
remarkable regression of advanced tumors, with objective responses reported
between 40-70% (Rosenberg et al., 2011). While these therapies have demonstrated
encouraging results in patients, they suffer from several limitations: 1) prerequisite
of existing tumor-responsive T cell population within the tumor, 2) ability to reverse
exhaustion of these T cell subpopulations and elicit expansion, and 3) scaling
limitations due to intensive labor and cost. As has been revealed through minigene
approaches in identifying the antigen targets of expanded TILs, these T cells are
responding to neoantigens derived from SNVs as characterized by tumor sequencing
(Lu et al., 2014b). Combined, these facts make it unlikely that TIL-based therapies will
be successful in low-to-medium mutation tumors, and extremely unlikely in cold
tumors lacking infiltrating T cells.

Transfer of T cells genetically modified with TCRs targeting NY-ESO-1 and
MART-1 have recently led to the a number of clinical responses in synovial sarcoma,
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melanoma, and multiple myeloma, reporting objective responses between 55-80%
and complete regressions between 2-20% (Hammerl, Rieder, Martens, Trajanoski, &
Debets, 2018; Robbins et al., 2015). TCR-based therapies face unique challenges in
the identification of peptides presented on the MHC of tumors and not in that of
normal tissues. Of 276 known cancer germline antigens (cancer/testis antigens), only
60 have been reported to be transcriptionally silent in non-germline tissue (Caballero
& Chen, 2009). This matter is further complicated by antigens that are specifically
expressed in tumors, but may elicit cross-reactivity similar peptides derived from
normally expressed genes, such as resulted in lethal cardiac toxicity due to a MAGEA3 affinity-enhanced TCR cross-reacting with a peptide derived from Titin in heart
tissue (Linette et al., 2013).

Immunotherapy bottlenecks
The field of immuno-oncology is blossoming after a prolonged nascent period,
fueled by a research-driven understanding of the immune system which has
translated into a number of clinical successes, namely: 1) immune checkpoint
inhibitors which reinvigorate the existing repertoire of T cells in the patient, 2)
adoptive T cell therapies which either expand existing tumor infiltrating lymphocytes
(TILs), or use synthetically designed receptors to redirect the immune system. Other
therapies including vaccines, bispecific engagers, universal (allogeneic) T cells, and
cellular alternatives to T cells (such as NK cells and macrophages) are showing
preliminary signs of efficacy. The production, manufacturing, and delivery
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technologies is rapidly evolving, with the goal of scaling delivery of cell therapy to an
increasing population of patients.

Several bottlenecks currently limit the full implementation of personalized
precision oncology. One of the major bottlenecks is the availability of safe and potent
targets that are accessible by the immune system. This problem can be broken down
into two subsets: 1) Most cellular immunotherapies are directed at cell surface
targets, which comprise only 16% of the 719 cancer genes defined by the Cancer Gene
Census (Sondka et al., 2018). Of these, relatively few are differentially expressed to
the degree necessary for a sufficient therapeutic window necessary for effective
immunotherapy. 2) Most current efforts directed at intracellular cancer targets
(immune checkpoint inhibitors included), are directed at neoantigens. While these
therapies have been remarkably successful in tumors bearing a high burden of
mutations (i.e. melanoma, lung cancer), the vast majority of patients do not meet this
threshold. Furthermore, even patients expressing neoantigens may lack the T cells
necessary to engage those targets. In our modeling of immunogenicity in The Cancer
Genome Atlas (TCGA), we find that <10% of mutations are predicted to generate
neoantigens on a given HLA allele, far fewer of those are actually processed and
presented as antigens, of which only a small fraction are able to initiate an immune
response. In fact, most neoantigens that are presented and are immunogenic, are
derived from mutations that are not essential to the survival of the tumor
(Schumacher & Schreiber, 2015), and most of these neoantigens are private (they
require a unique combination of given mutation and HLA allele), and thus are non-
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recurrent across cancer patients. We find that mutations in some of the most
important and common cancer driver genes (i.e. KRAS G12D and BRAF V600E), are
immunogenically silent, meaning that they are predicted to bind none of the most
common HLA alleles representing 99.4% of the US population. Taken together, we
predict that >70% of cancer genes are inaccessible to current immunotherapies.

Beyond the paucity of targets, solid tumors pose a number of challenges for T
cell-based immunotherapy. The presence of myeloid-derived suppressor cells
(MDSCs), cancer-associated fibroblasts, M2 macrophages, and tumor-suppressive
extracellular matrix, contribute to an immunosuppressive microenvironment. T cells
within the tumor are further challenged by hypoxic conditions, and competition with
glycolytic tumor cells for nutrients. While multiple groups are investigating efforts to
mitigate the challenges of the tumor microenvironment, our focus is on target
discovery, receptor engineer, and safety optimization.
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Chapter 2: Therapeutic Targeting of Lineage Restricted
Oncoproteins in Immunologically Silent Cancer
Summary
Despite the recent clinical successes of CAR T cells in leukemias, similar
activity has not been realized in solid malignancies, at least in part due to the paucity
of known tumor-specific immunotherapeutic targets. High-risk neuroblastoma is a
lethal childhood cancer that is characterized by low mutational burden, low MHC
expression, and the absence of T cells in the tumor microenvironment, making it an
excellent model for cancers unresponsive to current immunotherapeutic modalities.
Here, we used DNA and RNA sequencing paired with MHC-bound peptide mass
spectrometry in 16 human neuroblastoma samples to identify and prioritize tumorspecific antigens for preclinical development. We first show that despite low MHC
expression, these tumors present an abundance of tumor-specific epitopes on
common HLA alleles derived from recurring self-antigens, including transcription
factors functioning as non-mutated oncoproteins. We then validated these antigens
and develop TCR and CAR T cell constructs capable of recognizing tumor-specific selfantigens presented on the MHC that mediate specific tumor cell killing. These
methods can be employed for the identification of novel targets across low mutational
tumors and for engineering receptors to specifically target these antigens. We think
that this strategy provides a robust and reproducible process that can potentiate
therapeutic targeting of many human cancers for which safe and effective
immunotherapies have yet to be developed.
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Introduction
The field of immunotherapy has entered a renaissance period in recent years
with developments in adoptive T cell therapy, immune checkpoint inhibition, and
cancer vaccines. Clinical successes have been achieved with various treatment
modalities in a limited subset of cancer patients. However, widespread efficacy
remains limited by several challenges including a paucity of tumor-specific
immunotherapy targets, physical and biochemical immune suppression within the
tumor microenvironment, and availability of tumor-specific immune cells in the
repertoire. To date, immune checkpoint inhibitors have found the greatest success in
tumors with high mutational burden, while CAR T cells have been most successful in
leukemias, leaving the majority of cancer patients with low-to-medium mutation
solid tumors with few if any immunotherapeutic options.

TCR therapies are believed to be more sensitive to low antigen density, less
likely to cross-react towards the MHC, and to date have shown signs of efficacy in
some solid malignancies. CAR T approaches are able to bind non-MHC-antigens, with
the major focus to date on targeting plasma membrane-bound proteins such as CD19.
Efficacy of CAR T cells have been limited in solid malignancies for multiple reasons
that span specificity of the targets and nuances of cellular engineering and
biomechanics of T cell navigating immunosuppressive TMEs. To date, and nonspecific binding to the HLA molecule has limited the ability to target nonimmunogenic intracellular oncoproteins (Maus et al., 2016).
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Due to negative thymic selection, the presence of TCRs directed against tumor
self-antigens may be absent or minimal in cancer patients, thereby potentially
limiting the immune response against peptides derived from lineage restricted
oncoproteins. Thus far, most TCR-based therapies have targeted cancer/testis (CT)
antigens (i.e. NY-ESO-1, MART-1, MAGE-A3). Though initially believed to be restricted
to tumors and 276 antigens were reported to be CT antigens, RNA-sequencing
revealed that only 60 of these were transcriptionally silent in normal tissue
(Caballero & Chen, 2009). Furthermore, while some CT antigens may be specific to
tumors and silent in normal tissue, these antigens are not considered essential
tumorigenesis. While de novo engineering of TCRs has remained limited by the
complexity of V, D, and J family genes in addition to CDR hypervariable loops,
saturation mutagenesis techniques paired with phage technology has allowed for the
generation of highly diverse scFv libraries with novel specificities that can be
deployed in targeting non-immunogenic epitopes.

Neuroblastoma is a childhood tumor derived from the developing sympathetic
nervous system, and suffers from four challenges as related to immunotherapy: 1)
low mutational burden (Pugh et al., 2013), 2) low MHC expression (Woelfl et al.,
2005), 3) low infiltration of T cells into the tumor (Layer et al., 2017), and 4)
immunosuppressive tumor microenvironment (Pistoia et al., 2013). These factors
combine to make neuroblastoma an ideal model for overcoming several of the major
challenges currently preventing the widespread implementation of cancer
immunotherapies. Immunotherapy has been credentialed in this disease, with recent
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Food and Drug Administration approval of the GD2-directed chimeric monoclonal
antibody dinutuximab that can prolong relapse-free survival (Mora, 2016; Yu et al.,
2010). In addition, antibody- and T cell-based therapies are in clinical testing for
neuroblastoma-specific plasma membrane proteins ALK, CD276 (B7H3), GPC2 and
L1CAM (Kristopher R. Bosse et al., 2017; Künkele et al., 2017; Richards et al., 2018;
Sano et al., 2019; Seaman et al., 2017). To date, these therapies have not let to durable
responses in patients, suggesting the need for discovery of additional neuroblastomaspecific immunotherapeutic targets. As a tumor derived from neuroblast progenitor
cells, neuroblastomas express an array of transcription factors involved in
maintaining cell fate, metabolism, migration, epigenetic states, growth, and
proliferation. These transcriptional circuits are repressed upon differentiation into
mature nerve cells and not expressed in adult tissues, making these potentially ideal
immunotherapy targets, as they have generally been considered undruggable using
small molecules or degrader approaches.

Here we report the characterization of antigen presentation and T cell
response in neuroblastoma and the discovery of tumor-specific antigens derived
from lineage-restricted genes, non-canonical parent transcripts, and newly
discovered phospho-peptides. Focusing on self-peptides derived from lineagerestricted oncoproteins in neuroblastoma, we prioritized 6 antigens for preclinical
development of TCR and CAR T approaches. We show that we can achieve potent
tumor killing using both approaches and are pursuing optimization of these receptor
constructs to improve specificity for preclinical development.
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Results
Neuroblastoma cells can process and present antigens on MHC
class I despite low MHC expression
As has been previously reported (Woelfl et al., 2005), here we show by IHC
that neuroblastoma tumors are low in MHC expression (Figure S6). We show that
IHC staining correlates with HLA expression measured by RNA-sequencing, but that
PDX tumors express an 26.8-fold greater expression of HLA than their matched cell
lines, suggesting that HLA expression may be artificially low in tumor cells grown in
tissue culture (Figure S6C; p = 0.004). To test whether low MHC expression would
preclude neuroblastoma from inducing a T cell response, we measured cytokine
release upon co-culture of HLA-A*02 neuroblastoma cells with the M1 influenza
matrix protein antigen-specific T hybridoma after treatment of neuroblastoma cells
with either synthetic peptide derived from the influenza matrix protein CEF1 or
infection with H1N1 influenza virus (Figure S1B). We find that despite low MHC
expression, many of the neuroblastoma cell lines are able to induce a response
comparable in magnitude to A375 melanoma cells. We find that 4/7 HLA-A*02 lines
tested induce T cell activation with synthetic peptide, and 3/7 lines induce a response
to H1N1 virus exposure (Figure S1C). NLF demonstrates a response to synthetic
peptide, but demonstrates no T cell reactivity with infected cells, suggesting a defect
in antigen processing machinery in this line. We found no correlation between HLA
expression and ability to induce a response to viral antigen in neuroblastoma (Figure
S1D/E). While no correlation with MHC expression is observed, MYCN amplified
tumors showed a diminished ability to induce a T cell response unrelated to MHC
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expression, suggesting that MYCN may act to suppress T cell activation through
alternative mechanisms (p = 0.0006; Figure S1D/E). These data in cell lines that have
been in culture for many years suggest that low MHC expression is not an
insurmountable barrier to MHC-directed therapies in neuroblastoma, and that
further investigation is needed into immune evasion mechanisms beyond MHC
downregulation.

Identification of tumor-specific antigens in neuroblastoma using
combined proteomics and genomics approaches
We next sought to explore the presence of tumor-specific antigens in
neuroblastoma. We performed MHC capture, peptide elution, and LC/MS/MS
(Kowalewski & Stevanović, 2013) in 8 PDX tumors selected based on diversity of
genomic features, selecting tumors based on varying levels of MHC expression, and
presence of an array of recurrent mutations found in NBL (Figure S1A). We identified
a total of 497,501 peptides from these 8 tumors, which were significantly enriched in
peptides derived from highly expressed genes (p = 0.0006 – 2.2e-16), with the number
of antigens derived from each tumor correlated to the mass of the tumor and HLA
expression (R2 = 0.56; Figure S2H). We used the PHLAT algorithm (Bai, Ni, Cooper,
Wei, & Fury, 2014) on genomic sequencing data previously generated in the lab (Pugh
et al., 2013), to perform HLA-typing, which was validated through direct genotyping
of 15 HLA alleles (Figure S2B). We then used imputed mutations from genomic data
paired with tumor HLA to predict for neoantigens in each tumor. Of the 4,105
potential 8-14mer neoantigens derived from 75 mutations across these eight PDX
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models, none were detected in our mass spectrometry data, consistent with expected
rates of neoantigen detection using ligandomics in highly mutated tumors (BassaniSternberg et al., 2016).

Not having detected any neoantigens in our immunopeptidomics data, we next
sought to identify lineage-restricted self tumor-derived antigens. We used NetMHC4.0 (Andreatta & Nielsen, 2016) to predict binding affinities between peptides
identified by ligandomics with HLA alleles imputed by PHLAT for each tumor. Of the
497,501 peptides identified by ligandomics, we first filtered for those with sufficient
binding affinity to act as T cell epitopes using <500nM as a stringent cut-off, resulting
in 14,119 peptides. We then further filtered for differential gene expression as
calculated from RNA sequencing data from 153 neuroblastoma tumors from the
TARGET project (https://ocg.cancer.gov/programs/target) and the GTEx (GenotypeTissue Expression) database of 1641 normal tissues (https://gtexportal.org/home/),
resulting in 338 peptides derived from differentially expressed genes. Finally, we
filtered the remaining peptides against a database of MHC peptides experimentally
determined to be presented in one or more of 190 normal tissues, leaving only 83
peptides (Figure 1B). To select those peptides most relevant for preclinical
development, we prioritized these peptides based on p/MHC binding affinity, HLA
alleles frequency, degree of differential expression, relative abundance by MS/MS,
recurrence across multiple NBL tumors, and relevance to tumor biology (Furlan,
Lübke, Adameyko, Lallemend, & Ernfors, 2013; Guo et al., 2018; Lee et al., 2016; Z. Li
et al., 2019; Marachelian et al., 2017; Raabe et al., 2007), selecting 6 peptides as top
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candidates for clinical development (Figure 1C). We find multiple tumor-specific
peptides recur across multiple tumors, including a single peptide derived from the
differentially expressed gene CHRNA3 identified in 7/8 PDX tumors. We validated the
presence of these peptides in tumors by performing LC/MS/MS on synthetic peptides
(Figure S5G).

Having identified promising clinical immunotherapy targets in PDX tumors,
we repeated the ligandomics experiment using 8 high risk primary tumors, selected
for HLA-A*02:01 and HLA-A*24:02 and ranging in HLA expression. We confirmed the
presence of 4/5 prioritized targets from PDX tumors, and identify an additional two
that were not detected in PDX tumors. Interestingly, a GO analysis performed on the
parent genes of the peptides not previously observed in the healthy ligandomics
dataset results in a single result: sympathetic nervous system development (Figure
1D), in concordance with neuroblastoma being a tumor of neural crest cells,
highlighting the uniqueness of the global neuroblastoma ligandome. Importantly, we
show that the PDX ligandome is representative of that in patient tumors, suggesting
that PDX tumors are a useful model for identification of tumor antigens presented on
MHC. To predict the ability of a tumor to evade the immune response by
downregulation of target genes, we examined the binding of neuroblastoma core
regulatory circuit transcription factors (MYCN, HAND2, ISL1, PHOX2B, GATA3, and
TBX2) to the parent genes of the prioritized antigens (Boeva et al., 2017; Decaesteker
et al., 2018; Durbin et al., 2018; van Groningen et al., 2017). We find that all six core
regulator circuit proteins bind to the parent gene loci, and are associated with an
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H3K27Ac super-enhancer marker (Figure 1F), suggesting that antigen loss due to
downregulation of parent genes will be unlikely.

In addition to tumor-specific antigens derived from lineage-restricted
neuroblastoma genes, we characterized the presence of MHC-presented antigens
derived from non-canonical protein reads (i.e. those derived from alternative splice
junctions, indels, read-throughs, and frameshifts). Based on upregulation of
alternative splicing machinery in neuroblastoma (Figure S2F), we expected that noncanonical peptides may serve as another source of tumor-specific antigens. We
generated a search space of all possible peptides derived from non-canonical RNAseq reads, finding 116 peptides mapping to non-canonical reads in SKNAS tumors. In
addition,

performing

an

enrichment

for

phospho-peptides

uncovered

7

phosphorylated peptides presented on MHC (Figure S2E), 4 of which had not
previously been characterized in the PhosphoSitePlus database. Though these may
serve as promising tumor targets for future development, in this report we chose to
focus on tumor-specific antigens derived from lineage-restricted neuroblastoma
genes, as these offer the highest degree of confidence in the tumor-specificity of these
peptides.

TCR development
Due to limitations in obtaining sufficient quantities of PBMC from pediatric
patients, along with recent reports of normal HLA-matched donors as a superior
source of neoantigen-specific T cells (Strønen et al., 2016), we hypothesized that
normal HLA-matched donors can be a potential source of self-antigen specific T cells
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against non-mutated neuroblastoma antigens. We collected samples from four HLAA*02:01 patients and double-stained each with dextramers directed against two
different antigens presented on HLA-A*02:01 in neuroblastoma. We find a wide range
of antigen-specific CD8 cells across donors and antigens, but conclude that a rare
population (0.0016% - 0.12%; Figure S7B/C) of antigen-specific CD8 cells can be
detected in normal donors. In our initial attempt at identifying TCRs capable of
recognizing neuroblastoma antigens, we sorted antigen-specific CD8 cells and
performed paired alpha/beta V(D)J sequencing. While some TCRs identified
demonstrate strong binding to antigen, the functionality of these TCRs was minimal,
consistent with recent reports describing the decoupling of TCR affinity and
functionality (Sibener et al., 2018).

To select for functionally active T cells, we performed a magnetic bead
enrichment of CD8 cells stained with neuroblastoma antigen dextramers (Figure 2A),
then co-cultured with monocyte-derived matured dendritic cells pulsed with
synthetic neuroblastoma peptide. After two rounds of stimulation, we found a
significant expansion of tumor-specific antigens in samples pulsed with matched
peptide, but not in those pulsed with viral CEF1 peptide (Figure 2B). We double
stained the expanded CD8 cells with matched and mismatched dextramer, sorting for
the single-antigen specific cells. We performed single cell V(D)J paired alpha/beta
sequencing on the sorted population of expanded antigen-specific CD8 cells, finding
various degrees of clonal T cell expansion across antigens (Figure 2C). We prioritized
clones based on clonal expansion and homology of non-germline CDR3 loops (Dash
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et al., 2017) of sorted antigen-specific CD8 cells (Figure 2D) and synthesized
bicistronic constructs expressing alpha and beta chains separated by ribosomal skip
site F2A and cleavable furin site (Yang et al., 2008). We transduced TCR constructs
into Jurkat/MA cells transduced with an NFAT-driven luciferase construct (Calogero
et al., 2000) and stained with cognate dextramer, demonstrating IGFBPL1 antigenspecific binding (Figure 2E). Jurkat/MA cells transduced with a TCR vector encoding
the alpha and beta chains of the most significantly expanded T cell clone (A1), cocultured with T2 cells pulsed with matched and mismatched peptides, results in
specific activation when incubated with matched peptide and tumor cells but not
mismatched peptide (Figure 2F). Transduction of A1 into primary CD8 cells and coculture with a neuroblastoma cell line from which the tumor antigen was identified
shows a significant anti-tumor response (Figure 2G). We show that TCRs are present
in the repertoire of normal donors capable of inducing a functional response against
tumor self-antigens, and describe a process whereby rare antigen-specific cells can
be expanded, sequenced, and screened. Ongoing work is directed at testing the crossreactivity and safety of the TCRs identified in this screen and performing preclinical
efficacy studies.

CAR T cell engineering
To generate CAR T cells specific to neuroblastoma self-antigens, we used an
excess of irrelevant peptide bound to matched MHC, to deplete the library of crossreactive binders to the MHC molecule. We then used tumor p/MHC to select for
specific binders specifically binding to tumor antigen. After 3 rounds of selection, we
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performed sandwich ELISA to measure the binding affinity of the resulting scFvs,
using both the on-target and decoy p/MHC (Figure 3A). We prioritized those binders
with the highest degree of separation for sequencing and synthesized second
generation CAR constructs using 4-1BB signaling domains (Figure 3C; antiPHOX2B/HLA-A*24:02). We purified scFv and stained tumors cell lines derived from
matched PDX samples, identifying scFv constructs (Figure 3B; A7 PHOX2B construct)
that bind to tumor cells, but not in HLA-mismatched neuroblastoma lines. We
transduced the A7 anti-PHOX2B CAR construct into Jurkat cells and stained with
PHOX2B/HLA-A*24:02 dextramer, finding strong binding to the target antigen, but
not to antigens on HLA-A*02:01 (Figure 3C). We then transduced the A7 construct
into primary CD8 cells and co-cultured with HLA-A*24:02 neuroblastoma lines in
which the PHOX2B peptide was detected by ligandomics. We find that A7-transduced
CD8 cells are able to kill 100% of neuroblastoma cells within 24 hours of co-culture
at a 2:1 E:T ratio (Figure 3F, S8A), while CD8 cells transduced with non-specific CAR
results in significant tumor cell outgrowth (Figure S8A; Supplemental Video 1). To
screen for initial cross-reactivity, we double-stained A7 CAR with PHOX2B/HLAA*24:02 dextramer and mismatched peptide on HLA-A*24:02. We find that while the
construct predominantly binds to PHOX2B, a significant amount of cross-reactivity is
observed at higher affinities (Figure 3E). To test whether this would result in nonspecific tumor killing, we co-cultured A7 CAR with SW620 colon cancer cells as an
HLA+/antigen- control (Figure 3G, S8C). We find that A7 CAR is able to kill SW620,
but to a lesser extent than HLA+/antigen+ neuroblastoma cells (Figure 3G). We
hypothesized that while A7 preferentially binds to the PHOX2B/HLA-A*24:02
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complex, there is non-specific binding towards the HLA-A*24:02 molecule itself. We
thus set out to identify the A7/HLA-A*24:02 binding interface to abrogate nonspecific HLA binding. Using a bacterial line with defective DNA repair enzymes, we
created a library of randomly mutagenized A7 CAR constructs (Figure S9A),
transduced them into Jurkat cells, and double-stained with PHOX2B and mismatched
peptide on HLA-A*24:02. We find that while most mutations result in non-productive
CAR receptors, a rare population of cells have single-specificity to PHOX2B and not
mismatched peptide on HLA-A*24:02 (Figure S9B), suggesting that random
mutations are able to abrogate the binding interface between A7 scFv and HLAA*24:02. Ongoing work is focused on identifying the amino acids at the interface of
the scFv/HLA and performing saturation mutagenesis at these sites to optimize the
specificity of this CAR. An additional CAR construct (F11) has been identified against
the IGFBPL1 tumor peptide presented on HLA-A*02:01, with no measurable crossreactivity towards matched HLA (Figure S10B), and activity against neuroblastoma
cells (Figure S10C). We demonstrate that CAR constructs can be engineered with
potent tumor killing ability against tumor self-antigens, and that cross-reactivity of
the constructs against HLA molecules can be abrogated using mutagenesis
techniques.
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Discussion

As rapid progress is made in engineering T cells to overcome immune barriers
in T cell exhaustion and immune cell exclusion and suppression within
microenvironment, a major remaining challenge is the identification of tumorspecific targets for tumors harboring neither neoantigens nor highly differentially
expressed surface proteins. In neuroblastoma we find that low MHC expression does
not prohibit a productive antigen-specific T cell response. Interestingly, we show that
a number of MHC antigens can be identified from tumors that do not stain for MHC
using immunohistochemistry, suggesting that the sensitivity of ligandomics is below
the detection threshold of IHC. We show that neuroblastoma ligandome results in
only one GO enrichment term (developmental nervous system genes), highlighting
the uniqueness of the global neuroblastoma ligandome. Given that we did not identify
neoantigens resulting from known mutations in tumor samples, we searched for
tumor-specific antigens from alternative sources. From this set of presented peptides,
we identify and prioritize 6 targets with excellent properties for preclinical
development based on recurrence across multiple tumors, binding affinity, relative
abundance, level of differential expression, absence on the normal tissue ligandome,
and relevance to tumor biology. Though we chose to focus on lineage-restricted selfantigens in this study, we also find MHC-presented peptides derived that map to noncanonical RNA reads from as well as novel phospho-peptides.
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We show that both CARs and TCRs can be generated to self-tumor-antigens,
and demonstrate potent anti-tumor activity against cell lines matched to PDX tumors
from which tumor antigens were originally identified. Ongoing work is focused on
safety and efficacy screening of current CAR/TCR constructs and development of
additional receptors for other neuroblastoma antigens. We anticipate that we will be
able to test a range of constructs to compare efficacy against different neuroblastoma
targets as well as a comparison between CARs and TCRs directed at a single target.
We expect that the methods presented herein will facilitate the discovery of tumorspecific targets in additional low-to-medium mutational burden tumors, and provide
approaches for developing and optimizing receptors that specifically identify these
targets. It is our hope that these methods can be paired with rapidly-evolving
multiplexing technologies in pursuit of personalized immunotherapy.
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Figures and Legends
Figure 1. Tumor-specific antigen discovery in neuroblastoma
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Figure 1. Tumor antigen discovery in neuroblastoma. (A, B) Tumor discovery
workflow. MHC was purified and peptides eluted from PDX and primary
neuroblastoma tumors and characterized peptide sequences by MS/MS. HLA types
were inferred from exome sequences for these tumors using PHLAT, and
subsequently obtained predicted MHC binding affinities for eluted peptides using
NetMHC. Antigens derived from differentially expressed genes (determined by
comparing 153 NB cases to the GTEx database of normal tissue gene expression) were
compared against a database of MHC presented peptides from 190 healthy tissues,
resulting in the discovery of 83 neuroblastoma antigens not previously observed in
healthy tissues. (C) Antigens were prioritized for preclinical development based on
relative abundance on MHC, frequency of HLA allele on which peptide is presented,
binding affinity to MHC, recurrence across tumors, and relevance of parent gene to
neuroblastoma biology. Prioritized antigens derive from IGFBPL1, GFRA2, CHRNA3,
PHOX2B, and TH. (D) Representation of predicted binders from neuroblastoma
ligandome on primary tumors. 11,587 unique peptides derived from 5,002 parent
genes represented on x-axis. Percent of neuroblastoma tumors on which each antigen
is presented (red) and percent of normal tissue on which the same antigen is
presented (blue) on y-axis. GO analysis of parent genes from antigens uniquely
presented in on neuroblastoma yields single enrichment term: sympathetic nervous
system development. (E) Differential expression of parent genes for two prioritized
antigens (PHOX2B). First column depicts box-and-whisker plot of RNA-seq data from
153 neuroblastoma tumors and subsequent columns depict normal tissue expression
from 1,643 normal tissues from GTEx database across various organ sites. (F) Binding
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of 6 prioritized neuroblastoma antigens by 6 transcription factors in the core
regulatory circuit (ASCL1, GATA3, HAND2, ISL1, MYCN, PHOX2B, and TBX2) as well
as H3K27Ac peaks.
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Figure 2. Development of antigen-specific TCRs for neuroblastoma antigens. (A)
Bead enrichment of dextramer stained CD8 cells in the presence of dasatinib results
in 18-fold enrichment of antigen-specific T cells. (B) Co-culture of enriched antigenspecific T cells derived from 100e6 normal donor CD8 cells with matured dendritic
cells pulsed with tumor peptide results in significant expansion of antigen specific
population. CEF1 flu antigen causes significant CD8 cell expansion, but does not stain
with NB antigen dextramer (left panels), whereas staining of NB antigen-expanded
cells shows in significant antigen-specific expansion (right panels). Double staining of
TH antigen with mismatched dextramer on y-axis reveals non-specific population, as
well as single specific population used for sorting. (C) Clonality plot of TCRs detected
by single-cell V(D)J sequencing of IGFBPL1-expanded CD8 cells reveals dominant
clone (A1) representing 24.6% of sequenced cells. (D) Hierarchical clustering of nongermline CDR3 motifs from sorted IGFBP1 antigen-specific CD8 cells reveals
enrichment of preferred alpha and beta sequences used to prioritize A1 clone. (E)
Staining of Jurkat cells transduced with A1 alpha/beta pair shows antigen-specific
staining with IGFBPL1 dextramer. (F) T2 cells pulsed with matched peptide and EBC1
tumor cells from which IGFBPL1 peptide was identified, induce robust luciferase
signal, but not in T2 cells pulsed with mismatched peptide. (G) Primary CD8 cells
transduced with A1 construct co-cultured with EBC1 tumor cells show significant
anti-tumor activity as measured by cleaved caspase 3/7 on Incucyte, but not in EBC1
cells co-cultured with low activity TCR.
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Figure 3. Development of an5gen-speciﬁc CARs for neuroblastoma
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Figure 3. Development of antigen-specific CARs for neuroblastoma antigens. (A)
ELISA of PHOX2B scFv A7 using PHOX2B p/MHC and decoy peptide on HLA-A*24:02.
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(B) PHOX2B scFvs bind to EBC1 tumor cells as detected by anti-FLAG antibody. (C)
Schematic of second-generation CAR constructs. (D) A7 CAR transduced into primary
CD8 cells binds PHOX2B dextramer but not HLA-A*02:01 dextramer. (E) A7 CAR
preferentially binds PHOX2B dextramer but cross-reacts with mismatched peptide
on HLA-A*24:02 at high affinity. (F) A7 CAR shows potent killing against SKNAS cells
at (E:T) ratios from 2:1 to 1:2. (G) A7 CAR preferentially kills HLA+/antigen+ cells,
but also kills HLA+/antigen- tumor cells.
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Figure S1. Neuroblastoma an4gen processing, presenta4on, and
immunogenicity
A

B

100

1) antigen-specific
T cell hybridoma

90

IL-2

80
CEF1 peptide pulsing

% cells infected

70

MHC class I (HLA:A2)

60

2) H1N5
influenza
virus

50
40

flu protein

30

NB cell

20

proteasome

ER

TAP

10
0
0

BE2C

50

EBC1

100
Flu dose (HAU)
NBSD

NB1

150

NB69

200

SKNAS

THP1

60

null

C

5uM peptide
50

50 HAU PR8

40

30

20

10

**
-

IFN-gamma

+

-

SKNFI

D

T-cell ac3va3on (pg/mL IL-2)

HLA-A2NB

-

+

A375

+

NB69

-

+

EBC1

+

NBSD

HLA-A2+
melanoma

10000

-

+

BE2C

NLF

15000

E

S1.

Neuroblastoma

+

-

IMR5

+

NB1

**NB1: HLA-A*02:06
CEF1 binding affinity:

45
40
35
30
25
20
15
10
5
0

MNN
MNA
P=0.013

0

IFN-gamma induced HLA class I

Figure

-

+

HLA-A*02:06: 41.2nM
HLA-A*02:01: 15.7nM

MNN
MNA
P=0.0006

5000

-

HLA-A2+ NB lines

50
45
40
35
30
25
20
15
10
5
0
0

-

T-cell ac3va3on (pg/mL IL-2)

0

5

10

15

20

HLA-A RPKM

antigen

processing,

presentation,

and

immunogenicity. (A) Viral titration of neuroblastoma cells using H1N5 influenza
77

virus at doses measured by FACS staining of viral nucleoprotein expression at doses
0-200 HAU. (B) Experimental schematic of assay: 1) HLA-A2 neuroblastoma cells are
pulsed with 5uM CEF1 peptide and co-cultured with M1 antigen-specific hybridoma
and IL-2 release is measured by ELISA; 2) Neuroblastoma cells are infected with 50
HAU of H1N5, co-cultured with M1 antigen-specific hybridoma, and IL-2 release
measured by ELISA. (C) Four of seven tested HLA-A2 elicit T hybridoma response
when pulsed with synthetic peptide; three of seven lines induce a response when
infected with virus. (D, E) T hybridoma activation is not associated with HLA
expression, but activation is not measured in MYCN amplified tumors.
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Figure S2. An-gen discovery strategies in neuroblastoma
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Figure S2. Antigen discovery strategies in neuroblastoma. (A) Eight PDX tumors
selected based on diversity in mutations and range of HLA expression. (B) PHLAT
HLA typing algorithm validated on 15 HLA class I alleles using three neuroblastoma
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cell lines characterized using clinical HLA typing methods. (C) 75 point mutations
result in 2,700 potential neoepitopes (example show for ALK F1174L) used to search
ligandomics data; no neoantigens identified.

(D) Strategies for combining

ligandomics data with genomics data: predicted neoantigens arising from point
mutations, tumor-associated antigens arising from differentially expressed genes,
and neoepitopes arising from non-canonical RNA reads (alternative splice junctions,
indels, frameshifts, read throughs, or endogenous retroviruses). (E) 4/7 phosphopeptides detected from SKNAS PDX tumor are newly identified. (F) Algorithm for
generating search space for neoepitopes generated from non-canonical RNA reads.
(G) Eight primary tumors selected based on HLA type, mass, and HLA expression. (H)
number of peptides detected correlates with mass of tumor material.
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Figure S3. Priori-zed an-gens are highly diﬀeren-ally expressed in NB
IGFBPL1: Insulin-like growth factor
in neuronal regenera5on

PHOX2B: Neural crest
transcrip5on factor
(hereditary NB gene)

TH: Neuroblastoma marker

GFRA2: Neurotrophic
factor receptor

CHRNA3: Neuronal
acetylcholine receptor

HMX1: Development of
craniofacial structure

Figure S3. Differential expression of parent genes for six prioritized antigens.
First column depicts box-and-whisker plot of RNA-seq data from 153 neuroblastoma
tumors and subsequent columns depict normal tissue expression from 1,643 normal
tissues from GTEx database across various organ sites.
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Figure S4. Valida/on of ligandomics an/gen discovery by LC/MS/MS of
synthe/c pep/de and refolding/crystalliza/on of pMHC complex
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Figure S4. Validation of antigens detected by ligandomics. (A, B) Spectra of two
peptides eluted from tumor MHC (top) compared to synthetic peptide (bottom). (C,
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D) Crystal structures of two neuroblastoma antigens confirm proper refolding on
predicted HLA allele of IGFBPL1 on HLA-A*02:01 and PHOX2B on HLA-A*24:02.

Figure S5. Proper.es of neuroblastoma ligandome
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Figure S5. Properties of neuroblastoma ligandome. (A) Majority of peptides are
+2 charged. (B) Logo plots for peptides detected on HLA-A2 and HLA-A24. (C)
Histogram of peptide lengths; 9mers most frequently detected. (D) Histogram of
frequency of appearances of peptide across 8 PDX tumors of all peptides and tumor
specific peptides. (E) Peptides are derived from parent genes that are significantly
overexpressed. (F) Gene ontologies of parent genes of neuroblastoma ligands most
significantly enriched in RNA binding proteins. (G) Most frequently represented
genes in across 8 PDX tumors. Several genes are presented as multiple unique
peptides and across majority of tumors. (H) Number of unique peptides detected by
HLA allele.
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Figure S6. MHC expression in neuroblastoma
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Figure S6. MHC expression in neuroblastoma. (A) IHC staining using W6/32 panHLA antibody. (B) RPKM values of HLA-A, HLA-B, and HLA-C genes in cell lines. (C)
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RPKM values of HLA-A, HLA-B, and HLA-C genes in cell lines is order of magnitude
lower than of matched PDX tumor. (D) RPKM values are predictive of MHC IHC scores.
(E) HLA expression in TARGET database shows wide range of expression.

Figure S7. Healthy donors harbor tumor self-an9gen-speciﬁc CD8 cells
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Figure S7. Detection of tumor self-antigen specific CD8 T cells in normal donors.
(A) Gating used to select CD8 T cells. (B) Four normal donors stained with IGFBPL1
dextramer on x-axis and GFRA2 on y-axis shows rare population of antigen-specific
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cells varying by donor and antigen. (C) Frequencies and intensities of antigen specific
cells across donors.

Figure S8. PHOX2B A7 CAR
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Figure S8. PHOX2B A7 CAR. (A) SKNAS tumor cells co-cultured with A7 CAR shows
potent killing. SKNAS cells plated on day 0 (top), non-targeting CAR (left) and A7 CAR
(right) added after 18 hours; measuring tumor confluence (green) and cleaved
caspase (red) on day 2 shows tumor outgrowth with non-specific CAR and killing of
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all tumor cells with A7 CAR. (B) A7 CAR shows activity against HLA-A*24:02 colon
cancer cell line SW620. (C) SW620 is HLA+/antigen- control.

Figure S9. PHOX2B A7 CAR op7miza7on by random mutagenesis
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Figure S9. Random mutagenesis of A7 construct results in single-antigenspecific population. (A) Sanger sequencing of WT A7 CAR compared to mutagenized
A7 CAR library. (B) Flow cytometry of Jurkat cells transduced with A7 CAR stained
with PHOX2B dextramer on x-axis and mismatched PBK peptide on HLA-A*24:02 on
y-axis. Mutagenized library (right) shows rare population with loss of non-specific
HLA-A*24:02 binding.
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Figure S10. IGFBPL1 CAR F11 does not cross-react with HLAA*02:01 and shows anB-tumor acBvity
F11 scFv ELISA
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Figure S10. IGFBPL1-directed CAR F11 does not cross-react with HLA-A*02:01
and demonstrates anti-tumor activity. (A) ELISA of F11 scFv against IGFBPL1
pMHC (blue) and decoy peptide on HLA-A*02:01 (orange). (B) F11 construct
transduced into Jurkat cells binds IGFBPL1 dextramer but not MART1 dextramer on
same HLA. (C) F11 CAR construct transduced into primary cells shows anti-tumor
activity against EBC1 cells at 2:1 E: T.
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Methods

Isolation of HLA ligands by immunoaffinity purification
HLA class I molecules were isolated using standard immunoaffinity purification as
described previously. (1, 2) In brief, cell pellets were lysed in 10 mM CHAPS/PBS
(AppliChem/Lonza) containing 1x protease inhibitor (Complete; Roche). Mouse MHC
molecules were reduced using a 1 h immunoaffinity purification with H-2K-specific
mAb 20-8-4S, covalently linked to CNBr-activated sepharose (GE Healthcare).
Remaining HLA molecules were purified overnight using the pan-HLA class I-specific
mAb W6/32 or a mix of the pan-HLA class II-specific mAb Tü39 and the HLA-DRspecific mAb L243, covalently linked to CNBr-activated. MHC-peptide complexes
were eluted by repeated addition of 0.2% trifluoroacetic acid (Merck). Elution
fractions E1-E4 were pooled and free MHC ligands were isolated by ultrafiltration
using centrifugal filter units (Amicon; Merck Millipore). MHC ligands were extracted
and desalted from the filtrate using ZipTip C18 pipette tips (Merck Millipore).
Extracted peptides were eluted in 35 µl of acetonitrile (Merck)/0.1% trifluoroacetic
acid, centrifuged to complete dryness and resuspended in 25 µl of 1%
acetonitrile/0.05% trifluoroacetic acid. Samples were stored at 20°C until analysis
by LC-MS/MS.

Analysis of HLA ligands by LC-MS/MS
Peptide samples were separated by reversed-phase liquid chromatography
(nanoUHPLC, UltiMate 3000 RSLCnano, Dionex) and subsequently analyzed in an online coupled Orbitrap Fusion Lumos (Thermo Fisher Scientific). Samples were
analyzed in 3 technical replicates. Sample volumes of 5 µl (sample shares of 20%)
were injected onto a 75 µm x 2 cm trapping column (Acclaim PepMap RSLC, Dionex)
at 4 µl/min for 5.75 min. Peptide separation was subsequently performed at 50°C and
a flow rate of 300 nL/min on a 50 µm x 25 cm separation column (Acclaim PepMap
RSLC, Dionex) applying a gradient ranging from 2.4-32.0% of acetonitrile over the
course of 90 min. Eluting peptides were ionized by nanospray ionization and analyzed
in the mass spectrometer implementing the TopSpeed method. Survey scans were
generated in the Orbitrap at a resolution of 120,000. Precursor ions were isolated in
the quadrupole, fragmented by either collision induced dissociation (CID) in the dualpressure linear ion trap for MHC class I-purified peptides or higher-energy collisional
dissociation (HCD) for MHC class II-purified peptides in the ion-routing multipole.
Finally, fragment ions were recorded in the Orbitrap. For fragmentation mass ranges
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were limited to 400-650 m/z with charge states 2+ and 3+ for MHC class I or 3001500 m/z with charge states 2+ to 5+ for MHC class II, respectively.

HLA typing
FASTQ files from TARGET and RNA-seq data from cell lines were processed using
PHLAT algorithm, previously validated on 15 HLA alleles (Yarmarkovich et al.,
submitted).

Database Search and Spectral Annotation
Data was processed against the human proteome as comprised in the Swiss-Prot
database (www.uniprot.org, release: September 27th 2013; 20,279 reviewed protein
sequences contained) using the SequestHT algorithm (3) in the Proteome Discoverer
(v1.3, ThermoFisher) software. [For the non-canonical peptide search data was
processed against sample-specific fasta files created from RNA-Seq reads.] Precursor
mass tolerance was set to 5 ppm, fragment mass tolerance to 0.02 Da. Search was not
restricted to an enzymatic specificity. Oxidized methionine was allowed as a dynamic
modification. False discovery rate (FDR) was determined by the Percolator algorithm
based on processing against a decoy database consisting of shuffled sequences. FDR
was set at a target value of q≤0.05 (5% FDR). Peptide-spectrum matches (PSMs) with
q≤0.05 were filtered according to additional orthogonal parameters to ensure
spectral quality and validity. Peptide lengths were limited to 8-12 amino acids for
MHC class I and 8-25 aa for MHC class II. HLA annotation was performed using
SYFPEITHI and NetMHC-4.0 or HLA class I or NetMHCIIpan for HLA class II,
respectively.

scFv biopanning and CAR design
scFv binders against MHC presented peptides were retrieved from a large (2×1010)
naïve phage display scFv library (Zhu and Dimitrov, 2009). A competitive panning
process was developed to identify specific binders targeting the peptide-MHC
complex (pep/MHC) based on previous protocols (Zhang and Dimitrov, 2009).
Biotinylated pep/MHC monomers (target antigens) and non-biotinyated tetramers
(decoy competitors) were obtained from the NIH tetramer core facility. 1012 copies
of phages were depleted against magnetic beads (Invitrogen Dynabeads™ MyOne™
Streptavidin T1) for 30 min before incubation for 1.5 hrs with 5 ug biotinylated
pep/MHC conjugated beads in the presence of 20 ug irrelevant decoy competitors.
After incubation, the beads were washed by PBS containing 0.05% Tween-20 (PBST
buffer) for 5 times followed by twice PBS washing. The remaining bound phage were
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recovered by log-phase TG1 and rescued by M13KO7 helper phage. The amplified
phage was collected the next day by PEG/NaCl precipitation and used for the next
round panning. The target antigen input was decreased from 5 ug for the 1st round
panning to 2 ug, 0.5 ug for the 2nd and 3rd rounds, respectively, and the washing
conditions are more stringent along with the panning rounds. After three rounds
panning, polyclonal phage ELISA was performed to evaluate the enrichment. The TG1
cells from the 2nd and 3rd rounds were randomly picked into 96-well plates for soluble
expression-based monoclonal ELISA (semELISA), as described previously (Chen et
al., 2010; Zhang and Dimitrov, 2009). Clones producing signals binding to aim
antigens while not the decoy competitors were amplified and sequenced. For protein
preparation, these clones were transformed into HB2151 cells for expression, and
proteins were purified by one-step Ni-NTA resin. Protein purity and homogeneity
were analyzed by SDS-PAGE. Protein concentration was measured
spectrophotometrically (NanoVue, GE Healthcare). 2nd generation CAR constructs
were synthesized using scFv sequences with 4-1BB and CD3ζ co-stimulatory domains
and cloned into pMP71 vector for screening.

Retroviral production and transduction of Jurkat and primary CD8
T cells
Retrovirus for transduction of Jurkats and primary CD8 T cells was produced using
Platinum-A (Plat-A) cells, a retroviral packaging cell line. Cells were plated in 6-well
plates at 7x105cells/well and transfected with 2.5 mg of the appropriate TCR or CAR
construct in the retroviral vector pMP71 using Lipofectamine 3000 (Life
Technologies, Invitrogen). After 24 hours, medium was replaced with IMDM-10%
FBS or AIM-V-10% FBS for Jurkat cells or primary cells, respectively. Supernatants
were harvested and filtered with 0.2 mM filters after 24 hours incubation.
Jurkat cells were plated in 6-well plates pre-treated with 1 mL well/Retronectin (20
mg/mL, Takara Bio. Inc.,) at 1x106cells/well and spinoculated with 2 mL of retroviral
supernatant at 800xg for 30 min at RT. After 24 hours, cells were harvested, and
grown in IMDM-10% FBS.
Primary T cells were thawed and activated in culture for 3 days in the presence of 100
U/ml IL-2 and anti-CD3/CD28 beads (Dynabeads, Human T-Activator CD3/CD28, Life
Technologies) at a 3:1 bead:T cell ratio. On days 4 and 5, activated cells were plated
in 6-well plates pre-treated with 1 mL well/Retronectin (20 mg/mL, Takara Bio. Inc.)
at 1x106cells/well and spinoculated with 2 mL of retroviral supernatant at 2400 rpm
for 2 hours at 32°C. On day 6, cells were harvested and washed, beads were
magnetically removed, and cells were expanded in AIM-V-10% FBS supplemented
with 25 U/ml IL-2.
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Dextramer staining and flow cytometric analysis
Surface expression and binding affinity of TCR- and CAR-transduced Jurkat cells and
primary T cells was measured by staining with PE- or APC-conjugated dextramers
carrying NB antigen peptide-MHC (Immudex). Cells were harvested from culture,
washed with 2 ml PBS at 800xg for 5 min, incubated with 1 ul dextramer for 10 min
in the dark, washed again, and resuspended in 300 ul PBS for analysis. Typically 5x105
cells were used for staining, and analyzed on a BD LSR II (BD Biosciences) or an
Attune Acoustic Focusing Cytometer (Applied Biosystems, Life Technologies).

Antigen-specific CD8 T cell enrichment and expansion
Normal donor monocytes were plated on day 1 in 6-well plates at 5x106/well in
RPMI-10 FBS supplemented with 10 ng/ml IL-4 (Peprotech) and 800 IU/ml GM-CSF
(Peprotech) and incubated at 37°C overnight. On day 2, fresh media supplemented
with 10 ng/ml IL-4 and 1600 IU/ml GM-CSF was added to the monocytes and
incubated at 37°C for another 48 hours. On day 4, non-adherent cells were removed
and immature dendritic cells washed and pulsed with 5 uM peptide in AIM-V-10%
FBS supplemented with 10 ng/ml IL-4, 800 IU/ml GM-CSF, 10 ng/ml LPS (SigmaAldrich), and 100 IU/ml IFN-g (Peprotech) at 37°C overnight. Day 1 was repeated on
days 4 and 8 to generate dendritic cells for the second and third stimulations on days
8 and 12, respectively.
On day 5, normal donor-matched CD8+ T cells were enriched using protein kinase
inhibitor dasatinib (Sigma-Aldrich), dextramers, and anti-PE or anti-APC beads
(Miltenyi Biotec) as previously described (Dolton et al., 2018a). Enriched T cells were
co-incubated with the appropriate pulsed dendritic cells in AIM-V-10% FBS. Day 5
protocol was repeated on day 8 and day 12 using dendritic cells generated on days 4
and 8 for the second and third stimulation, respectively. Expanded T cells were
validated for antigen-specificity by staining with the appropriate dextramers and for
activation marker 41BB/CD137 (BioLegend).

Antigen-specific T cell sorting, sequencing and cloning
Expanded T cells were stained with CD3, CD8, CD14, CD19, live/dead, and matched
and mismatched dextramer an single-antigen-specific T cells were sorted using a
FACSAria Fusion (BD Biosciences).
Sorted cells were loaded onto 10x Genomics 5’ V(D)J chips and libraries prepared
according to manufacturer protocols. TCR alpha/beta amplicons were run on MiSeq
using 5000 reads per cell. Sequencing data were processed using Cell Ranger and
analyzed using Loupe VDJ Browser. TCR alpha and beta chains were codon optimized,
and synthesized into bicistronic expression cassettes using engineered cysteine
residues in the TCR constant domains, using F2A ribosomal skip sites and furin
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cleavage sites (Yang et al. 2008). TCR cassettes were cloned into pMP71 retroviral
vector.

Luciferase Assay
T2 cells were pulsed with 5 uM peptide at 37°C for 90 min. Next, 1x105 transduced
Jurkat cells were co-incubated with 0.5x105 peptide-pulsed T2 cells or 0.5x105
tumor cell targets (2:1 effector:target ratio) in 96-well plates at 37°C. After 24 hours,
supernatants were collected for ELISA, and cells were washed and measured for
luciferase activity using a luminescent substrate (Luciferase Assay System, Promega).

Incucyte Cytotoxicity Assay
Tumor cell targets were incubated with 100 U/ml IFN-g at 37°C overnight. Next,
0.5x105 tumor cell targets were co-incubated with varying ratios of transduced
primary cells (5x105, 2.5x105, 1x105, 0.5x105, and 2.5x104 for 10:1, 5:1, 2:1, 1:1, and
1:2 effector:target ratios, respectively) in 96-well plates at 37°C in the presence of
0.05 µM caspase-3/7 red (Incucyte, Essence BioScience). Plates ran on the Incucyte
for 24-72 hours and measured for apoptosis activity via caspase cleavage and
comparison of relative confluency. Following the assay, supernatants were collected
for ELISA.

Antigen processing and presentation
Neuroblastoma cell lines were titrated with H1N5 influenza virus and infectivity was
measured by flow cytometry using virus nucleoprotein (NP) antibody. HLA-A2
neuroblastoma cell lines were cultured with either 5uM CEF1 or 50 HAU of H1N5
virus then co-cultured with M1 antigen-specific T cell hybridoma (Canaday, 2013). T
cell activation was measured using IL-2 ELISA (Abcam).
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Chapter 3: Immunogenicity and Immune Silence in Human
Cancer

Summary
Despite recent advances in cancer immunotherapy, the process of
immunoediting early in tumorigenesis remains obscure. Here, we employ a
mathematical model that utilizes the Cancer Genome Atlas (TCGA) data to elucidate
the contribution of individual mutations and HLA alleles to the immunoediting
process. We find that common cancer mutations including BRAF-V600E and KRASG12D are predicted to bind none of the common HLA alleles, and are thus
“immunogenically silent” in the human population. We identify regions of proteins
that are not presented by HLA at a population scale, coinciding with frequently
mutated hotspots in cancer, and other protein regions broadly presented across the
population in which few mutations occur. We also find that 9/29 common HLA alleles
contribute disproportionately to the immunoediting of early oncogenic mutations.
These data provide insights into immune evasion of common driver mutations and a
molecular basis for the association of particular HLA genotypes with cancer
susceptibility.
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Introduction
The immune system is thought to play a dual role in carcinogenesis (Ichim,
2005b). First, when a proper immune response is mounted, the immune system is
capable of eliminating neoplastic cells arising from early tumor-initiating events
(immunoediting). In contrast, the immune system can initiate signaling of wound
healing pathways that can help foster an environment conducive to tumorigenesis.
The human leukocyte antigen (HLA) proteins present a snapshot of all nucleated cell’s
proteomes on the cell surface for surveillance by T cells. While an individual harbors
six distinct HLA Class I alleles (A, B and C), a total of 13,145 unique Class I alleles have
been characterized to date at these highly polymorphic loci (Robinson et al., 2015).
Presentation of processed pathogen-derived peptide by at least one of these HLA
alleles is a major bottleneck in the initiation of an adaptive immune response. Each
HLA allele possesses the ability to present a distinct set of peptides to the immune
system, based on the biophysical properties within the peptide binding groove which
restrict specificity to a limited set of available peptides. Peptide binding is largely
dictated by two HLA-facing anchor residues, which are restricted to a few amino acids
at these positions (Fritsch et al., 2014). Recently, algorithms such as NetMHC and
SYFPEITHI have allowed the prediction of binding affinity of peptide sequences to
specific HLA alleles, resulting in the correct prediction of >75% of binders, with
positive predictive values in the range of 90-95% (Andreatta & Nielsen, 2016; He,
Rappuoli, De Groot, & Chen, 2010).
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Presented neoantigens can be divided into two distinct classes: group 1
resulting from mutations in the TCR-facing residues and correspondingly less likely
to change the binding affinity of the peptide/HLA complex, and group 2 resulting from
the anchor residues of the peptide, and thus presenting a longer sequence of novel
polypeptides to the immune system, as compared to single-residue alterations in
group one antigens (Fritsch et al., 2014). A properly mediated interaction between
the HLA protein, presented peptide, and T cells serves to maintain the genomic
integrity of the organism by eliminating cells harboring foreign genetic material both
from external pathogens and those arising from somatic mutations. The tumor
immunoediting theory predicts that early pathogenic events giving rise to
precancerous cell growths can be eliminated by the adaptive immune system unless
cancer cells evolve the ability to escape this selective pressure (Dunn, Old, &
Schreiber, 2004).

While it has become increasingly appreciated that the adaptive immune
system has the potential to play a significant role in the elimination of existing tumors,
its role in the clearance of cancer cells during early initiating events has remained
difficult to study. Though it has been well demonstrated that immunosuppression in
humans is linked to an increased incidence of cancer (Gallagher et al., 2010; Grulich,
van Leeuwen, Falster, & Vajdic, 2007; Penn & Starzl, 1973), it has remained difficult
to quantify early immunoediting events, and to attribute the clearance of
precancerous lesions in immunocompetent individuals to clearance of tumor-derived
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neoantigens, as opposed to other mechanisms such as the elimination of cells
harboring cancer-inducing viruses.

Here, using the large cohort of patients characterized by the TCGA, we created
an immunogenicity map of neoantigens resulting from 125 consensus cancer-related
genes and developed a mathematical model of immunoediting, quantifying the
underrepresentation of specific neoantigens and their potential HLA pairs as a metric
for prior clearance of these neoantigens by the immune system. We also employ an
HLA presentation score to characterize population-scale HLA presentation along the
span of individual proteins to uncover both protected and unprotected regions within
proteins commonly mutated in cancer. Further, we introduce an HLA-centric metric
of immunoediting, allowing the modeling of the degree of immunoediting in early
tumor initiating events that generate strongly immunogenic antigens presented by
HLA Class I at a population scale occurring across various point mutations, histotypes,
patients, and HLA alleles. We have released a companion web application that can be
used to explore immunogenicity of tumor neoantigens across the population and HLA
presentation along the span of individual proteins for the identification of shared
tumor neoantigens and tumor vaccine design.
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Results
HLA immunogenicity map shows that common mutations generate
peptides that are immunogenically silent.

To generate a map of immunogenicity across all frequently observed single
nucleotide mutations in cancer driver genes, we filtered DNA sequencing data from
the TCGA (7300 subjects representing 33 cancer histologies) for all observed
mutations harbored in 125 consensus oncogenes and tumor suppressor genes
((Vogelstein et al., 2013), Table S1), resulting in 26,361 unique variants. For each
variant we then generated 17mer amino acid sequences to cover all possible 9mer
peptides resulting from amino acid sequences flanking the mutated site (9 potential
variants per mutation), and calculated binding affinity using NetMHC-4.0 across 84
common HLA Class I alleles (Andreatta et al., 2016), with the alleles studied estimated
to represent at least one allele in 99.4% of the US population (calculated based on the
ethnicity-adjusted allele frequency from the Bone Marrow Registry). This analysis
generated 237,249 potential neoantigens, each with a predicted MHC binding affinity
across all available HLA alleles, resulting in 19,928,916 binding affinities. From these
data we aggregated all neoantigens arising from each individual mutation and filtered
for neoantigens classified as strong binders (≤0.5% rank binding for its HLA alleles),
thereby identifying those neoantigens most likely to induce an immune response
resulting in their immunoediting and elimination during early tumorigenesis (Figure
1, Table S2). We find that only 211,852 of 2,214,324 (9.6%) aggregated mutant/HLA
pairs derived from cancer driver proteins are predicted to be strong binders.
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Upon analyzing HLA binding by neoantigens derived from each mutant
variant, we observed that while the majority of mutants produced binders across
multiple HLA alleles, a subset of mutations was predicted to not produce any strong
binders across all of the 84 HLA alleles studied, here defined as immunogenically
silent mutations. Extending the observations of Marty and colleagues (Marty et al.,
2017), these were enriched for the most common mutations in the TCGA, including
BRAF V600E and KRAS G12D (Figure 2A). A total of 1,806 putative neoepitopes
(6.85% of characterized variants) were predicted not to bind any of the 84 HLA alleles
with high affinity (Table S2). For each variant, we calculated the probability of a
TCGA patient carrying at least one allele capable of binding that variant, and found
that the most common variants in the TCGA were enriched in those mutations
predicted to bind HLA less frequently across the population (Figure 2A, Table S2
p=0.0004), suggesting that mutations generating neoantigens capable of being
presented with high affinity by multiple, or more common HLA alleles, have a higher
likelihood of being immunoedited and eliminated, and thus are underrepresented in
the TCGA. The highest ranking of these, MAP3K1 D3727Y, is predicted to bind MHC
with high affinity in 94.5% of the population, producing various epitopes with strong
binding affinity to 50 of 84 HLA alleles tested, and this mutation is only observed once
in the entire TCGA dataset. Analysis across all variants deriving from TP53 reveals
that common variants are highly enriched in loci that are not capable of generating
neoantigens (Figure 2B, p=0.008). Furthermore, our analysis reveals a wide range in
the breadth of tumor neoantigens restricted to specific HLA alleles, ranging from
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3.5% of neoantigens arising from driver genes bound by HLA-B*37:01 to 18.6% of
neoantigens bound by HLA-B*83:01 (Figure 2C).

Having identified immunogenically silent neoepitopes, we hypothesized that
HLA alleles evolved to preferentially present particular protein motifs, which may
leave other regions of cancer proteins unprotected. We applied the algorithm used to
generate the immunogenicity map, calculating the presentation scores of 9mers
starting at each amino acid along the span of the entire protein across 84 HLA alleles
and calculating the percentage of the population predicted to present a given peptide.
We then determined the combined population-wide presentation scores of the
neighboring 8 amino acids in either direction to calculate the regional immunity of
the protein to represent all 9mers centered at each amino acid position. We generated
immunity maps of TP53, PI3KCA, and BRAF, and mapped this onto the frequency of
point mutations at each amino acid (Figure 3A-C). We find that common hot-spot
mutations frequently occur in protein domains that score low in population-scale
HLA presentation, while domains that are widely protected rarely harbor recurring
mutations, suggesting that mutations in unprotected regions are enriched in cancer
due in part to consequent immune evasion. We also mapped the presentation score
of neoantigens in TP53 onto the regional HLA presentation score (Figure 3D),
observing a strong overlap between presentation scores for individual neoantigens
and the corresponding wild-type protein scores, suggesting that regional scores are a
good predictor of the immunogenicity of neoantigens, particularly group 1
neoantigens that do not alter the HLA restriction of the peptide.
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In addition to understanding the immune evasion of proteins arising from
unprotected domains of proteins, we sought to apply regional HLA presentation to
identifying shared tumor epitopes derived from clinically-relevant oncogenes that
can be broadly therapeutically applicable across the widest population of patients.
We performed mass spectrometry on 16 neuroblastoma tumors to characterize the
ligandome and test the predictive ability of the HLA regional scoring across the span
of a protein. We mapped the regional presentation score of the most highly
represented protein in the neuroblastoma ligandome, NPY (29 MHC Class I peptides
detected in 16 neuroblastomas), finding a highly significant concordance between the
empirically detected peptides and those regions of the protein expected to be highly
presented (Figure 3E; p=0.000011), and find no peptides in the ligandome derived
from the signal peptide region (aa 1-28) which is cleaved from the full-length proNPY protein. Based on the high degree of presentation across the NPY protein across
68/84 HLA alleles, its high level of differential expression (Figure S6), and its role in
promoting tumor growth (Tilan & Kitlinska, 2016), we postulate that NPY is a
promising candidate for vaccination strategies. Surprisingly, we find that despite the
elevated population presentation score in the highly presented regions, none of the
peptides presented in these regions are predicted to bind to HLA-A*02:01,
highlighting the utility of a population-scale analysis of HLA presentation in
identifying broadly presented epitopes that may be overlooked due to lack of
presentation

by

HLA-A*02:01.

We

next

searched

the

neuroblastoma

immunopeptidomics dataset we created for peptides derived from the MYCN
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oncogene, a major cancer driver in neuroblastoma, finding only a single peptide
(KATEYVHSL) presented on the relatively rare HLA-C*16:01 (Figure 3F). Applying
the HLA protein scoring map, we find that this peptide is predicted to bind strongly
to 10/84 HLA alleles, representing 31.9% of the population (ranking 15th of 456
peptides in population binding score), and suggesting that this peptide can have
broad application as a therapeutic target in this pediatric cancer population. This
peptide overlaps with the previously reported immunogenic HLA-A*02:01 peptide
VILKKATEYV (Himoudi et al., 2008), suggesting that immunization using this region
of MYCN may have wider implications beyond HLA-A*02:01 patients. Using our
analysis, we find that the highest scoring MYCN peptide (TVRPKNAAL) has predicted
binding to 9 HLA alleles, representing 58.1% of the population, and we expect
analysis of more neuroblastoma tumor specimens will validate this prediction. We
further analyzed regional scores across 17mer and 33mers, we find that these regions
are predicted to generate peptides binding to 73.1% and 85.4% of the population,
respectively (Figure 3F). We suggest that these tools can be used to design and
prioritize more broadly applicable therapeutic targets and vaccines for cancer,
particularly when paired with ligandomics data. Analyses of population-scale
presentation along the span of individual proteins and of specific neoantigens is
available

through

the

Shiny-NAP

web

application

(http://reslnmaris01.research.chop.edu:3838/shinyNAP/).
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HLA allelic immunogenicity and cancer susceptibility.

We hypothesized that specific HLA alleles capable of generating strongly
bound neoantigens would be underrepresented in the population of TCGA patients
harboring those variants due to early immune based elimination of neoplastic cells.
To validate this prediction, we inferred HLA haplotypes from individual patient
sequencing data using the PHLAT HLA typing algorithm (Bai et al., 2014), resulting in
563 unique HLA alleles characterized across the TCGA. To assure predication
accuracy, we directly genotyped 15 unique HLA allele calls with the lowest confidence
predictions using DNA from cancer cell lines and showed 100% concordance (Table
S3). We then used the immunogenicity map to determine neoantigen binding across
all TCGA driver mutations as defined above (Table S4). To estimate the degree of
immunoediting across each HLA allele, we used the immunogenicity map to generate
a list of all predicted strong binders at each HLA allele having greater than 5%
population frequency in the TCGA (29/84 alleles), subset the unique set of patients
harboring these mutations, and compared the frequency of their HLA alleles to
predicted in the TCGA population from the Bone Marrow Registry data derived
largely from younger adults (Figure S2). Performing this analysis across 29 HLA
alleles, we calculated the magnitude of immunoediting for each allele by the
underrepresentation of that allele in the subset of patients harboring strong
neoantigens for that allele, as compared with the predicted TCGA population
frequency calculated from the bone marrow registry data (Figure 4A). As a metric of
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immunoediting by each allele, we calculated the proportion of observed HLA
frequencies in the neoantigen-harboring cases compared to the population
frequency, in which a proportion of 0 would represent perfect immunoediting of all
early neoantigens and 1 would represent no immunoediting (Figure 4B).

We observe a wide range of immunoediting across the 29 HLA alleles, the
highest of which was HLA-A*68:01 with a 44% underrepresentation in the subset of
patients harboring predicted binders. We also found that many common HLA alleles
appear to not contribute significantly to immunoediting in cancer. Nine of 29 HLA
alleles were significantly associated with a protective effect against early neoantigens
(Figure 4, Table S2; p = 7.7e-6-0.05, FDR = 0.0001%-15.9%). Our modeling suggests
that individual HLA alleles have differential ability to initiate an immune response
capable of clearing early oncogenes, and across differential breadths of variants. We
generated an immunoediting score to determine the degree to which each HLA allele
was protective, factoring both breadth and magnitude (% neoantigens bound * %
allele underrepresentation), and determined HLA-A*68:01 to score the highest in
protectivity against mutations in cancer driver genes (Figure S3A, Table S2). We
postulated that the binding affinity between those HLA alleles and tumor neoantigens
may contribute to immunoediting. By comparing the nine HLA alleles that contribute
to immunoediting to the 21 alleles that were found to not contribute significantly to
immunoediting, we find that the mean binding among neoantigens in the alleles
contributing to immunoediting is 982.8nM, significantly stronger than 1612.6nM in
non-contributing alleles (Figure 4C, p = 0.015). Furthermore, we scored the
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contribution of these alleles at a population level as a metric for how many
neoantigens these alleles are editing at a population scale by calculating the product
of the immunoediting score with the frequency of the HLA allele in the US population
(Figure S3B, Table S2), with HLA-A*02:01 emerging as the most significant
contributor to population-scale immunoediting.

Immunoediting in TCGA across patients, tumors, and point
mutations.
We next focused on immunogenically silent mutations defined above and
showed that these are enriched in the TCGA dataset, comprising 9.1% of observed
mutations, while only representing 6.85% of all characterized variants (p = 2e-16).
Indeed, we find that 1974 of 7300 patients (27%) in the TCGA harbor at least one
immunogenically silent mutation. In addition to immunoediting contributions of HLA
alleles and evasion through immunogenically silent mutations, we explored editing
events across individual patients, tumor types, and specific point mutations. To model
the degree of immunoediting across these variables, we calculated the expected
frequency with which a given patient, tumor, or point mutation, should harbor at least
one HLA allele capable of binding the subset of strongly binding neoantigens in that
group, calculated the collective probabilities of the subpopulation generating
neoantigens, and compared the observed frequencies to the predicted frequency of
binding to at least one HLA allele. To simplify the modeling of predicted allele
frequencies, we treated HLA allele frequencies as independent events and
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disregarded linkage between HLA alleles, thus slightly underestimating the expected
frequencies and biasing our prediction of immunoediting towards a more
conservative estimate. These analyses lend insight into tumor cell extrinsic
mechanisms for recurrent hot spot mutations in cancer (Table S5). For example,
while KRAS G12D is immunogenically silent and is predicted to bind no common HLA
allele with high enough affinity to allow for recognition by T cells, the KRAS G12A
mutation is predicted to generate strong neoantigens with four HLA alleles (HLAA*02:05, HLA-A*02:06, HLA-A*69:01, and HLA-C*03:03). KRAS G12A scored as the
2nd most significantly underrepresented driver SNV in the TCGA and was not
observed in any patient tumor sample with any of the four predicted HLA binders in
its 35 occurrences (4.3 predicted neoantigen/HLA pairs, Table S5, p = 0.01).

We also examined immunoediting contributions of group 1 and group 2
neoantigens (as defined above) in HLA-A*02:01 by comparing neoantigens arising
from mutations in the anchor positions at residues 2 and 9 to those mutations outside
of these residues. We found no significant difference in underrepresentation between
group 1 and 2 neoantigens (Figure S4), suggesting that both types of neoantigens
participate in immunoediting in the context of HLA-A*02:01. Analyzing
immunoediting across individual patients, we found a subset of patients with
disproportionate degrees of immunoediting. The most significant of these, uterine
cancer patient TCGA-E6-A1LX, harbored 3.4-fold fewer immunogenic neoantigens
than predicted (p = 3.1e-10). Interestingly, this patient also harbored 12
immunogenically silent mutations (ranking 3rd highest in immunogenically silent
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mutations out of 7300 TCGA patients, Table S6), suggesting that this patient’s tumor
had experienced a significant degree of immunoediting, however was being driven
largely by immunogenically silent mutations. Although the combined cases of uterine
cancer taken together are the least significantly immunoedited histology, a particular
subset of these patients are highly enriched among individuals with highest degrees
of immunoediting (5 out of the top 10 immunoedited individuals in the TCGA),
highlighting these as interesting case studies for the mechanisms underlying
enhanced early immunoediting and eventual immune escape. In our analysis across
histologies, we find that glioblastoma is the most significantly immunoedited in early
tumor formation (Figure S5; p=0.008), in line with recent evidence that these tumors
do not arise in immune privileged sites (Louveau, Harris, & Kipnis, 2015; Louveau,
Smirnov, et al., 2015). Overall, these data illustrate differential degrees of
immunoediting and immune evasion across TCGA patients, histologies, and variants,
suggesting that an enrichment in immunogenically silent mutations may be driving
the evolution of tumors in otherwise immunocompetent individuals.
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Discussion

Here we describe a model for quantifying immunoediting during early
tumorigenesis that provides insight into immunologic contributions to recurrent
somatic mutation hotspots observed in human cancer, as well as immunologic
contributions to cancer susceptibility. The model described herein employs
orthogonal methods to recent studies in demonstrating evidence of immunoediting
in the TCGA cohort (Marty et al., 2017; Rech et al., 2018; Rooney, Shukla, Wu, Getz, &
Hacohen, 2015). Using an HLA-based hypothesis, we converge on the conclusion that
common driver mutations evade the immune system and provide a population-scale
HLA-centric basis for their overrepresentation in human cancer. In each of these
studies, the immunoediting process is demonstrated to be imperfect, precipitating a
need to understand this disparity in immune response. Here we provide methods that
can be employed to elucidate immunoediting across HLA alleles, patients, individual
variants, and other genomic or clinical features. We think that our HLA-centric
population-scale model provides a baseline of comparison against which we can
estimate the degree of immunoediting, with several examples of disparities across
these features highlighted in this manuscript.

This is the first report that we are aware of to map known driver neoantigens
across common HLA alleles, and quite strikingly the most recurrent hotspot
mutations in human cancer are predicted to bind no common HLA allele with high
enough affinity to engage the adaptive immune system, highlighting an immunologic
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mechanism underlying the evolutionary advantage of common mutations in addition
to their oncogenic potency. This is also the first report we are aware of to quantify the
contributions of individual HLA alleles to the immunoediting process in cancer,
revealing a high disparity in immune protection against cancer across the HLA alleles.
Our data suggest that the ability of individual HLA alleles to bind cancer neoantigens
with high affinity is strongly associated with its ability to contribute to cancer
immunoediting. Though our data support the cancer immunoediting theory, we and
others show that the immunoediting process leads to incomplete elimination of
neoantigens arising from early driver mutations. While we demonstrate that a
significant degree of immune evasion may be attributed to immunogenically silent
mutations, the absence of complete immunoediting in patients not harboring
immunogenically silent mutations may be attributed to factors including tumor
intrinsic immune evasion, downregulation of MHC, lack of T cell response of the
proper magnitude and quality, poor TCR repertoire, exclusion of T cells from tissue,
or peripheral tolerance. We believe that our model can be coupled with genomic
surrogates of these features to interrogate these variables in future studies using
tumor genomic data.

Here we show that not all HLA alleles are found to be significantly protective
against the neoantigens that they present. We postulate that alleles not found to
significantly participate in immunoediting may induce sublethal T cell responses or
possess biophysical and/or geometric properties that confer suboptimal interactions
with germline-encoded binding regions of the TCR. Our findings that specific regions
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of cancer driver proteins are unprotected by HLA presentation combined with the
disparity in binding across HLA alleles raises the question of whether HLA alleles
have evolved to confer protectivity against particular viral domains that coincide with
motifs found in cancer proteins, and whether the unpresented areas remain
unprotected due to lack of evolutionary pressure on these motifs. These results also
raise the question of whether HLA presentation of group 2 neoantigens is associated
with mutational signatures arising from particular groups of DNA damage that
generate variants with more favorable binding properties in the anchor residues
(Alexandrov et al., 2013). We have made available the tools for other investigators to
test

these

and

other

hypotheses

(http://reslnmaris01.research.chop.edu:3838/shinyNAP/).

We also present a tool for mapping the presentation scores across the span of
any given protein in the population. We find a highly significant concordance between
the peptides empirically detected in the combined ligandome of 16 neuroblastoma
tumors carrying various HLA alleles, and the regions of the NPY protein predicted to
be most highly presented by HLA across the population. Based on these results paired
with the high level of differential expression, and its role in promoting tumor growth,
we suggest that NPY is a promising candidate for vaccine development for
neuroblastoma patients. Using this tool, we also suggest that current vaccination
strategies used against MYCN may have broader application across the population.
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As access to genomic data from cancer patients continues to expand, and the
peptide/MHC binding and T cell epitope prediction tools improve, this model will
benefit from additional statistical power in stratifying subsets of the patient
population based on molecular features occurring in smaller subpopulations. Despite
the fact that our model predicted no HLA alleles binding to neoantigens derived from
the KRAS G12D mutation, it was recently reported by Tran and colleagues that KRAS
G12D neoantigen GADGVGKSA is able to mediate a T cell response in the context of
HLA-C*08:02. This antigen is predicted to be a weak HLA binder (15,390 nM),
highlighting the fact that T cell epitopes are not always predicted using this algorithm,
particularly on rare alleles for which there are limited training data, and that new
methods will help identify neoantigens with non-canonical motifs (Abelin et al.,
2017). Here, we restricted our analysis of immunoediting by CD8 T cells through MHC
class I presentation of 9mer antigens only, and did not account for immunoediting
that may be triggered by other Class I antigens of varying lengths, Class II antigens, or
the activities of the innate immune system from NK cells or macrophages, as we were
focused on maintaining statistical power by using common HLA alleles and the most
common Class I peptide length. In the future, we will be expanding the analysis to
additional peptide lengths and releasing additional features to the Shiny-NAP
application.

We find that the highest statistically significant immunoediting takes place in
glioblastoma, whereas, taken together, sarcomas, pancreatic tumors, ovarian,
adrenocortical tumors and lymphomas show no significant evidence of
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immunoediting. Given that the immunogenically silent KRAS G12D mutation is
pathognomonic of pancreatic cancer, our findings may help explain the lack of efficacy
of treatments such as checkpoint inhibitors in pancreatic cancer (Winograd et al.,
2015) and the lack of immunoediting observed in our analysis, as these tumors are
driven largely by an immunogenically silent mutation. We suggest that our methods
could ultimately be used to inform the stratification of groups of patients most likely
to respond to immunotherapies such as checkpoint inhibitors and to prioritize
peptide vaccines based on patient HLA and antigen immunogenicity. This model can
also be used to predict how an individual’s HLA profile can determine the types of
mutations most likely to develop or be protected against.

Using the model of immunogenicity described herein, it may be possible to
infer physical properties of neoantigens that elicit high immunoediting as compared
to other neoantigens that are presented but not eliminated by the immune system,
study the contributions of various molecular pathways across tumor types and across
individual patients that contribute to variable degrees of immunoediting, and as a
basis for exploring the mechanisms by which specific HLA alleles may contribute to
cancer protection and predisposition. With alleles such HLA-A*68:01 emerging as
disproportionately high in their immunoediting score, we will be interested to see
whether contributions of HLA alleles to early immunoediting will translate to
improved abilities to induce T cell responses against tumor neoantigens in patients,
and whether such alleles are associated with improved outcomes in patients treated
with modern immunotherapies. We suggest that the immunogenicity map, HLA
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typing data, and immunoediting model contained herein will facilitate investigation
into neoantigen immunogenicity at the level of HLA alleles, mutations, patients,
histologies, and aid in prioritization of shared tumor epitopes for therapeutic
development, and further our mechanistic understanding of immune evasion in
tumor evolution.
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Table Legends
Table S1. Driver oncogenes and tumor suppressor genes. List of 125 cancer
driver genes implicated in carcinogenesis, including oncogenes and tumor
suppressor genes that regulate cell fate, cell survival, and genome maintenance
(Vogelstein et al, 2013).

Table S2. Immunogenicity map of TCGA. Map of all characterized variants derived
from 125 cancer driver genes (Table S1) and their binding score across each of 84
characterized HLA alleles. Binding score reported as the strongest rank score from
the aggregated pool of all peptides resulting from each variant to particular HLA
allele, with lower scores representing higher binding affinity relative to binders of
each HLA allele.

Table S3. Validation of HLA genotyping. Comparison of HLA predictions across 15
HLA alleles as inferred from PHLAT algorithm from exome sequencing data of 3
neuroblastoma cell lines compared to clinical genotyping performed using next
generation sequencing of amplified HLA loci.

Table S4. TCGA mutations and patient HLA types. List of variants used to analyze
immunoediting across patients, variants, and histologies. Table populated with all
mutations in driver genes from the TCGA with matched HLA typing inferred from
PHLAT.
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Table S5. Immunoedited variants from TCGA. List of variants most
underrepresented when measured with population of patients harboring HLA alleles
predicted to bind neoantigens derived from variant (p ≤ 0.05). Frequency of mutation
is number of occurrences of mutation in Table S4. Percent of population with binders
is the probability of a TCGA subject harboring an HLA allele capable of binding a
neoepitope derived from the particular variant. Observed mutation is frequency
calculated from the number of patients with at least one HLA allele from the set of
those capable of binding the variant.

Table S6. Immunoedited subjects from TCGA. List of subjects with highest degrees
of immunoediting in the TCGA (p ≤ 0.05). Expected binders calculated by summing
the probability of all individual variants in each patient being bound to an HLA allele
in the TCGA. Observed binders is the summed number of variant/HLA pairs that
generate at least one epitope across each variant. Observed/expected represents the
degree of underrepresentation of presented neoantigens in each patient (0 being
perfect immunoediting). Despite being ranked the lowest in significance for
immunoediting, uterine cancer represents 5 of the top 10 patients with the most
significant degrees of immunoediting. The most significantly immunoedited subject
also ranks 3 of 7300 in number of immunogenically silent mutations.
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Figures and Legends
Figure 1. Pipeline for Generating Immunogenicity Map

1,783,708
characterized unique mutations
TCGA (MuSE & Somatic Sniper)
125 driver genes
(Vogelstein et al. 2013)
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19,928,916
binding affinities

Figure 1. Pipeline for generating immunogenicity map. TCGA mutations imputed
by MuSE and Somatic Sniper were filtered for those arising from 125 characterized
driver mutations (Vogelstein et al., 2013). 17mers peptides sequences were
generated for all possible 26,361 variants arising from (covering 9 potential epitopes
for each variant) each variant/WT pair (237,249 pairs) and analyzed for MHC binding
affinity using NetMHC 4.0 across 84 HLA alleles resulting in 19,928,916 binding
affinities. Peptide affinities were aggregated for all peptides arising from each variant
and filtered for those that are strong binders (<0.5% rank), revealing 24,555 strong
binders and 1,806 immunogenically silent mutations.
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Figure 2B. Most common TP53 rarely produce MHC binding neoantigens
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Figure 2A. Frequency of mutations in TCGA compared to number of HLA alleles bound
by neoantigens derived from mutant
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Figure 2C. Percent of TCGA neoantigens bound by HLA alleles

Figure 2. Mutation frequency in TCGA inversely correlates with populationscale HLA binding. (A) Mutation frequency for 26,361 TCGA variants compared to
the proportion of the population predicted to bind a given neoantigens derived from
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that mutation reveals immunogenically silent mutations in 1,806 variants (6.85% of
mutation in the TCGA, including BRAF V600E and KRAS G12D highlighted) and
enrichment of common driver mutations in those which are predicted to not bind any
HLA alleles (p = 0.0004). (B) TP53 mutations are enriched in those that are
immunogenically silent or bind HLA alleles in a small portion of the population, and
mutations with high probability of binding at least one allele in a given are
significantly underrepresented in the TCGA (p=0.008). (C) Proportion of
characterized neoantigens bound by individual HLA alleles reveals broad range in
diversity of binding from 3.5% of neoantigens arising from driver genes bound by
HLA-B*37:01 to 18.6% bound by HLA-B*83:01.
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Figure 3. HLA presentation scores by protein region
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% population predicted to present peptide

Figure 3E. NPY peptides detected by ligandomics map onto predicted high scoring regions
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Figure 3. HLA presentation score by protein region reveals unprotected
domains and protein regions broadly applicable as cancer vaccine candidates.
(A-C) Regional HLA presentation scores determined by calculating the percent of the
population capable of presenting a 9mer epitope centered at each amino acid location
in p53, PI3K, and BRAF (grey bars). Each protein contains domains that are presented
on HLA in the majority of the population and other domains that are unprotected.
Mutation frequency at each location overlaid (green lollipop plot) reveals that many
common mutations are found in unprotected regions of the protein. (D) Overlay of
mutated neoantigen presentation score with regional presentation score for p53
shows strong correlation between regional protection of WT protein (grey bars) with
protection against mutated neoantigens (black lollipop plot). (E) 29 peptides
detected by ligandomics in 16 neuroblastoma tumors were mapped onto the HLA
population presentation scores. Empirically detected peptides were highly enriched
in high-scoring regions of the protein (p=0.000011). (F) Analysis of MYCN HLA
presentation across the span of the protein. Analysis of individual peptides (top)
reveals the most highly presented peptide derived from MYCN, TVRPKNAAL, to be
presented on 9 HLA alleles, representing 58.1% of the population. KATEYVHSL
peptide, detected by ligandomics is predicted to be presented 10 total HLA alleles
(31.9% of the population). Analysis of 17mer regions (middle) reveals a peptide
LERQRRNDLRSSFLTLR generating peptides predicted to bind 19 HLA alleles (73.1%
of the population). Analysis of 33mer regions reveals the highest scoring peptide
TVRPKNAALGPGRAQSSELILKRCLPIHQQHNY presented on 18 HLA alleles in 85.4%
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of the population, suggesting these as promising regions of the MYCN protein for
broadly applicable vaccination.
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Figure 4. Immunoediting by HLA
alleles
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Figure 4. Immunoediting across HLA alleles. (A) Expected TCGA frequency for
each allele as calculated from the Bone Marrow Registry and adjusted for ethnicity
(red) compared to observed HLA allele frequency in subset of the TCGA population
harboring strong neoantigen/HLA binding pairs (blue). To calculate observed HLA
frequencies, predicted mutant binders are used to filter TCGA data and HLA
frequencies are deduced from the subset of unique individuals. Decreased frequency
in TCGA binders compared to expected frequency is a surrogate metric for early
immunoediting events that are responsible for having cleared early tumors and are
thus underrepresented in TCGA data. (B) Ratio of observed:predicted binders. Area
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below dotted line represents immunoediting frequency for each allele. 0 represents
complete immunoediting while 1 represents no contribution of immunoediting by a
particular HLA allele. (C) Binding affinity between HLA alleles found to participate in
immunoediting of cancer neoantigens is stronger than non-contributing alleles (p =
0.015).
Figure S1. Pipeline for inferring HLA type from TCGA and comparing to predicted
frequencies
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Figure S1. Pipeline for inferring HLA type from TCGA and comparing to
predicted frequencies. BAM files for individual patients were converted to FASTQ
and processed using PHLAT to determine HLA type. HLA frequencies in TCGA were
determined using ethnicity-specific allele populations from Bone Marrow Registry
and compared to observed frequencies in TCGA. Patient HLA and mutation data were
combined to determine number of neoantigens in
each individual, allowing the comparison of predicted HLA frequencies to ethnicityadjusted HLA frequencies in the TCGA across individuals, mutations, and tumor
histologies.
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Figure S2. Workflow for modeling immunoediting for individual HLA alleles (example
show for HLA-A*02:01).
1,606/26,361 binding neoantigens
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ALK_P968S, ALK_Q218H, ALK_Q594K, ALK_R65H, ALK_R753Q, ALK_S1324F, ALK_S1324Y, ALK_S62L, ALK_V1229A, ALK_V60E, APC_A2650V, APC_A289V, APC_A591V, APC_A725V, APC_C1387S, APC_D1285Y, APC_D67Y, APC_L1382F,
APC_L592V, APC_P1634L, APC_P2216S, APC_P2508L, APC_P439L, APC_R1386K, APC_R2228S, APC_R640W, APC_S1389F, APC_S1730Y, APC_S713L, APC_S833I, APC_V588I, APC_Y2645C, ARID1A_A1616T, ARID1A_A1616V,
ARID1A_A2184V, ARID1A_D2157N, ARID1A_E1387G, ARID1A_E1683Q, ARID1A_E2000Q, ARID1A_G2012D, ARID1A_G2087E, ARID1A_G830A, ARID1A_I2015F, ARID1A_K1106E, ARID1A_L1713P, ARID1A_M875V, ARID1A_P1048S,
ARID1A_P1484L, ARID1A_P1583S, ARID1A_R1980C, ARID1A_R2158Q, ARID1A_R219L, ARID1A_S2156G, ARID1A_T1690N, ARID1B_A1138V, ARID1B_A2157V, ARID1B_F1139V, ARID1B_G2020W, ARID1B_I1966F, ARID1B_L1634I,
ARID1B_L2068F, ARID1B_P1073L, ARID1B_P1084S, ARID1B_P2055L, ARID1B_P2171S, ARID1B_Q1662K, ARID1B_R1070T, ARID1B_R1416L, ARID1B_R2134T, ARID1B_R2208Q, ARID1B_S2118T, ARID1B_T1639M, ARID1B_T1654S,
ARID1B_T2155M, ARID1B_V991L, ARID1B_W1640L, ARID1B_W2000L, ARID2_A207V, ARID2_C1814F, ARID2_D174Y, ARID2_E300V, ARID2_E427K, ARID2_H800Y, ARID2_L204F, ARID2_L422I, ARID2_P170Q, ARID2_R623L, ARID2_S319F,
ARID2_S417L, ARID2_T426M, ARID2_V162L, ARID2_W1642L, AR_A270T, AR_A700V, AR_A766S, AR_A871V, AR_D865E, AR_E682V, AR_E898D, AR_F814L, AR_F814V, AR_H875Y, AR_I817F, AR_K862R, AR_L273F, AR_N706S, AR_R264W,
AR_R31C, AR_R31H, AR_R31S, AR_S117L, AR_S704N, AR_S815I, AR_S885A, AR_V867L, ASXL1_I217V, ASXL1_L1413V, ASXL1_P1392L, ATM_A1958V, ATM_A623T, ATM_A623V, ATM_C1286F, ATM_D1080Y, ATM_D126E, ATM_D1930Y,
ATM_D2003E, ATM_D317G, ATM_D351Y, ATM_D841Y, ATM_E953V, ATM_H1213N, ATM_H1568L, ATM_H996L, ATM_I124V, ATM_I238V, ATM_I2899M, ATM_I487M, ATM_K1289N, ATM_K1440N, ATM_K482Q, ATM_L100W,
ATM_L1028V, ATM_L1217M, ATM_L1347V, ATM_L1936S, ATM_L2005I, ATM_L2033V, ATM_L2132V, ATM_L2492R, ATM_M1040I, ATM_M1916V, ATM_M349I, ATM_N230I, ATM_N2494Y, ATM_P2903L, ATM_P955L, ATM_R1466G,
ATM_R1466Q, ATM_R457Q, ATM_R692C, ATM_S1179P, ATM_S1179Y, ATM_S1905L, ATM_S214P, ATM_S2168L, ATM_S707P, ATM_S933Y, ATM_V1021L, ATM_V2951F, ATM_V320L, ATM_W1461C, ATRX_A1282V, ATRX_A771V,
ATRX_C1575F, ATRX_C1576F, ATRX_C1590Y, ATRX_C2404S, ATRX_D1573N, ATRX_D1714Y, ATRX_E1757G, ATRX_E1832Q, ATRX_E585K, ATRX_E733K, ATRX_F1619S, ATRX_I2402S, ATRX_K1344E, ATRX_L1879V, ATRX_N1754K,
ATRX_N2443H, ATRX_P1829L, ATRX_P1886A, ATRX_P1886L, ATRX_Q1874H, ATRX_R1342W, ATRX_R2028P, ATRX_R2407L, ATRX_R2407Q, ATRX_S2046Y, ATRX_T1621M, ATRX_T2205N, ATRX_V2405I, ATRX_W1572L, AXIN1_E391K,
AXIN1_G507W, AXIN1_P278L, AXIN1_R477S, AXIN1_S91F, B2M_D54V, B2M_E89G, B2M_P92A, B2M_Y83F, B2M_Y86D, BAP1_D107V, BAP1_F170C, BAP1_F170V, BAP1_G23C, BAP1_H169Q, BAP1_I557M, BAP1_R163Q, BAP1_S697Y,
BAP1_V439L, BAP1_V99L, BAP1_V99M, BCL2_K17M, BCL2_P208S, BCOR_A385V, BCOR_C1649S, BCOR_D1581Y, BCOR_E1640Q, BCOR_E197D, BCOR_E983K, BCOR_F1578L, BCOR_G632S, BCOR_H1515N, BCOR_K219N, BCOR_L1583V,
BCOR_L1665M, BCOR_L1744V, BCOR_N1584H, BCOR_N1584S, BCOR_N1731D, BCOR_P1648S, BCOR_S1405L, BCOR_S1667L, BCOR_S373L, BCOR_S637F, BCOR_S897L, BCOR_T1730M, BCOR_Y1650F, BRAF_E80D, BRAF_H539P,
BRAF_H542Y, BRAF_L485F, BRAF_L678I, BRAF_S616F, BRCA1_G1471R, BRCA1_G1801S, BRCA1_H1860P, BRCA1_K1476R, BRCA1_P977L, BRCA1_P982L, BRCA1_Q1135L, BRCA1_R446T, BRCA1_R979H, BRCA1_S1473Y, BRCA1_S1651F,
BRCA2_A1896T, BRCA2_C3097R, BRCA2_C738Y, BRCA2_E1245D, BRCA2_E1895K, BRCA2_G1771C, BRCA2_G2584C, BRCA2_I1136M, BRCA2_I1772S, BRCA2_I2177V, BRCA2_K1139N, BRCA2_L413V, BRCA2_N991D, BRCA2_P2329L,
BRCA2_P740S, BRCA2_S1597F, BRCA2_S3144Y, BRCA2_S3218F, BRCA2_S3332Y, BRCA2_V2079M, BRCA2_V3145A, CARD11_A790D, CARD11_E134K, CARD11_I1065M, CARD11_P1114S, CARD11_R884W, CARD11_S34N, CARD11_S34T,
CARD11_S644Y, CARD11_S881I, CARD11_T792I, CASP8_C312F, CASP8_C313Y, CASP8_D438A, CASP8_D438G, CASP8_D73A, CASP8_E111A, CASP8_F67L, CASP8_I314L, CASP8_L66V, CASP8_M146V, CASP8_P394L, CASP8_R68Q,
CASP8_R71I, CASP8_R71T, CASP8_S109L, CASP8_T444P, CASP8_T444S, CASP8_Y448C, CBL_A678D, CBL_C404F, CBL_D64N, CBL_M469I, CBL_P35L, CBL_R593W, CBL_R68L, CBL_S253F, CBL_S675F, CBL_T730M, CDC73_N248K,
CDH1_A634V, CDH1_D288V, CDH1_D587Y, CDH1_G278V, CDH1_I584F, CDH1_L798V, CIC_G235C, CIC_G235D, CIC_P1502L, CIC_P925R, CIC_P974L, CIC_Q374H, CIC_R1384W, CIC_S950L, CIC_V978M, CREBBP_A1093T, CREBBP_E656D,
CREBBP_F1161I, CREBBP_G119V, CREBBP_G57V, CREBBP_I1453T, CREBBP_K657N, CREBBP_M493I, CREBBP_Q1994H, CREBBP_Q610R, CREBBP_R1446L, CREBBP_R1514L, CREBBP_R1664C, CREBBP_R2072L, CREBBP_R2072Q,
CREBBP_R2072W, CREBBP_S1687F, CREBBP_S1687Y, CREBBP_S326F, CREBBP_T1688M, CREBBP_V1743M, CREBBP_W1165R, CRLF2_A11P, CRLF2_A239V, CRLF2_G16E, CRLF2_I35M, CRLF2_S245C, CRLF2_S245F, CRLF2_S82L,
CRLF2_S98F, CRLF2_V244M, CSF1R_A136E, CSF1R_A527T, CSF1R_A894P, CSF1R_D829H, CSF1R_E135Q, CSF1R_I810T, CSF1R_P132Q, CSF1R_P425L, CSF1R_Q877K, CSF1R_R192W, CSF1R_S620Y, CSF1R_V325M, CTNNB1_D6A,
CTNNB1_I256M, CTNNB1_I256T, CTNNB1_K335I, CTNNB1_K335T, CTNNB1_L402F, CTNNB1_N161I, CTNNB1_P597S, CTNNB1_P606L, CTNNB1_R342K, CTNNB1_R486C, CTNNB1_S681F, CTNNB1_T257I, CTNNB1_T339N, CYLD_A502V,
CYLD_I303V, CYLD_I739M, CYLD_L25I, CYLD_L25V, CYLD_L603V, CYLD_R695M, CYLD_S159F, CYLD_S615Y, CYLD_T222K, DAXX_A95V, DAXX_E570D, DAXX_E68K, DAXX_F67I, DAXX_F67L, DAXX_I127V, DAXX_P562L, DAXX_R234C,
DAXX_R371W, DAXX_S102L, DNMT1_A1301T, DNMT1_A496V, DNMT1_A554P, DNMT1_A554T, DNMT1_D1162E, DNMT1_D583N, DNMT1_D629N, DNMT1_D89Y, DNMT1_D937Y, DNMT1_E1189D, DNMT1_E1266D, DNMT1_E432K,
DNMT1_E432V, DNMT1_E93V, DNMT1_N430S, DNMT1_N87S, DNMT1_P1325L, DNMT1_P1325S, DNMT1_R582W, DNMT1_S84C, DNMT1_T578A, DNMT1_T630A, DNMT3A_A192V, DNMT3A_A760T, DNMT3A_D857V,
DNMT3A_G646V, DNMT3A_G890C, DNMT3A_G890D, DNMT3A_P195L, DNMT3A_R729W, DNMT3A_R736H, DNMT3A_V258M, EGFR_A17V, EGFR_D1084N, EGFR_F78L, EGFR_G652W, EGFR_G663V, EGFR_I91V, EGFR_P20L,
EGFR_Q276L, EGFR_S1130T, EGFR_S116F, EGFR_S177L, EGFR_S437Y, EGFR_V651M, EP300_D1237Y, EP300_D1367Y, EP300_E1113V, EP300_E1423K, EP300_E635D, EP300_F1125V, EP300_H1261Q, EP300_H582Y, EP300_K636E,
EP300_N1126S, EP300_P671L, EP300_P784L, EP300_Q795R, EP300_R1627G, EP300_R1627L, EP300_R1627W, EP300_R613W, EP300_W1122L, EP300_W1129C, ERBB2_D769Y, ERBB2_D821H, ERBB2_D821Y, ERBB2_G439D, ERBB2_I767F,
ERBB2_I767M, ERBB2_L667F, ERBB2_P802S, ERBB2_Q106H, ERBB2_S413L, ERBB2_S653F, EZH2_F665V, EZH2_F667L, EZH2_K735N, EZH2_M662T, EZH2_N668S, EZH2_S228F, EZH2_Y641F, FBXW7_A502V, FBXW7_D703Y, FBXW7_E287Q,
FBXW7_E287V, FBXW7_G499D, FBXW7_G551V, FBXW7_H500D, FBXW7_H500Q, FBXW7_H500R, FBXW7_H500Y, FBXW7_H553Y, FBXW7_L251F, FBXW7_L288F, FBXW7_R278Q, FBXW7_R513W, FBXW7_V418M, FBXW7_V554L,
FGFR2_C382Y, FGFR2_D126Y, FGFR2_D738N, FGFR2_E116K, FGFR2_E377D, FGFR2_E695K, FGFR2_M391I, FGFR2_N439Y, FGFR2_R165W, FGFR2_R22Q, FGFR2_R737G, FGFR2_R737M, FGFR2_S437F, FGFR2_T454M, FGFR2_V122M,
FGFR2_V392A, FGFR2_V393A, FGFR2_V86M, FGFR3_A391T, FGFR3_A733V, FGFR3_A790V, FGFR3_C119F, FGFR3_C119Y, FGFR3_E686K, FGFR3_F384L, FGFR3_F386L, FGFR3_H349Y, FGFR3_L385M, FGFR3_P358L, FGFR3_P696L,
FGFR3_P699L, FGFR3_R640W, FGFR3_R728Q, FGFR3_R728W, FGFR3_V745L, FLT3_A181S, FLT3_A181T, FLT3_A546V, FLT3_D835H, FLT3_D835Y, FLT3_D839G, FLT3_D839H, FLT3_E880K, FLT3_F882L, FLT3_G863C, FLT3_K429E,
FLT3_L313M, FLT3_M837L, FLT3_P986L, FLT3_R311L, FLT3_R311W, FLT3_S188N, FLT3_S454L, FLT3_V843A, FOXL2_N109S, FOXL2_T76M, FUBP1_A194V, FUBP1_F381V, FUBP1_S99Y, GATA1_G366C, GATA1_G368C, GATA1_R293L,
GATA2_P41L, GATA3_A39T, GATA3_P42L, GATA3_P44L, GATA3_S230I, GATA3_V226M, GATA3_Y41C, GNA11_I61F, GNA11_R166H, GNA11_R60H, GNAQ_D236N, GNAQ_G188W, HNF1A_A160T, HNF1A_A501T, HNF1A_D526Y,
HNF1A_G288A, HNF1A_G40E, HNF1A_G410W, HNF1A_G453D, HNF1A_M405L, HNF1A_P340L, HNF1A_P409L, HNF1A_P475L, HNF1A_R114C, HNF1A_R114H, HNF1A_R159L, HNF1A_T10M, HNF1A_T525I, HNF1A_V480A, HRAS_D33N,
HRAS_L53M, IDH1_D375Y, IDH1_E17K, IDH1_F355V, IDH1_P33S, IDH1_R338T, IDH1_V35M, IDH2_G323V, IDH2_G325C, IDH2_Q296R, JAK1_C189Y, JAK1_E284K, JAK1_F369I, JAK1_G741D, JAK1_H525Y, JAK1_K1057E, JAK1_S703I,
JAK1_T533M, JAK2_A676V, JAK2_D319G, JAK2_D319N, JAK2_F1019L, JAK2_F265L, JAK2_L1047I, JAK2_L664I, JAK2_P823L, JAK2_Q959P, JAK2_R374T, JAK2_S1035L, JAK2_S364C, JAK3_A25V, JAK3_A634T, JAK3_A961V, JAK3_D200G,
JAK3_D609N, JAK3_F106V, JAK3_F341Y, JAK3_G969V, JAK3_G987S, JAK3_H962L, JAK3_I688T, JAK3_I955F, JAK3_R687G, JAK3_R899W, JAK3_S580L, JAK3_S720N, JAK3_S789L, JAK3_T685N, JAK3_V585M, KDM5C_C14S, KDM5C_C825Y,
KDM5C_F508L, KDM5C_G1053D, KDM5C_G1354E, KDM5C_G536W, KDM5C_H350Y, KDM5C_K498M, KDM5C_L358M, KDM5C_L756H, KDM5C_L756I, KDM5C_P12A, KDM5C_P480L, KDM5C_Q168L, KDM5C_R108L, KDM5C_R854Q,
KDM5C_R936H, KDM5C_S539L, KDM5C_T713M, KDM5C_V581M, KDM5C_W474L, KDM5C_Y535C, KDM6A_A337S, KDM6A_E1102K, KDM6A_G1191C, KDM6A_I889M, KDM6A_L416F, KDM6A_L914F, KDM6A_N1196S, KDM6A_P1269S,
KDM6A_P417S, KDM6A_P566L, KDM6A_Q154L, KDM6A_Q398H, KDM6A_R1111C, KDM6A_R1111P, KDM6A_R393L, KDM6A_S985P, KDM6A_V195F, KDM6A_Y109C, KIT_C537S, KIT_F848V, KIT_G866A, KIT_K209I, KIT_K558E, KIT_K642E,
KIT_K642N, KIT_M552L, KIT_P551H, KIT_P627L, KIT_R122H, KIT_R888L, KIT_V120F, KIT_V530I, KLF4_A237V, KLF4_A24V, KRAS_D33E, KRAS_I36L, KRAS_P34L, KRAS_R73M, MAP2K1_D336H, MAP2K1_I310L, MAP2K1_L313F,
MAP2K1_Q335E, MAP2K1_S241Y, MAP2K1_S327T, MAP3K1_A801T, MAP3K1_D372Y, MAP3K1_E453V, MAP3K1_F573I, MAP3K1_F772L, MAP3K1_H357Y, MAP3K1_K675T, MAP3K1_P1141L, MAP3K1_P287L, MAP3K1_R1355C,
MAP3K1_R1355H, MAP3K1_R364G, MAP3K1_R364Q, MAP3K1_R790M, MAP3K1_R825G, MAP3K1_R853L, MAP3K1_R855C, MAP3K1_S1131I, MAP3K1_S1358L, MAP3K1_S455R, MED12_A1383T, MED12_A1385V, MED12_A147G,
MED12_A578S, MED12_A860V, MED12_C1488Y, MED12_D1306Y, MED12_D891N, MED12_D913Y, MED12_D977N, MED12_F1110L, MED12_F300L, MED12_G1094E, MED12_G247V, MED12_G862D, MED12_G862S, MED12_H1508Y,
MED12_K200N, MED12_L1486I, MED12_L1489V, MED12_L198I, MED12_L377F, MED12_M863L, MED12_M880I, MED12_N1056S, MED12_N1381Y, MED12_P2025T, MED12_P374T, MED12_P579H, MED12_P579L, MED12_P579S,
MED12_Q1509H, MED12_Q1844K, MED12_Q199H, MED12_Q308H, MED12_Q572H, MED12_R1138G, MED12_R1138W, MED12_R155W, MED12_R251K, MED12_R251S, MED12_R356W, MED12_R483Q, MED12_R730L,
MED12_R730Q, MED12_R931W, MED12_S1483L, MED12_S912L, MED12_V1223L, MED12_V1277A, MED12_V1428M, MED12_V1588M, MEN1_D423Y, MEN1_G110W, MEN1_G42S, MEN1_V439M, MET_D1180Y, MET_D1228Y,
MET_H1351Y, MET_I446V, MET_I706M, MET_L953M, MET_P1285L, MET_R1148Q, MET_R1279I, MET_R417L, MET_S33F, MET_S441C, MET_S653F, MET_T440I, MET_T618M, MET_T621I, MET_V370I, MET_V939F, MLH1_D644A,
MLH1_E620K, MLH1_F614L, MLH1_H264Y, MLH1_I262M, MLH1_L658I, MLH1_R265C, MLH1_S401N, MLH1_V253L, MLH1_V4L, MLH1_V647L, MPL_A21V, MPL_D34Y, MPL_G600W, MPL_L498V, MPL_P518S, MPL_R514M, MPL_S476L,
MPL_T10S, MPL_V114M, MSH2_A305T, MSH2_A710P, MSH2_A733T, MSH2_D379Y, MSH2_E731Q, MSH2_G520V, MSH2_G68W, MSH2_N412H, MSH2_Q493H, MSH2_Q493L, MSH2_R383L, MSH2_R524C, MSH2_S13I, MSH2_S271F,
MSH2_V525L, MSH6_D797Y, MSH6_E810K, MSH6_F689L, MSH6_F689V, MSH6_H826N, MSH6_M875I, MSH6_P591Q, MSH6_T1355A, MSH6_V474M, MSH6_V586M, MSH6_V734M, NCOR1_A1828V, NCOR1_C2056S, NCOR1_D426N,
NCOR1_E425D, NCOR1_E425G, NCOR1_L400F, NCOR1_P1418S, NCOR1_P427L, NCOR1_Q1990L, NCOR1_R398L, NCOR1_R933L, NCOR1_S1154L, NCOR1_T1619I, NF1_A1240V, NF1_A1540T, NF1_A1544T, NF1_A1676S, NF1_A1676T,
NF1_A2441T, NF1_A2646V, NF1_A330V, NF1_C1682R, NF1_D2375H, NF1_D241Y, NF1_E524G, NF1_G2001V, NF1_G842D, NF1_H2414L, NF1_I791M, NF1_K1444E, NF1_K2044E, NF1_K936T, NF1_L1104R, NF1_L1114M, NF1_L1301M,
NF1_L2073V, NF1_L2639I, NF1_L274F, NF1_L695P, NF1_L899V, NF1_M1285I, NF1_M1981V, NF1_M739I, NF1_M991K, NF1_M992I, NF1_N1004D, NF1_N1673S, NF1_N2679D, NF1_N2777S, NF1_N2780D, NF1_N839Y, NF1_P1951L,
NF1_P698L, NF1_Q1447H, NF1_R1204W, NF1_R1250W, NF1_R1306Q, NF1_R1462W, NF1_R16L, NF1_R897W, NF1_R997M, NF1_R997S, NF1_R997T, NF1_S144F, NF1_S1786L, NF1_S2093A, NF1_S2157P, NF1_S2781F, NF1_S833F,
NF1_T1589M, NF1_T2034I, NF1_T2108N, NF1_T2344I, NF1_T700S, NF1_T862I, NF1_V1049A, NF1_V1674I, NF1_V2170L, NF1_W1048L, NF2_A145T, NF2_A145V, NF2_R376L, NF2_V146I, NFE2L2_A124G, NFE2L2_A124V, NFE2L2_D29G,
NFE2L2_D29Y, NFE2L2_E311K, NFE2L2_F127I, NFE2L2_H465R, NFE2L2_L562F, NFE2L2_P467L, NFE2L2_S137L, NFE2L2_S347L, NOTCH1_A1570V, NOTCH1_A1571T, NOTCH1_A1742V, NOTCH1_C2189Y, NOTCH1_D374E, NOTCH1_F1749S,
NOTCH1_G1572D, NOTCH1_H1993Y, NOTCH1_P2151L, NOTCH1_P2222L, NOTCH1_Q2487L, NOTCH1_R1598P, NOTCH1_R1991H, NOTCH1_R2111K, NOTCH1_R2549C, NOTCH1_T1996M, NOTCH1_T1997M, NOTCH1_V1096L,
NOTCH1_V1099M, NOTCH1_V1222M, NOTCH1_V1575L, NOTCH1_V1739L, NOTCH1_V2038L, NOTCH2_A1464V, NOTCH2_A2346V, NOTCH2_C1313S, NOTCH2_G1657W, NOTCH2_H2055Y, NOTCH2_L9M, NOTCH2_M2183V,
NOTCH2_P1947L, NOTCH2_P2219L, NOTCH2_R1567L, NOTCH2_R2036L, NOTCH2_R2347C, NOTCH2_S220N, NOTCH2_V1664L, NOTCH2_W1983L, NOTCH2_W749L, NOTCH2_Y217F, NPM1_S4L, NRAS_D33H, NRAS_D57A, NRAS_P34L,
PAX5_G314W, PAX5_H318N, PAX5_I187V, PAX5_P313S, PAX5_S373I, PBRM1_A75V, PBRM1_D115V, PBRM1_E184D, PBRM1_E860K, PBRM1_K183M, PBRM1_L1672M, PBRM1_L531I, PBRM1_N528S, PBRM1_N80Y, PBRM1_Q660H,
PBRM1_R522L, PBRM1_S343L, PBRM1_S956R, PBRM1_T1247I, PBRM1_Y746C, PDGFRA_C23W, PDGFRA_C501F, PDGFRA_D1015V, PDGFRA_D135N, PDGFRA_D842Y, PDGFRA_E217V, PDGFRA_E362A, PDGFRA_E408D, PDGFRA_E408Q,
PDGFRA_F889V, PDGFRA_H945Y, PDGFRA_H974Q, PDGFRA_I139T, PDGFRA_I888N, PDGFRA_K1001M, PDGFRA_L542F, PDGFRA_L885F, PDGFRA_L885V, PDGFRA_N907T, PDGFRA_P1021L, PDGFRA_P250L, PDGFRA_P441S,
PDGFRA_P577L, PDGFRA_S46Y, PDGFRA_S470L, PDGFRA_S851L, PDGFRA_S890F, PDGFRA_T134M, PDGFRA_T355I, PDGFRA_T526M, PDGFRA_T740A, PDGFRA_T83M, PDGFRA_V536M, PDGFRA_V544I, PDGFRA_Y136D, PHF6_C242Y,
PIK3CA_D300V, PIK3CA_D746Y, PIK3CA_E1012Q, PIK3CA_E453D, PIK3CA_E453Q, PIK3CA_E65K, PIK3CA_G1007R, PIK3CA_G451R, PIK3CA_I1058M, PIK3CA_I841V, PIK3CA_L279I, PIK3CA_L445I, PIK3CA_L569I, PIK3CA_L752V,
PIK3CA_L956F, PIK3CA_M1004I, PIK3CA_M1004V, PIK3CA_M1005V, PIK3CA_M282V, PIK3CA_N170S, PIK3CA_N345Y, PIK3CA_P18L, PIK3CA_P449L, PIK3CA_P449S, PIK3CA_P449T, PIK3CA_P835H, PIK3CA_Q958R, PIK3CA_R19I,
PIK3CA_R693H, PIK3CA_R93W, PIK3CA_S629C, PIK3CA_S66C, PIK3CA_V344M, PIK3CA_V636L, PIK3CA_Y165H, PIK3CA_Y432C, PIK3R1_E175K, PIK3R1_L244S, PIK3R1_L581F, PIK3R1_P194S, PIK3R1_P196H, PIK3R1_S208Y,
PPP2R1A_A457V, PPP2R1A_C329F, PPP2R1A_D492Y, PPP2R1A_E84Q, PPP2R1A_H520Y, PPP2R1A_M350I, PPP2R1A_N360S, PPP2R1A_P406R, PPP2R1A_Q325L, PPP2R1A_Q372L, PPP2R1A_R221W, PPP2R1A_R48Q, PPP2R1A_S146L,
PPP2R1A_S95L, PPP2R1A_T142I, PPP2R1A_Y456C, PPP2R1A_Y456H, PRDM1_K801M, PRDM1_P441L, PRDM1_P441Q, PRDM1_P441S, PRDM1_P665L, PTCH1_A113E, PTCH1_A113T, PTCH1_A918T, PTCH1_C1043R, PTCH1_E1066K,
PTCH1_E221K, PTCH1_E339V, PTCH1_F109V, PTCH1_F1152L, PTCH1_G1129D, PTCH1_G492R, PTCH1_G759R, PTCH1_I219L, PTCH1_I228L, PTCH1_L223I, PTCH1_L341F, PTCH1_L590F, PTCH1_P1318L, PTCH1_P155S, PTCH1_P568L,
PTCH1_P957S, PTCH1_R401M, PTCH1_R571W, PTCH1_R982W, PTCH1_S489L, PTCH1_S616I, PTCH1_T1064M, PTCH1_T1372M, PTCH1_V1034M, PTCH1_V1065F, PTCH1_V419M, PTEN_A34S, PTEN_A34T, PTEN_A39V, PTEN_D92V,
PTEN_H118L, PTEN_H118Y, PTEN_H272P, PTEN_K144E, PTEN_K144T, PTEN_L181P, PTEN_M35I, PTEN_N276S, PTEN_N31K, PTEN_P204L, PTEN_P246L, PTEN_P38L, PTEN_P38T, PTEN_R142W, PTEN_R47M, PTEN_T202I, PTEN_T277I,
PTEN_V175L, PTEN_V275L, PTEN_Y177C, PTEN_Y177D, PTEN_Y177F, PTEN_Y177S, PTEN_Y178C, PTPN11_F71L, PTPN11_P284L, PTPN11_V345M, RB1_A488V, RB1_A490T, RB1_A562E, RB1_A562P, RB1_E492D, RB1_E79D, RB1_F226L,
RB1_I703F, RB1_I703N, RB1_K80E, RB1_L218F, RB1_M708K, RB1_Q384H, RB1_R908L, RB1_S751Y, RB1_V157A, RB1_W195C, RB1_W563S, RET_F299L, RET_G849V, RET_P117T, RET_P20S, RET_P259L, RET_P405L, RET_R57W, RET_R912L,
RET_S396L, RET_S649L, RET_T451M, RET_T946A, RET_V648I, RET_V939G, RET_V945M, RET_W942S, RNF43_H86Y, RNF43_I75V, RNF43_L82S, RNF43_M18V, RNF43_P14S, RNF43_P154L, RNF43_R127W, RNF43_S720L, RNF43_S85F,
RUNX1_A311V, RUNX1_F326L, RUNX1_P86S, RUNX1_S314F, RUNX1_S361L, SETBP1_E959K, SETBP1_F1038Y, SETBP1_H921Y, SETBP1_L957M, SETBP1_P1003S, SETBP1_P558L, SETBP1_R1189W, SETBP1_S1039C, SETBP1_S1039R,
SETD2_G1659V, SETD2_I1745V, SETD2_K1610N, SETD2_K891M, SETD2_L1577I, SETD2_L1778F, SETD2_M766I, SETD2_P1470S, SETD2_P226L, SETD2_S2199F, SETD2_S2199Y, SETD2_V1656F, SF3B1_D1015G, SF3B1_D564E,
SF3B1_D894A, SF3B1_D894G, SF3B1_E1160K, SF3B1_E873Q, SF3B1_G895D, SF3B1_G913C, SF3B1_H1283N, SF3B1_L1212M, SF3B1_L502F, SF3B1_L897R, SF3B1_P1171Q, SF3B1_P351L, SF3B1_P351S, SF3B1_P930S, SF3B1_S1207L,
SF3B1_T434A, SF3B1_T916A, SF3B1_V1169I, SF3B1_V576A, SF3B1_V917M, SF3B1_Y898H, SMAD2_C412Y, SMAD2_F356C, SMAD4_A406T, SMAD4_A406V, SMAD4_D332G, SMAD4_D537V, SMAD4_D537Y, SMAD4_F408L,
SMAD4_K340E, SMAD4_P544L, SMAD4_S485L, SMARCA4_A1002V, SMARCA4_A1117V, SMARCA4_A1218V, SMARCA4_D614Y, SMARCA4_E920K, SMARCA4_F1102L, SMARCA4_F927S, SMARCA4_G784V, SMARCA4_K1219M,
SMARCA4_K991E, SMARCA4_K991R, SMARCA4_L921F, SMARCA4_M1105I, SMARCA4_P49L, SMARCA4_P913L, SMARCA4_R1077Q, SMARCA4_R1093L, SMARCA4_R370C, SMARCA4_R849L, SMARCA4_S1482I, SMARCA4_T859M,
SMARCA4_W764S, SMARCA4_W922C, SMARCB1_A312T, SMARCB1_K8N, SMARCB1_R201L, SMARCB1_R377L, SMARCB1_S87I, SMARCB1_T309I, SMARCB1_Y47S, SMO_A459S, SMO_A754T, SMO_C127F, SMO_D287H, SMO_G328D,
SMO_G409S, SMO_G416C, SMO_L325P, SMO_L362R, SMO_L363F, SMO_L412F, SMO_P368A, SMO_P753L, SMO_R113Q, SMO_R290C, SMO_T245M, SMO_T364I, SMO_V404M, SMO_V414A, SOCS1_E149K, SOCS1_F209S,
SOCS1_P208L, SOCS1_P208S, SOCS1_Q210H, SOCS1_S206Y, SOCS1_Y203F, SOCS1_Y203S, SOX9_P108S, SOX9_P92S, SOX9_R474C, SOX9_R474H, SOX9_R94C, SOX9_R94H, SOX9_T87K, SOX9_V93L, SOX9_Y127C, SPOP_A275V,
SPOP_A277V, SPOP_D272N, SPOP_F133V, SPOP_G148W, SPOP_L142F, SPOP_N147T, SPOP_R198W, SPOP_R221C, SPOP_R99L, SPOP_Y87C, SPOP_Y87F, SPOP_Y87N, SPOP_Y87S, SRSF2_G77W, STAG2_A532V, STAG2_D1222E,
STAG2_D486G, STAG2_D486N, STAG2_D831N, STAG2_E1223K, STAG2_E472G, STAG2_E490D, STAG2_I201M, STAG2_K290E, STAG2_L791M, STAG2_M197I, STAG2_M227I, STAG2_N286I, STAG2_N412Y, STAG2_N778K, STAG2_R216L,
STAG2_R422W, STAG2_S419L, STAG2_T379I, STAG2_T782I, STAG2_V417L, STK11_D141N, STK11_D237Y, STK11_E165Q, STK11_G163S, STK11_G227V, STK11_G251C, STK11_G251R, STK11_G251V, STK11_L164Q, STK11_Q137H,
STK11_R28S, TET2_G1860W, TET2_G1861R, TET2_P408L, TET2_P869L, TET2_P989L, TET2_R1974M, TET2_S1970Y, TET2_T1251M, TET2_T492I, TET2_V1639M, TET2_V205L, TNFAIP3_E472D, TNFAIP3_H106Y, TNFAIP3_P402S,
TNFAIP3_R728C, TNFAIP3_S471G, TNFAIP3_T389M, TP53_A70T, TP53_C135F, TP53_C135S, TP53_C135W, TP53_C135Y, TP53_C141F, TP53_C141W, TP53_C141Y, TP53_D259V, TP53_G105D, TP53_G105S, TP53_G105V, TP53_G108S,
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TSHR_L587M, TSHR_M453T, TSHR_P168L, TSHR_P168S, TSHR_P168T, TSHR_P556S, TSHR_P639Q, TSHR_P652H, TSHR_P668L, TSHR_P668T, TSHR_S756L, TSHR_T441P, TSHR_V595I, TSHR_Y163F, VHL_N131Y, WT1_P132Q
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Figure S2. Workflow for modeling immunoediting for individual HLA alleles
(example show for HLA-A*02:01). All strong neoantigens predicted to bind given
HLA are aggregated and used to filter the TCGA dataset. Resulting mutations are
filtered for unique patients to remove patients harboring multiple binders to a single
allele. Frequency of unique patients harboring at least one strong neoantigen binding
to predicted HLA allele compared to ethnicity-adjusted predicted value for TCGA
frequency to determine level of immunoediting by specific HLA allele.
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Figure S3. HLA allele immunoediting scores and population editing scores
Figure S3A.

Figure S3B.

Figure S3. HLA allele immunoediting scores and population editing scores.
Immunoediting scores represent overall ability of HLA alleles to edit mutations,
accounting for the repertoire of antigens they are able to bind and the level of editing
that they exhibit for that subset of antigens (calculated by % neoantigens bound by
allele * % underrepresentation of HLA allele), with HLA-A*68:01 scoring highest in
immunoediting of neoantigens arising from mutations in early driver genes.
Immunoediting population score is used to estimate the total immunoediting
contribution of HLA alleles across the US population (calculated by the product of the
immunoediting score with the US HLA allele frequency). (A) Immunoediting scores in
HLA alleles shown to be statistically significant. (B) Population immunoediting scores
in HLA alleles shown to be statistically significant.
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Figure S4. Immunoediting of group 1 and group 2 neoantigens
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Figure S4. Immunoediting of group 1 and group 2 neoantigens. Neoantigens
resulting from group 1 neoantigens (those with neoantigens occurring from mutation
at positions outside of anchor residues) were compared with group 2 neoantigens
(mutations occurring at anchor residues 2 and 9) in HLA-A*02:01. No significant
difference in underrepresentation was found between groups 1 and 2 in HLAA*02:01.
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Figure S5. Immunoediting by cancer histology

p = 0.008

Figure S5. Immunoediting by cancer histology. Combined observed binding
neoantigens compared to expected. 0 represents complete immunoediting while 1
represents no contribution of immunoediting by a particular HLA allele. Glioblastoma
is the only significantly immunoedited histology in this analysis (p=0.008). Uterine
cancer is the least significantly immunoedited tumor, though is highly enriched in
individuals exhibiting high degrees of immunoediting (4/8 of the most significantly
edited patients in the TCGA, Table S6).
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Figure S6. NPY is highly differentially expressed in neuroblastoma and is a promising
target for vaccination

Figure S6. NPY is highly differentially expressed in neuroblastoma and is a
promising target for vaccination. RNA-sequencing data from 153 neuroblastoma
tumors in TARGET (first column) compared to 1643 normal tissues from GTEx
compiled by organ (subsequent columns) reveals high expression of NPY in
neuroblastoma as compared to normal tissues.
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Methods
EXPERIMENTAL MODEL AND SUBJECT DETAILS
TCGA subjects
7300 TCGA subjects were used in analysis based on cases sequences using Illumina
HiSeq 2000. HLA-A*01:01 was excluded from analysis due to ambiguous calls made
by PHLAT algorithm for this allele, and HLA-E alleles were excluded.
METHODS DETAILS

HLA typing
BAM files from TCGA were converted to FASTQ using Bedtools and subsequently
processed using PHLAT algorithm. Pipeline was created on Cavatica and processing
was performed on Seven Bridges Genomics cloud server. Subsequent analysis was
performed using R Studio.

Immunogenicity map of all driver mutation in TCGA
To generate a map of immunogenicity across all initiating cancer events, TCGA
mutants arising from 125 early tumor driver genes imputed by MuSE and Somatic
Sniper were used to generated amino acid sequences for all possible 9mer peptides
resulting from mutant amino acid plus flanking sequences. Binding affinities were
predicted using NetMHC-4.0 across 87 common HLA alleles. HLA alleles not occurring
in the TCGA and HLA-E alleles were removed from the analysis, resulting in 84 HLA
alleles. Combined binding affinities across all resulting peptides (i.e. those resulting
from multiple of 9 potential epitopes) for each variant were aggregated, then filtered
for antigens producing epitopes most likely to be recognized by T cells (≤0.5% allele
rank).

HLA immunoediting model
To model early immunoediting, we compared the frequency of HLA alleles in the
population of patients harboring mutations expected to yield a strong neoantigen to
the HLA allele frequency in the Bone Marrow Registry after adjusting for ethnic
distribution within the TCGA population. To estimate the degree of immunoediting
across each HLA allele, we used the immunogenicity map to generate a list of all
predicted strong binders, subset all TCGA patients harboring at least one of the
mutations, filtered for unique patients harboring these mutations, and compared the
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frequency of their HLA alleles to that of predicted TCGA frequency. TCGA population
frequency was calculated by matching ethnicity-specific HLA allele frequencies from
the Bone Marrow Registry to the representation of these ethnicities in the TCGA.

Prediction of expected HLA binders
To calculate predicted HLA binders for specific mutant variants, tumor types, and
individual patients, we calculated the probability of an individual not possessing at
least one binding allele, and subtracted this probability from 1 using the formula,
which gives the probability that an individual carrying at least one such a binding
allele,
1 – ∏)
*+,(1 − 𝑝_𝑘)
where k ∈ set of K binding alleles and p_k is the probability of individual carrying at
least one copy of the allele k. Note that this probability calculation assumes that these
K binding alleles occur independently in the population. Dependency among these K
binding alleles due to positive linkage disequilibrium (Maiers, Gragert, & Klitz, 2007)
may lead to over-estimate of the true probability, which may make our estimate of
immunoediting conservative.
Expected occurrence of HLA allele in population of mutants, patients, and tumors was
calculated using the formula:
2

)_1

.(1 − /(1 − 𝑃_𝑘))
1+,

*+,

where k ∈ set of K_j binding alleles, P_k is the probability of individual carrying at
least one copy of the allele k, and j ∈ set of J mutants, patients, or tumors, respectively.
p values were calculated using one-sided binomial test to compare the observed
number of binders with expected based on the population frequency using R and false
discovery rate (FDR) was calculated using the Benjamini/Hochberg method to adjust
for multiple comparisons.

Isolation of HLA ligands by immunoaffinity purification
Eight patient-derived xenograft tumors and eight primary patient tumors were lysed
in 10 mM CHAPS/PBS (AppliChem /Lonza) containing 1x protease inhibitor
(Complete; Roche, Basel, Switzerland). Mouse MHC molecules were reduced using a
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1 h immunoaffinity purification with H-2K-specific mAb 20-8-4S, covalently linked to
CNBr-activated sepharose (GE Healthcare, Little Chalfont, UK). Remaining HLA
molecules were purified overnight using the pan-HLA class I-specific mAb W6/32 or
a mix of the pan-HLA class II-specific mAb Tü39 and the HLA-DR-specific mAb L243,
covalently linked to CNBr-activated. MHC-peptide complexes were eluted by
repeated addition of 0.2% trifluoroacetic acid (Merck). Elution fractions E1-E4 were
pooled and free MHC ligands were isolated by ultrafiltration using centrifugal filter
units (Amicon; Merck Millipore). MHC ligands were extracted and desalted from the
filtrate using ZipTip C18 pipette tips (Merck Millipore). Extracted peptides were
eluted in 35 µl of acetonitrile (Merck)/0.1% trifluoroacetic acid, centrifuged to
complete dryness and resuspended in 25 µl of 1% acetonitrile/0.05% trifluoroacetic
acid. Samples were stored at -20°C until analysis by LC-MS/MS.

Analysis of HLA ligands by LC-MS/MS
Peptide samples were separated by reversed-phase liquid chromatography
(nanoUHPLC, UltiMate 3000 RSLCnano, Dionex) and subsequently analyzed in an online coupled Orbitrap Fusion Lumos (Thermo Fisher Scientific). Samples were
analyzed in 3 technical replicates. Sample volumes of 5 µl (sample shares of 20%)
were injected onto a 75 µm x 2 cm trapping column (Acclaim PepMap RSLC, Dionex)
at 4 µl/min for 5.75 min. Peptide separation was subsequently performed at 50°C and
a flow rate of 300 nl/min on a 50 µm x 25 cm separation column (Acclaim PepMap
RSLC, Dionex) applying a gradient ranging from 2.4-32.0% of acetonitrile over the
course of 90 min. Eluting peptides were ionized by nanospray ionization and analyzed
in the mass spectrometer implementing the TopSpeed method. Survey scans were
generated in the Orbitrap at a resolution of 120,000. Precursor ions were isolated in
the quadrupole, fragmented by either collision induced dissociation (CID) in the dualpressure linear ion trap for MHC class I-purified peptides or higher-energy collisional
dissociation (HCD) for MHC class II-purified peptides in the ion-routing multipole.
Finally, fragment ions were recorded in the Orbitrap. For fragmentation mass ranges
were limited to 400-650 m/z with charge states 2+ and 3+ for MHC class I or 3001500 m/z with charge states 2+ to 5+ for MHC class II, respectively.

Database Search and Spectral Annotation
Data was processed against the human proteome as comprised in the Swiss-Prot
database (www.uniprot.org, release: September 27th 2013; 20,279 reviewed protein
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sequences contained) using the SequestHT algorithm in the Proteome Discoverer
(v1.3, ThermoFisher) software. [For the non-canonical peptide search data was
processed against sample-specific fasta files created from RNA-Seq reads.] Precursor
mass tolerance was set to 5 ppm, fragment mass tolerance to 0.02 Da. Search was not
restricted to an enzymatic specificity. Oxidized methionine was allowed as a dynamic
modification. False discovery rate (FDR) was determined by the Percolator algorithm
based on processing against a decoy database consisting of shuffled sequences. FDR
was set at a target value of q≤0.05 (5% FDR). Peptide-spectrum matches (PSMs) with
q≤0.05 were filtered according to additional orthogonal parameters to ensure
spectral quality and validity. Peptide lengths were limited to 8-12 amino acids for
MHC class I and 8-25 aa for MHC class II. HLA annotation was performed using
SYFPEITHI and NetMHC-4.0 for HLA class I or NetMHCIIpan for HLA class II,
respectively.
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Chapter 4: Cross-reactivity and High-throughput
Multiplexing
Cross-reactivity Algorithm
The development of therapeutic TCRs has faced obstacles concerning the
cross-reactivity of transgenic receptors delivered to a large population of activated T
cells. The administration of an affinity-enhanced TCR developed by AdaptImmune
targeting MAGE-A3 presented on HLA-A1 resulted in the death of two patients due to
cardiac toxicity. Although the MAGE-A3 peptide is not expressed in cardiac tissue, a
similar peptide derived from the Titin protein was determined to be responsible for
the cross-reactivity of the TCR (Linette et al., 2013). Other toxicities have been
reported with a TCR targeting a MAGE-A3 peptide on HLA-A2, cross-reacting with
MAGE-A12 which was found to be expressed in brain tissue (R. A. Morgan et al., 2013).
These unfortunate cases have prompted the field to develop better techniques for
assessing the safety of pMHC/TCR pairs beyond the assessment of differential
expression of target antigens in tumor vs. normal tissue. It has been suggested that
affinity optimization of TCRs may result in novel specificities that can be directed
against self-antigens (Kunert, Obenaus, Lamers, Blankenstein, & Debets, 2017),
possibly resulting due to the fact that affinity-optimized receptors have not
undergone negative thymic selection against self-peptides.

To address these concerns, a technique has been developed to identify the
crucial motifs of peptides that dictate their interaction with a particular TCR. Using a
set of altered peptide ligands (APLs), each residue of the target peptide is substituted
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with an alanine residue (endogenous alanines are mutated to glycine), and T cell
response is measured against each individual peptide. The resulting data highlight
the residues of the epitope that are crucial in mediating its interaction with a given
TCR (Kunert et al., 2017). The motif pattern of these residues can be used to search
for normal protein sequences containing these motifs using search tools such as
ScanProSite (de Castro et al., 2006). These tools are limited in that they require an a
priori existing pMHC/TCR pair before these interactions can be assessed. This
requires a lengthy and laborious process or target discovery and TCR development
and optimization, which may result in an antigen that is intrinsically too similar to
self-peptides to be targeted using TCR therapy.

Based on these limitations, we sought to develop computational tools that
could be used to assess the potential cross-reactivity of a tumor antigen to normal
peptides based on the sequence of the tumor peptide alone. We developed an
algorithm to scan the entire normal proteome for potential cross-reactive peptides
presented on the same MHC as the peptide of interest. First, we predicted MHC
binders derived from the entire proteome, resulting in 1,143,861 peptides for HLAA1. For each of the resulting MHC binders, we scored each position as it compares to
the tumor antigen, assigning a score based on the properties of the amino acid being
compared (polarity, charge, hydrophobicity, and group). Exact matches are scored
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most highly, followed by residues with similar charge and polarity, and penalties
assigned for opposite charges and polarities.

Figure 1. Parameters for cross-reactivity algorithm: TCR contact residues, peptide similarity, MHC binding,
gene expression in normal and tumor tissue, and tissue of origin of peptide parent gene.

Furthermore, if the residues of a peptide that protrude from the MHC groove
are known by structural analysis or modeling (Borg et al., 2005; Hawse et al., 2014),
these residues are weighed more heavily, as these are expected to be the “hot-spot”

Figure 2. Output of cross-reactivity search of 1,143,861 HLA-A1 binders using MAGE-A3 peptide EVDPIGHLY
reveals Titin peptide ESDPIVAQY peptide as fourth-highest ranking for predicted cross-reactivity.
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interfaces between the pMHC and TCR. Once we have calculated the peptide matching
score, we multiply the score by the maximum gene expression of the peptide’s parent
protein based on the GTEx database of RNA-sequencing in normal tissues, and divide
by the binding affinity of the peptide to MHC. We tested the algorithm using the
MAGE-A3 HLA-A1 peptide EVDPIGHLY, and find that the Titin-derived peptide
ESDPIVAQY ranked #4 out of 1,143,861 HLA-A1 binders (Figure 2).

Figure 3. Sample of top predicted cross-reactive peptides for PHOX2B neuroblastoma antigen QYNPIRTTF
presented on HLA-A24.

Using this method, we predicted potential cross-reactive binders for the
neuroblastoma peptides described in chapter 2. Based on these data, we are able to
preemptively screen potentially cross-reactive normal peptides, as well as potentially
problematic tissues. These methods can be used to prioritize candidate tumor
antigens for development based on their predicted profile of cross-reactivity with
normal peptides (PHOX2B cross reactivity in Figure 3).

pMHC/TCR multiplexing
Single-cell sequencing technologies have enabled a myriad of novel
approaches, elucidating previously immeasurable heterogeneity in both tumors and
immune cells. More recently, technologies such as cellular barcoding have been
developed to enable the reconstruction coupling of alpha and beta chain receptors at
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a single cell level (De Simone, Rossetti, & Pagani, 2018). These developments have
significantly advanced the field in enabling the identification of immunodominant
clones, and when paired with pMHC multimer sorting (i.e. tetramer or dextramer),
allow for the identification of antigen-specific TCR sequences. Despite these great
strides, major limitations still exist on these technologies. Current approaches only
allow for the probing of a single antigen-specificity per sample run using costly
reagents. Given that the samples used as TCR sources are often scarce and require
laborious preparation, extracting maximal data from these samples would be of great
value.

Recent technologies (Cellular Indexing of Transcriptomes and Epitopes by
Sequencing: CITE-seq) have been developed for coupling single-cell sequencing with
cell-membrane protein expression (Mimitou et al., 2019; Stoeckius et al., 2017)
employing antibodies labeled with DNA-oligo barcodes for staining prior to singlecell sequencing. The antibody-associated barcodes are further labeled with cellular
barcodes during the single-cell library preparation, allowing the use of antibody
barcode sequencing reads as a surrogate of protein expression at a single cell level.
Cell-membrane protein expression can then be paired with RNA-sequencing data
from the same cell, allowing the simultaneous measurement of RNA and protein in a
single experiment at cellular resolution.

Peptide-MHC multimer production (Altman et al., 1996) has revolutionized
the field of immunology, allowing for the identification of antigen-specific T cells,
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tracking of immune responses over time, and the isolation of specific T cell subsets.
Though production of tetramers has evolved over time, the methods of generating
tetramers remains laborious, time-consuming, and limited in throughput. Recently,
techniques have been developed for scaling the production of tetramers using a
placeholder peptide paired with a TAPBPR exchange protein (Overall et al.,
submitted), allowing the rapid production libraries consisting of 1000s of tetramers
in a short time period (Figure 4).
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Figure 4. Schematic of tetramer barcoding paired with T cell staining and single cell sequencing.
Tetramers are generated using peptide exchange facilitated by TAPBPR, conjugated to DNA oligo
barcodes, filtered, and pooled together. Pooled tetramer library is used to stain T cells from patient or
donor, allowing sorting for a library of antigens. T cells stained with barcoded tetramers can be loaded
for single-cell sequencing, allowing the coupling of TCR sequences with antigen specificities.

We have developed an approach that combines single cell high throughput
tetramer production, single cell TCR sequencing, and oligo barcoding of tetramers, to
enable high-throughput multiplexed decoupling of thousands of pMHC/TCR pairs in
parallel using a single sample. To test the feasibility of this approach, we used normal
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donor T cells spiked with Jurkat cells
transduced with the DMF5 receptors
specific for the MART-1 antigen. We
stained these cells with an oligobarcoded tetramer library of 29
neuroblastoma antigens (and MART-1)
binding to HLA-A2 as identified from
the
Figure 5. Proof-of-concept for detection of antigenspecific TCRs using barcoded tetramers. Y-axis
shows tetramer reads of T cell pool spiked with
DMF5-transduced cells stained with a library of
barcoded tetramers. T cells with DMF5 TCR stain
have significantly higher MART-1 tetramer reads as
compared to non-antigen-specific TCRs in sample.

neuroblastoma

ligandome

described in Chapter 2. We compared
the read counts for MART-1 oligo
barcode between cells carrying the
DMF5 gene and those that were

expanded using neuroblastoma peptides, measuring a significant detection of the
MART-1 barcode in the population of cells with the DMF5 TCR (p = 1.54e-10), and
demonstrating proof-of-concept in our ability to detect antigen-specific TCRs in a
pool of T cells using a library of tetramers.

This approach allows for the screening of reactivity to hundreds of pMHC
antigens using a single patient/donor sample. This methodology can be paired with
the cross-reactivity algorithm described above, using hundreds of predicted selfpeptides, such as to quantify and assess cross-reactivity of TCRs of interest. The
deployment of this technology over time will generate vast quantities of data coupling
TCR sequences with binding of specific pMHC complexes in a quantitative manner.
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These large datasets can eventually be used as a training set for a machine learning
algorithm, such as to develop an understanding of the interaction between pMHCs
and TCRs. Ultimately such an algorithm could be deployed in safety predictions and
the computationally assisted design of TCR and CAR receptors for use in
immunotherapy.
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Methods
Generation of DMF5 T-cell line
Retrovirus for transduction of Jurkat/MA25 and primary CD8 T cells was produced
using Platinum-A retroviral packaging cell line. DMF5 cassette was assembled using
previously described CDR3 sequences and V(D)J family genes,26 codon optimized,
synthesized, and cloned into pMP71 retroviral vector.27 Jurkat/MA cells were plated
in 6-well plates at 7 x 105 cells/well and transfected with 2.5 mg of retroviral vector
pMP71 using Lipofectamine 3000 (Life Technologies, Invitrogen). After 24 hours,
medium was replaced with IMDM-10 % FBS or AIM-V-10 % FBS. Supernatants were
harvested and filtered with 0.2 mM filters after 24 hours incubation and transferred
to Jurkat/MA cells in 6-well plates pre-treated with 1 mL well/Retronectin (20
mg/mL in PBS, Takara Bio. Inc.,) at 1 x 106 cells/well and spinoculated with 2 mL of
retroviral supernatant at 800 g for 30 min at RT. After 24 hours, cells were washed
and PBS, and cultured in IMDM-10% FBS. Jurkat/MA cells were stained with MART1 dextramer and sorted for dextramer-positive cells.

PBMC/DC co-culture
Normal donor monocytes were plated on day 1 in 6-well plates at 5 x 106/ well in
RPMI-10 FBS supplemented with 10 ng/ml IL-4 (Peprotech) and 800 IU/ml GM-CSF
(Peprotech) and incubated at 37°C overnight. On day 2, fresh media supplemented
with 10 ng/ml IL-4 and 1600 IU/ml GM-CSF was added to the monocytes and
incubated at 37°C for another 48 hours. On day 4, non-adherent cells were removed
and immature dendritic cells washed and pulsed with 5 uM peptide in AIM-V-10 %
FBS supplemented with 10 ng/ml IL-4, 800 IU/ml GM-CSF, 10 ng/ml LPS (SigmaAldrich), and 100 IU/ml IFN-y (Peprotech) at 37°C overnight. Day 1 was repeated on
days 4 and 8 to generate dendritic cells for the second and third stimulations on days
8 and 12, respectively. On day 5, normal donor-matched CD8+ T cells were cocultured with the pulsed dendritic cells in AIM-V-10 % FBS. Day 5 protocol was
repeated on day 8 and day 12 using dendritic cells generated on days 4 and 8 for the
second and third stimulation, respectively.

Flow cytometry
Tetramer analysis was carried out by staining 2 x 105 cells with anti-CD8 mAb (BD
Biosciences) and 1 g/mL HLA-A02:01/MART-1 tetramer or 50 g/mL H-2Dd/P18I10 tetramer for 1 h on ice, followed by two washes with 30 volumes of FACS buffer
(PBS, 1% BSA, 2 mM EDTA). All flow cytometric analysis was performed using a BD
LSR II instrument equipped with FACSDiva software (BD Biosciences). For cell sorting
experiments, cryopreserved human splenocytes were thawed and rested in RPMI
media (10 % FBS, 1 % L-glutamine, 1 % Pencillin/Streptomycin). CD8+ T cells were
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enriched by negative selection using magnetic beads according to the manufacturer’s
protocol (STEMCELL Technologies). Cells were then treated with dasatinib (50 nM,
Sigma-Aldrich) for 30 minutes prior to staining. Afterward, 50 L each of PE and APC
versions of the tetramer library were added (final amount was 0.5 g pMHC per
tetramer) were added for 15 minutes at room temperature. Cells were stained with
anti-CCR7–APC-Cy7 (G043H7, BioLegend) for 10 minutes at 37 oC; with LIVE/DEAD
Fixable Aqua (Thermo Fisher Scientific) for 10 minutes at room temperature; with an
antibody cocktail containing: anti-CD14–BV510 (M5E2, BioLegend), anti-CD19–
BV510 (HIB19, BioLegend), anti-CD3-APC-R700 (UCHT1, BD Biosciences), anti-CD4–
PE-Cy5.5 (S3.5, Thermo Fisher Scientific), anti-CD8–BV605 (RPA-T8, BioLegend), and
anti-CD45RA PE-CF594 (HI100, BD Biosciences) for 20 minutes at room temperature.
Cells were washed and resuspended in BD pre-sort buffer (BD Biosciences). Cell
sorting was performed on a FACS Aria FUSION (BD Biosciences)
Live cells were gated based on forward and side scatter profiles and data was
analyzed using FlowJo software (Tree Star). For EC50 determination, tetramer
concentrations were calculated based on total amount of pMHC-I at the time of
exchange. Titrations were performed on the appropriate cell line in duplicate in two
independent experiments. The percentage of tetramer+ T-cells was measured
relative to the staining achieved at the highest concentration tested within each
experiment. EC50 values were calculated by fitting a Boltzmann sigmoidal function to
the data with the lower constraint set to 0 and upper constraints set to 95 for B4.2.3
and 28 for DMF5 in GraphPad Prism 7.

ECCITE-seq
Post sorting, samples were prepped for the 10X Genomics 5P V(D)J kit workflow, and
processed according to the ECCITE-seq protocol[ref], with these modifications:
1) For
cDNA
amplification,
1uL
of
0.2uM
tetramer
additive
(GTCTCGTGGGCTCGGAGATG) was spiked into the reaction.
2) Post cDNA PCR, a 0.6x SPRI cleanup was performed, resulting in the larger
cDNA fragments being retained on the beads, and the tetramer tags in the
supernatant. After separation of the two fractions and elution from the beads,
a portion of the cDNA was used to perform TCR alpha/beta amplification and
library prep, as described in the 10X genomics protocol.
3) A separate portion of the cDNA elution was used to perform a DMF5 receptor
specific enrichment, using a hemi-nested PCR strategy akin to that used for the
TCRα/β enrichment. All PCRs were performed using 2X KAPA Hifi Master Mix.
Primers for PCRs: PCR - DMF5_PCR1 (GAAATTCACGGCGCACAGG) with SI-PCR
primer
(10x).
PCR2
DMF5_PCR2
(CCTTGGCACCCGAGAATTCCAGCTTGGCTGGCTGTCTCTGATC) and P5_generic
(AATGATACGGCGACCACCGAGATCTACAC). PCR3 (to add P7 end and sample
index) - RPI-x primer (“x” nucleotides comprise a user-defined index)
CAAGCAGAAGACGGCATACGAGATxxxxxxxxGTGACTGGAGTTCCTTGGCACCCG
AGAATTCCA and P5_generic.
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4) The supernatant of the 0.6X SPRI purification in step 2 above was purified with
2 rounds of 2x SPRI. First, 1.4x SPRI was added to the supernatant to bring up
the volume to 2x, followed by two rounds of 80% ethanol washes. After eluting
in water, an additional 2x SPRI cleanup was performed. Post second cleanup,
the tetramer tags were converted to a sequenceable library by PCR with SIPCR and N7XX (“x” nucleotides comprise a user-defined index)
CAAGCAGAAGACGGCATACGAGATxxxxxxxxGTCTCGTGGGCTCGG.

Sequencing and Analysis
Individual tetramers were pooled in one library sample prior to sequencing. Samples
were sequenced on a Miseq using a v2 300 cycle kit (151 cycles R1, 8 cycles I1, 151
cycles read 2). Post sequencing, TCR fastq files were pooled together for each sample,
then analyzed using cellranger vdj 3.0.0 against the GRCh38 reference genome
(v2.0.0, as provided by the 10X website). To identify the DMF5 receptor, we used
CITE-seq-Count version 1.4.1 to search for the DMF5 specific tag, using default
parameters (hamming distance set to 5). For tetramers, we used CITE-seq-Count
version 1.4.1 using all default parameters, with the exception of hamming distance
set to 1, and a whitelist to search for only cells with TCR found by 10X.
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Conclusion
Discussion
Since the fields of biotechnology and immunology began their co-evolution in
the mid-1970s in the development of hybridoma technology, the nascent field of
immunotherapy has rapidly translated curative therapies for cancer patients. The
first generation of antibodies directed at tumors relied an antibody dependent
cellular cytotoxicity, either mediated through secondary immune cells or through
blockade of essential pathways to tumor growth (Gajria & Chandarlapaty, 2011;
Gómez Román, Murray, & Weiner, 2014). Follow-on strategies targeting tumor cells
took advantage of the specificity of antibodies to deliver cytotoxic payloads to tumor
cells using antibodies conjugated to drugs (ADCs). More recent uses of antibodies
have been directed at targeting the immune cells rather than the tumor cells, namely
through immune checkpoint inhibitors, which have proven particularly effective
against certain tumors and have reinvigorated the appreciation of the immune
system’s ability to clear tumors. Breakthroughs in the ability to generated fully
human antibody recognition domains, coupled with the understanding of T cell
biology, have allowed the engineering non-immunogenic antibody recognition
domains tethered to T cell signaling domains, engendering the ability to
therapeutically redirect T cells towards a target of choice using chimeric antigen
receptors (CARs). This specificity can be redirected at any protein on the surface of
the cell, and the current understanding of T cell biology does not present any
theoretical limitations preventing the use of engineered T cell therapies for all tumor
types, given a functional T cell is able to enter the tumor with specificity directed
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against a tumor antigen. For these reasons, immunotherapy has the potential to
deliver upon the promises of personalized medicine of providing safe and effective
treatments based on the specific biology of a given patient’s tumor. Yet despite the
cures that have been achieved in leukemias with CAR T cells, the majority of the
cancer population cannot yet benefit from these therapies, particularly those patients
with low mutational solid tumors.

There are at least two major bottlenecks that prevent more widespread
adoption of these cellular immunotherapy: 1) the paucity of known tumor-specific
targets, and 2) the immunosuppressive tumor microenvironment. Though the focus
of this dissertation is on addressing lack of tumor-specific targets, many other groups
have been focused on the development of strategies of maintaining T cells in a cellular
state optimal for killing activity and preventing exhaustion, using a variety of
strategies including gene knock-out or knock-in (June & Sadelain, 2018), epigenetic
regulation of methylation or histone architecture (Henning, Roychoudhuri, & Restifo,
2018), the use of various co-stimulatory domains (Quintarelli et al., 2018), metabolic
modulation (Le Bourgeois et al., 2018), and use of antibodies, cytokines or small
molecules in combination with T cells (Le Bourgeois et al., 2018; Rosen et al., 2016;
Shum, Kruse, & Rooney, 2018; Sterner et al., 2019; Yoon, Osborn, Tolar, & Kim, 2018).
These efforts have been driven by basic research investigating the mechanisms of
tumor intrinsic mechanisms of immune evasion, as well as the study of tumor cells’
ability to co-opt surrounding stromal and immune cells such as to maintain an
immunosuppressive and tumor-promoting microenvironment. In this emerging field

152

of study, it remains to be determined which of these strategies will be most relevant
in specific tumor types, and the hierarchy of their involvement in overcoming
immunosuppression. While both innate and adaptive arms of the immune system are
crucial in immunoediting and anti-tumor responses, as well as both CD4 and CD8
arms of the T cell response, here we focus on CD8 cells and their interaction with
peptides presented of MHC class I, postulating that this interaction is the most critical
in driving a target-defined cytotoxic response.

This work has been performed in neuroblastoma, which presents a unique
combination of challenges that have prevented the successful application of
immunotherapy: 1) low somatic mutational burden, 2) low MHC expression, and 3)
lack of infiltrating T cells in tumors. These hallmarks of an immunogenically silent
tumor are shared by many other solid tumors, and make neuroblastoma an ideal
disease for addressing these challenges. We expect that the methods generated to
address these specific challenges will be more widely applicable to other tumors for
which immunotherapies are currently lacking.

A main tenet of this thesis is that optimal immunotherapeutic targets will be
derived from cancer driver genes, and that continuous expression of these proteins is
required for the survival of the tumor. Thus, while there are advantages of targeting
full length proteins on the cell membrane, only a small minority of these can be
considered oncoproteins. Presentation of intracellular proteins via MHC provides a
snapshot of the internal cellular state through peptides on the cell surface. We
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estimate that approximately 4.5 million unique peptides may be presented in a given
individual (Figure 1), and that the space of potential pMHC/TCR interactions is on

Human genome: 3
billion nucleotides
1.5% protein
coding

45 million nucleotides
3 nucleotides/
amino acid

15 million AAs
5% MHC binders

the order of 4.5e22, making the interface between
the T cell and MHC one of the most complex
interactions in biology. This complexity is further
complicated by existence of over 10,000 unique HLA
alleles in the population. While the interaction
between peptide and common HLA alleles has been
thoroughly characterized and can be predicted with

0.75 million binding
peptides/MHC
6 HLA alleles

4.5 million unique
pMHCs/individual
1015 possible T
cell receptor
recombination
4.5e21 possible
peptide-MHC-TCR
interactions/individual
Figure 1. Estimate of unique pMHCs
presented in an individual and estimate
of potential pMHC/TCR interactions.

a high degree of confidence using machine learning
algorithms, current tools offer no ability to predict
the interaction between pMHC and TCR. Here we
present methods for identifying tumor specific
peptides on MHC by combining computational and
experimental approaches, allowing the discovery
and prioritization of 6 tumor-specific antigens in
neuroblastoma from the theoretical pool of 4.5
million. We present an additional set of methods
allowing the identification of functional, tumor-

specific TCRs from a large population of CD8 cells, allowing us to identify 3 functional
TCRs against two different neuroblastoma-specific antigens using 100 million
starting CD8 cells derived from normal HLA-matched donors.
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Herein we presented methods for characterizing various aspects of immunity
related to T cell responses using experimental techniques and computational
methods. Taken together, these tools can be used to identify tumor antigens, engineer
T cell receptors, and evaluate immunogenicity of tumor cells. We evaluate
immunogenicity of tumors using both a computational model of immunoediting and
a viral system using known antigen-specific T cells for known HLA-restricted
antigens. Though the hypothesis we sought to test was centered on the ability of low
MHC tumors to elicit a T cell response, our findings that T cell responses were not
associated with MHC expression in neuroblastoma raise interesting questions
surrounding MHC-independent mechanisms modulating immunogenicity and
evasion of immune response. Lack of T cell responses to HLA-A2 viral peptides in
HLA-A2 neuroblastoma cells warrants further investigation into mechanisms of T cell
disengagement. Furthermore, the identification of the NLF tumor cell line as
immunogenic using pulsed peptide, but nonimmunogenic when infected with virus,
and harboring no mutations in known antigen presentation genes, suggests that
alternative mechanisms of suppressing antigen presentation are at play in this cell
line. These methods of evaluating immunogenicity can be expanded using additional
tumor types and using additional antigen-specific T cell models, to gain further
insight into non-MHC-related mechanisms that lead to variable levels of
immunogenicity in cells and in potentially identifying novel mechanisms of immune
evasion. We also present in silico methods of predicting immunogenicity using the
underrepresentation of HLA alleles in HLA/mutant combinations predicted to
present neoantigens to the immune system. These analyses provide another method
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for identifying putative tumors with varied levels of immunogenicity that can be
probed for mechanisms leading to an increase or decreased T cell response. The
pairing of computational models and experimental methods of evaluating
immunogenicity may offer novel insights into mechanisms of immune evasion that
provide insight for development of strategies for enhancing the activity of
immunotherapies.

Using an integration of genomics and proteomic experimentation, we show
that shared, tumor-associated antigens derived from lineage-restricted non-mutated
oncogenes can be readily identified in low MHC, low mutational neuroblastoma. Using
the techniques we have described, we have not detected any canonical neoantigens
(i.e. those derived from SNVs). This is consistent with our estimated frequency of
neoantigen presentation, coupled with the rate of detection of specific peptides using
mass spectrometry. We expect that the pool of peptides we have detected in
neuroblastoma is biased based on pMHC binding affinity, peptide abundance, and
biophysical properties that preferentially ionize during mass spectrometry. Based on
our GO analysis of the parent genes of MHC-presented peptides in only 8 primary
neuroblastoma tumors, we demonstrate that the ligandome of neuroblastoma cells is
highly unique, yielding only a single GO term, sympathetic nervous system
development. We present a workflow for prioritizing tumor-specific antigens based
on binding affinity to MHC, commonality of the HLA allele on which peptides are
presented (selecting HLA-A2 and HLA-A24 initially), degree of differential expression
between tumor and normal tissue, absence of peptide in the normal ligandome,
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recurrence across tumors, relative abundance of the peptide compared to other
peptides presented in tumors, relevance to tumor biology, and the degree of crossreactivity with peptides derived from normal proteins. Using this workflow, we are
able to narrow the 497,501 peptides identified by mass spec to 6 antigens for
preclinical development. Indeed, many of the tumor-specific peptides we identify are
genes that are highly upregulated during development and silenced upon
differentiation. Though we find a peptide derived from the MYCN oncoprotein, we did
not include this in the prioritized list of clinical candidates due to the low prevalence
of the HLA allele on which it is presented (HLA-C*16:01 in ~2% of the US population),
and the limited reagents currently available for that HLA. Considering that current
efforts to drug MYCN have failed, we plan to revisit this strategy as more reagents
become available. We posit that lineage restricted oncoproteins will make excellent
tumor targets in other developmental cancers, cancers that are epigenetically
dysregulated, and in cancer stem cell populations within other tumors. Included in
these, we found essential transcription factors that drive and maintain tumor
progression, such as PHOX2B, which were previously considered undruggable, and
have been shown to be essential in tumor survival (Durbin et al., 2018). We expect
that screening additional neuroblastoma tumors will allow for the discovery of
additional peptides, including peptides presented on less frequently occurring HLA
alleles, and allow for a more comprehensive understanding of the global
neuroblastoma ligandome as it relates to tumor subtypes.
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In addition to identifying self-peptides derived from lineage restricted
proteins, we find that neuroblastoma cells present a number of peptides that map to
non-canonical reads from RNA-seq data on matched tumors. Though not the focus of
our studies to date, we expect that these non-canonical antigen (i.e. those derived
from fusions, frame-shifts, alternative splicing junctions, read-throughs, or
endogenous retroviruses) will serve as an additional source of tumor-specific
epitopes in future work. We also find previously uncharacterized phosphorylated
peptides presented on MHC, suggesting that these may also serve as a class of tumor
antigens if proven to be tumor-specific. In addition to MHC class I molecules, we
identified a number of MHC class II peptides from neuroblastoma oncoproteins
including MYCN, suggesting that these too can be exploited as tumor targets in the
future. Though we find additional classes of antigens, at this time we have chosen to
proceed with lineage-restricted self-peptides due to their high recurrence and our
greatest confidence in their tumor specificity.

We show that the 6 prioritized peptides are regulated by the core regulatory
circuit in neuroblastoma (MYCN, HAND2, ISL1, PHOX2B, GATA3, and TBX2) and are
associated with an H2K27Ac super-enhancer mark and binding of each of these
transcription factors at each of our prioritized gene’s canonical promoter, suggesting
that immune evasion due to loss of parent gene expression will be unlikely, based on
the reinforced positive feedback loop among these drivers of neuroblastoma. Taken
together with the tumor specificity, target abundance, pMHC binding affinity,
recurrence across tumors, and lack of presentation in the normal ligandome, these 6

158

antigens possess the hallmarks of ideal cancer targets. However, tumors may still
evade immunotherapy directed at these antigens through loss of MHC, defects in
antigen presentation, or heterogeneity of antigen expression. Though it is currently
not possible to measure heterogeneity of antigens presented on MHC in tumors, it
may be possible to estimate the heterogeneity using techniques such as single cell
RNA sequencing. The development of scFvs specific to tumor peptide-MHC may allow
for antibody-based detection of heterogeneity within tumors using flow cytometry to
assess MHC antigen heterogeneity in the future. These factors can be used as
additional criteria in the scoring and prioritizing of peptide targets. With the proper
reagents it may be possible to identify sets of antigens that cover various tumor cell
subtypes such as to develop combinatorial therapeutic strategies to address issues of
antigen heterogeneity. To address loss of MHC, several existing strategies can be
employed including cytokines (Zhou, 2009) and epigenetic modifiers (Shi et al.,
2018), or the use of NK cells to target low MHC tumor cells (Marcus et al., 2014).

Given the unknown, but likely low, intrinsic immunogenicity of these tumorself-antigens, we employed CAR T strategies in parallel to the development of
antigen-specific TCRs, expecting that engineered CAR receptors may be capable of
inducing immunogenicity to otherwise non-immunogenic peptides. We find unique
challenges to each approach and have developed strategies to circumvent the
constraints of targeting self-peptides. Given that CAR receptors have not evolved to
recognize peptide within the context of MHC, a major challenge is engineering
receptor specificity to the peptide without binding to the MHC. To mitigate this, we
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first depleted the scFv library we screened of binders using a mismatched tumor
peptide on matched MHC, followed by selection of binders specific to tumor pMHC.
We were able to achieve potent tumor cell killing using CARs with specificity towards
tumor antigen, but not against the MHC, demonstrating that this technique can be
used to develop cytotoxic CARs specific to just the tumor peptide. We also discover
additional CAR constructs, that despite preemptive removal of MHC binders, that still
retained significant cross-reactivity sufficient to kill HLA+/antigen- cell lines. We are
utilizing a series of strategies to identify the interface for specific pMHC/scFv using
crystallography, random mutagenesis and saturation mutagenesis. We think that the
optimization of these approaches will allow for increased targeting of this class of
non-immunogenic antigens using engineered CAR receptors.

In parallel to developing CAR T cells targeting pMHC, we sought to identify
tumor-specific TCRs, expecting that, if found, these receptors may possess the antigen
sensitivity necessary to elicit a cytotoxic response in low MHC tumors (P. Sharma &
D. M. Kranz, 2016). We first tested whether HLA matched normal donors could be a
viable source of self-antigen-specific CD8 T cells, finding a rare population of these
cells that could be sorted. In our initial efforts to engineer TCRs by reconstructing
alpha/beta pairs from antigen-specific populations, we were able to isolate and
sequence TCRs from a rare population of antigen-specific CD8 cells from normal
donors. We found that high affinity TCRs were not necessarily functionally active, as
others had concomitantly reported (Sibener et al., 2018). Based on these results, and
the converse findings reported by others finding highly functional TCRs being within
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the range of binding affinity not currently detectable by standard methods (Dolton et
al., 2018b), we developed an approach for combining an enhanced enrichment
technique of antigen-specific T cells with a functional expansion of antigen-specific
cells using matured dendritic cells. By coupling these approaches, we were able to
achieve a significant expansion of antigen-specific CD8 cells which we sorted and
sequenced in a single cell manner. Using this method, we identified a low affinity
immunodominant clone with significant activity against tumor cells. We find that this
TCR construct transduced in T cells shows tumor antigen specific binding and
activation, and ongoing testing is aimed at characterizing potential cross-reactivity
and activity in murine models. We expect that this technique will be particularly
useful in identifying rare functional TCRs against tumor self-antigens, and will
generate data to help further elucidate the relationship between TCR binding and
functional activity. Together with the antigen discovery pipeline, these methods allow
for the empirical characterization of peptides and identification of tumor antigen
specific TCRs. The generation of large datasets of these sorts will allow for the
coupling of genomes with ligandomes, and of pMHCs with specific TCRs. We believe
that these data can ultimately be used to predict patient-specific ligandomes based
on genomic features, and can be used as training sets for machine learning algorithms
to help predict optimal CDR coding sequences and V/D/J gene families for given
pMHC epitopes. Interestingly, we find that both CAR and TCR approaches can elicit
potent tumor cell killing. Our ability to target the same antigen using both CARs and
TCRs can allow for direct comparisons of these two classes of receptors, allowing
investigations into: antigen density thresholds, comparison of signaling pathways,
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trafficking to tumors, cytokine release, tumor killing activity, exhaustion, metabolic
activity, etc.

We have also presented a model for quantifying immunoediting during early
tumorigenesis that provides insights into the contributions of recurrent somatic
mutations in human cancer. We find that many of the most common tumor driver
mutations including KRAS G12D and BRAF V600E are predicted to bind none of the
common HLA alleles for which algorithmic predictions are available. We hypothesize
that paired with their ability to drive tumor progression, the immunogenically silent
nature of these mutations confers additional evolutionary advantage to the tumors
and thus allows for a greater occurrence of these mutations in human cancer. While
we find that the G12D mutation in KRAS is not predicted be eliminated by the immune
system, another mutation at the same position, G12A, is the most underrepresented
based on our modeling, suggesting that this mutation is efficiently cleared by the
immune system during tumorigenesis, while the G12D variant is not presented on
HLA. We speculate that since the KRAS G12D mutation is pathognomonic in
pancreatic cancer, its immunogenic silence may help to explain the lack of efficacy in
reinvigorating the T cell response to recognize mutations through checkpoint
inhibition (Torphy, Zhu, & Schulick, 2018). We also show that within a given protein,
peptides derived from particular regions are broadly presented by HLA alleles that
represent a large majority of the population, while other regions are not predicted to
be presented on any common HLA allele. We show that hotspot mutations are
enriched in those regions of proteins not highly presented by HLA at a population
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scale, demonstrating that a wide range of protection exists within a given protein
depending on the position of a given mutation. These findings raise questions
regarding the evolutionary history of HLA alleles being selected to protect against
specific conserved motifs and domains of pathogenic viral proteins. We propose that
these tools that we have made available through the ShinyNAP web portal can be used
to test such questions. This tool can also be used to identify and prioritize shared
tumor antigens recurrently presented across the population for the prioritization of
peptide vaccines, and in scoring neoantigens, both in their capacity to be presented
across the population and in their immunogenicity.

Additionally, we find that HLA alleles contribute disproportionately to the
elimination of the neoantigens that they present. We find that HLA-A*68:01
contributes most to early immunoediting, suggesting that this and other HLA alleles
may confer a protective effect against developing tumors, and that the set of HLA
alleles in a given individual could be used to estimate their susceptibility to
developing cancer. These disparities in immunoediting across HLA alleles raise
questions of intrinsic properties of HLA alleles that contribute to immunoediting in
cancer. It is possible that the biophysical properties of certain HLA molecules enable
interactions with a broader set of the CDR1 and CDR2 loops encoded in by the V gene
family, thereby increasing the likelihood of recognition by a TCR for a given HLA
allele. It is possible that the geometry of the pMHC/TCR interaction (J. J. Adams et al.,
2011) is more favorable in eliciting TCR signaling for particular HLA types. Another
possibility is that the preferred anchor residues of particular HLA alleles are skewed
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towards protein regions more likely to harbor mutations important in tumor
development. We also find a disparity in early immunoediting across individuals,
suggesting the utility of these individuals as case studies for enhanced immunoediting
through genomic and transcriptional analyses. In fact, the individuals who have the
highest degree of immunoediting are also more likely to harbor immunogenically
silent mutations, suggesting that a proper immune response enabled significant
immunoediting to take place, but was unable to eliminate the immunogenically silent
driver mutations in these tumors. Taken together, these methods may also eventually
prove to be useful in predicting the efficacy of checkpoint inhibitors based on the
immunogenicity profile of the mutations in a patient and their set of HLA alleles. This
model is currently limited by the predictive abilities of peptide-MHC binding
algorithms, and the restriction of this analysis to 9mer peptides. We expect that these
models will be enhanced through the improvement of peptide-MHC binding
algorithms, the expansion of cancer genomic datasets, and the coupled analysis with
MHC class II peptides. We also expect that as TCR sequencing and T cell phenotyping
becomes more widely available, the paired analysis of TCR repertoires and T cell
subtypes will offer greater insight into the contributions of the MHC antigen
presentation as they interact with TCR repertoires and various T cell subsets.

Finally, we present a method for combining recently developed techniques in
high throughput tetramer production with single-cell protein barcoding technologies.
Using this approach, we show that antigen-specific T cells can be detected using
combinatorial tetramer libraries, coupling TCR sequences with a quantitative metric
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of binding across a large number of antigen specificities. Application of these
technologies to TCR and CAR engineering has the potential rapidly accelerate
development across three areas: 1) debottlenecking TCR development by allowing
simultaneous screening of TCRs against multiple antigens using a single precious
sample of donor or patient T cells, 2) allowing the up-front assessment of crossreactivity against similar peptides derived from normal genes, and 3) the use of highdimensional data can be used to train machine learning algorithms in elucidating the
“rules of engagement” between pMHC and TCRs/CARs. We have developed an
algorithm to generate a list of potentially cross-reactive normal peptides for use in
cross-reactivity studies. The algorithm scores peptide similarity based a number of
criteria: 1) amino acid matching at each position, using different weights for identical,
similar, and non-similar amino acids, 2) peptide/MHC binding affinity, 3) normal
tissue expression of parent gene, 4) similarity of amino acid residues believed to
interact with TCR/CAR, and 5) organ sites of peptide parent genes.

To validate this algorithm, we tested its ability to predict cross-reactivity of
MAGE-A3, which resulted in the unfortunate death of two patients due to crossreactivity with a Titin peptide expressed in cardiac tissue (Linette et al., 2013). Our
algorithm scored the Titin peptide as #4 out of 1,143,861 binders to the same HLA,
suggesting that this cross-reactivity could have been pre-emptively predicted using
this methodology. We posit that this scoring algorithm can be used as an additional
selection criterion the prioritization of peptide candidates for preclinical
development, and can be used as a rational methodology for performing safety
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studies. Pairing the prediction algorithm with barcoded multiplexing of peptides can
rapidly accelerate the development of safe and effective T cell therapies, and
ultimately pave the way for development of safe and effective T cell receptors
targeting multiple patient-specific antigens developed at a personalized scale.

This project has dovetailed on the continued marriage between biotechnology
and immunology that began in the 1970s. This work has been made possible by
parallel advances in genomics, proteomics, single cell sequencing, machine learning,
synthetic biology, biochemistry, and T cell immunology. Applying these tools to the
overwhelming complexity of the peptide/MHC/TCR interface has allowed for the
identification of tumor-specific peptides, the engineering of receptors, and has
established a proof-of-principle for future multiplexing technologies that can
ultimately lead to computational design of safe and effective immune receptors. We
expect that continued developments across these technological fronts will continue
to improve our understanding of interactions at the immunologic synapse, allowing
for enhanced use of existing therapies as well as novel capabilities. Improved
sensitivity of mass spectrometry in the past decade has allowed for the detection of
ligandomes in low MHC tumors. However, it is still estimated that only a small fraction
of the peptidome is currently detectable and that detected peptides are biased by
biophysical properties amenable to mass spectrometry (Bassani-Sternberg,
Pletscher-Frankild, Jensen, & Mann, 2015). As detection method continue to improve,
additional peptides will be revealed and methods such as unbiased de novo
proteomics (Freudenmann, Marcu, & Stevanović, 2018) and provide a more
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comprehensive view of tumor ligandomes. Ligandomics experiments will continue to
be performed on additional normal and tumor tissues, offering insight into antigen
processing and presentation preferences aside from that of peptide/MHC binding (i.e.
preference of proteasomal cleavage sites, transport into ER, and alteration of peptides
after proteasomal degradation).

As TCR sequencing technologies become more widely adopted, large
databases of tumor genomics paired with TCR repertoires will elucidate
immunogenic

and

immunodominant

epitope.

Recent

developments

have

demonstrated proof-of-principle in using known orphan TCR sequences to identify
their cognate pMHC antigen using single-chain pMHC phage libraries (Gee et al.,
2018). Such methods can be used to reveal novel immunogenic tumor epitopes
without prior knowledge of the tumor antigens or ligandomes. Pairing these data with
ligandomics data can allow shared antigens to be discerned from private antigens,
and immunogenic antigens from immunogenically silent peptides. While many
immunogenic peptides may be identified through these approaches, we expect that
many tumor-specific self-antigens will be non-immunogenic, but important tumor
targets. Here we employ scFv libraries as a solution to mitigate the expected
challenges of non-immunogenic self-antigen, but are also able to identify TCRs from
normal donors with immunogenicity against self-antigens. We employ the use of a
non-germline CDR3 clustering algorithm (Glanville et al., 2017), allowing the
prioritization of TCRs harboring enriched motifs that are expected the be critical in
determining antigen specificity. These motifs will also provide the basis for additional
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modifications to CDR3 loops to further enhance affinity, specificity, and functionality
of TCRs. Additional strategies can also be employed to address immunogenically
silent antigens, including the vaccination of mice with humanized HLA and TCR genes
(L.-P. Li et al., 2010; Pajot et al., 2004), the use of single-chain TCR libraries (Chervin
et al., 2013), the engineering of known TCRs binding to an antigen, sourcing TCRs
from HLA-mismatched donors (D'Orsogna, Roelen, Doxiadis, & Claas, 2012; de Witte
et al., 2006; Y. Wang et al., 2017), and the use of molecules to attenuate negative
thymic selection of TCRs reactive against self-antigens (Cheng & Anderson, 2018).
Other developments in enhanced cloning methods will allow for more rapid and
higher throughput synthesis of TCRs that will further accelerate the development of
immunotherapy and the understanding of the pMHC/TCR interaction (Z. Hu et al.,
2018).

Taken together, we present new tools and methods for addressing the
challenges

in

developing

immunotherapy

against

immunogenically

silent

neuroblastoma, covering target discovery, receptor engineering, and evaluation of
safety. It is our hope that these tools will be useful in expanding the application on
immunotherapy to a broader population of patients.
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Future prospects
Here we present a series of tools that we have applied towards the
development of immunotherapies neuroblastoma. As these tools were specifically
developed to address the challenges of developing immunotherapy for low
mutational, low MHC, developmental tumors, we believe that these tools will be
broadly applicable to developing immunotherapies for a large set of low-to-medium
mutational solid malignancies, and potentially in developing immunotherapeutic
strategies targeting the stem cell populations of tumors. We demonstrate the
discovery of novel antigens from previously undruggable oncoproteins (including
previously undruggable transcription factors), and present various methods of
targeting these antigens that result in tumor cell killing. We have developed CAR and
TCR methodologies to address the specific challenges inherent in developing
receptors targeting self-peptides presented on MHC. We also present novel tools for
predicting and measuring cross-reactivity of peptides and TCRs/CARs in a
multiplexed manner. As these experiments generate vast quantities of data, we expect
that repeatedly performing these experiments will generate sufficient datasets for
training machine learning algorithms that could be deployed in computationalassisted T cell receptor design.

We believe upon further optimized, these tools can shorten the process of
target discovery, receptor engineering, and safety/optimization, to fit within the
treatment period of a single patient, opening the possibility of personalized
immunotherapy tailored to a patient’s specific set of tumor antigens. As these
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techniques are repeated, we hope to generate a warehouse of target/receptor pairs
that could be deployed off-the-shelf. Coupling data from ligandomes with genomes,
we expect to ultimately learn to predict the most effective targets for a specific patient
based on their genomic profiling.

We think that the tools we present for analyzing immunoediting in the TCGA
can be used to elucidate mechanisms of defective or enhanced immunity in subsets of
patients, potentially revealing pathways that can be exploited for improving
outcomes of immunotherapy. We expect that these tools will aid the prioritization
and development of shared peptide antigens that are broadly presented across the
population, as well as identification of vaccine candidates. We expect that the
contribution of specific HLA alleles to immunoediting will open new avenues of
investigation in HLA allele contribution to cancer susceptibility, and that the protein
presentation mapping tools may be used to uncover the evolutionary pressures that
drove the selection of HLA alleles to recognize specific viral domains.

As many immunotherapy platforms are entering the clinic, the optimal
immunotherapy

platform

for

solid

tumors

remains

to

be

determined

(autologous/allogeneic T cell, bispecific engagers, vaccines, NK cells, macrophages,
etc.), in addition to optimal strategies for optimizing immune function within the
immunosuppressive tumor microenvironment. The identification of safe tumorspecific targets and the engineering of safe and specific receptors for these targets
will be essential to the success of any of these platforms. Our efforts in target
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discovery and receptor engineering remain agnostic to the mode of delivery and we
anticipate that these strategies will co-evolve as we enhance our methods, and
ultimately lead to potent immunotherapies directed at safe tumor-specific targets.

It is our plan to continue the development of both CARs and TCRs for the
neuroblastoma with the aims of generating IND-enabling data, in hopes of performing
a clinical trial for high-risk patients. We hope to build the infrastructure to scale
efforts in target discovery and immunotherapy development to address the unmet
needs in neuroblastoma and other cancers.
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Abbreviations
ADCC

Antibody dependent cell mediated cytotoxicity

ALK

Anaplastic lymphoma kinase

ALL

Acute lymphoblastic leukemia

APC

Allophycocyanin

APC

Antigen presenting cell

BiTE

Bispecific T cell engager

CAR

Chimeric antigen receptor

CD

Cluster of differentiation

CDR

Complementarity determining region

DC

Dendritic cell

ER

Endoplasmic reticulum

Fab

Fragment antigen binding

Fc

Fragment crystallizable

GM-CSF

Granulocyte macrophage colony stimulating factor

GWAS

Genome wide association studies

HLA

Human leukocyte antigen

IFN-γ

Interferon gamma

Ig

Immunoglobulin

IL-2

Interleukin-2

ITAMs

Immune-receptor tyrosine-based activation motifs

mAb

Monoclonal antibody
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MAP

Mitogen activated protein

MDSC

Myeloid derived suppressor cell

MHC

Major histocompatibility complex

MYCN

v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolo

NB

Neuroblastoma

NCAM

Neural cell adhesion molecule

NFAT

Nuclear factor of activated T cells

NK

Natural killer

PAMP

Pathogen associated molecular pattern

PBMC

Peripheral blood mononuclear cell

PE

Phycoerythrin

scFv

Single chain variable fragment

TCR

T cell receptor

VH

Variable heavy

VL

Variable light
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